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Abstract 
This work is composed of a number of topics in the healthcare area, which are approached 
separately with appropriate methodologies. The two topics deal with physician preference items 
via two different approaches. The first one investigates stock keeping unit (SKU) proliferation in 
healthcare organizations due to physician preference items (PPI). It captures perspectives of 
physicians and supply chain professionals about this problem through two surveys. The second 
topic builds a decision-making framework for the PPI selection process that can be used by 
healthcare organizations to make more objective decisions. A Multi-criteria decision making 
technique is implemented to illustrate the framework.   
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1 Chapter 1: Introduction and Overview 
A study done by (Shbool, et al. 2013) on the gap between healthcare and retail supply chains 
showed that the retail sector is more efficient. The focus on improving supply chain, inventory 
control, logistics, and material handling processes in other sectors, and the extensive 
technological evolution in healthcare makes the healthcare sector lagging in logistics innovation 
and in need for enhancements from a management perspective. 
The problems chosen for investigation in this work are inspired by similar topics in other 
sectors and by the need of healthcare stakeholders to address such issues. The two topics 
investigate the management of physician preference items (PPI) from two perspectives, 
physicians and supply chain professionals, and the selection decision process as a multi-criteria 
decision making process within healthcare organizations. This chapter provides a brief review of 
topics including: motivation of choosing each problem, contributions, and finally the 
organization of this document. 
Motivated by the stock keeping unit (SKU) proliferation problem found in the retail sector, 
the first topic is an investigation of how healthcare providers manage physician preference items 
(PPIs). Physician preference items are costly medical/surgical items, such as hip and knee 
implants, cardiac stents, mechanical devices etc., that are selected/preferred by the physician to 
use for a specific patient and procedure.  PPIs are selected by the physician and thus present 
management challenges for the supply system of a healthcare provider. The increasing number of 
items used for the same purpose in a healthcare organization will increase the cost and lower 
efficiency of the supply chain. One reason for that is the need to order lower quantities for more 
items which means more time to deal with orders, higher cost, and added difficulty to manage 
items within the system. There is a lack of literature found on this topic, and no rigorous 
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modeling or methodology to deal with the problem can be found. Most of the work done is 
opinions of professionals and experiences of people involved in case studies/projects to 
investigate potential solutions.  
The problem of PPI is investigated in this research from a management perspective. Survey 
is the method used, with two surveys developed for both physicians and healthcare supply chain 
professionals.  The survey helps in developing an understanding of and measuring some of the 
factors needed to describe the PPI problem.  In addition, it may provide a framework for 
describing approaches for addressing the issue in the healthcare sector. Being a health related 
problem implies two major issues, first the ethics and sensitivity of collected data, and second 
the difficulty of obtaining the data. Confidentiality was guaranteed through following University 
of Arkansas (UARK) procedure for conducting surveys, the Institutional Review Board (IRB) 
with approval number (IRB# 14-04-706 MOD 1406). The IRB approval is included in Appendix 
B.1: IRB Approval, and the signed protocols can be found in Appendix B.2: Survey Protocol. 
Researchers faced difficulty in gaining participants to contribute by filling out the survey. 
Appropriate statistical tests for the small sample size were used in analyzing the results. 
Since the PPI selection process involves multi-stakeholders and is based on multiple factors, 
it can be seen as a multi-criteria decision making (MCDM) process. The second investigation 
builds a decision making framework that can be followed by healthcare organizations to make 
better decisions. MCDM techniques have different capability with different features and 
characteristics. The use of a technique over another depends on the problems elements, and the 
result may not be an optimal choice, rather it improves the quality of the decision taken. A 
comprehensive review of different techniques and their features is necessary to choose the most 
appropriate one. The challenge is not in choosing the technique, but in the implementation 
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process. In other words, choosing criteria, combining them into a single key performance 
indicator, weighting factors, and consolidating stakeholders’ input are all challenges in this work. 
A MCDM technique is used on a case study and implemented to evaluate applicability in the 
healthcare area. Forms and templates are developed to survey feedback from stakeholders on the 
effectiveness of the decision process framework. The framework has been tested in a case study 
along with the evaluation process of professionals’ thoughts about the process resulting in the 
main contribution. 
The work in the dissertation is composed of a set of articles. The first paper concerns 
(physician preference items – management perspectives) and is found in chapter two. The 
chapter starts with an introduction that acquaints the reader with the motivation and background 
about the subject. Then, a literature review of work done and professionals’ opinions is 
summarized. The next section articulates the purpose of the survey, the survey construction 
process, and the dissemination/distribution procedures. Another section summarizes the results 
after conducting the survey and the main insights. The same outline is followed in the second 
article (Physician preference items – A Decision Making Framework) which is found in Chapter 
3. Definitions of terms used in this research can be found in Appendix A: Terms’ Definitions. 
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2 Chapter 2: Characterizing Physician and Supply Chain Perspectives for Managing 
Physician Preference Items 
 
Abstract 
The purpose of this work is to better understand the role that physician preference items 
(PPIs) play within the healthcare supply chain. Physician preference items are costly 
medical/surgical items, such as hip and knee implants, cardiac stents, mechanical devices, etc., 
that are selected/preferred by the physician to use for a specific patient and procedure. PPIs make 
up to 61% of total supply expenditure (Schneller and Smeltzer 2006), which (supplies) accounts 
for about 30% of total spend in a typical hospital (Tyson 2010). PPIs cause stock keeping unit 
(SKU) proliferation due to the variety of items used for the same purpose. There is a lack of 
literature found on this topic, and no rigorous modeling or methodology to deal with the problem 
was found. The problem of PPI is investigated in this research from a management perspective 
using survey methods. The purpose of the surveys is to gather information about the 
management process from two points of view: from the physicians and from the materials 
managers. The results of the survey help to document the critical issues in managing physician 
preference items, as well as recommendations based on results. 
 
2.1 Introduction 
Dramatic changes in the healthcare industry are going to take place within the next 5-10 
years (Dudas and Widhalm 2012). Hospitals will need to significantly reduce operational costs 
due to the effect on the reimbursement process caused by economic reform. In a typical hospital, 
the largest expense is incurred by labor (Schoen, et al. 2010) while the supplies represent the 
second largest expense (Moon 2004). “Supplies can account for about 30 percent of hospital’s 
total spend and represent a hospital's second-highest cost” (Tyson 2010) and (Jebson and Sweat 
2010). It is not an easy or straightforward task to reduce labor in a service organization; 
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consequently, this will likely increase the pressure on reducing expenses due to supplies. One of 
the most recent and active practical problems in inventory management is stock-keeping-unit 
(SKU) proliferation. Better management of this process has the potential to introduce savings in 
the supply chain system. 
SKU proliferation occurs when there is more than one brand in the inventory for the same 
product, or in other words many brands with equivalent functionality. The problem of SKU 
proliferation has been a growing issue for decision makers of the supply chain in healthcare as 
well as other sectors of industry. Brand competition, in addition to consumer preference factors 
can lead to an increase in the number of SKUs stocked by a company, which can be harmful if 
not managed properly. Healthcare is the target field of this research; hence the elements of the 
system are analyzed according to the appropriate characterization of problem parameters. 
However, it is likely that the methodology can be translated to other sectors of industry to 
address the same problem. Unfortunately, the literature found on this problem is very scant. A 
very limited amount of work has been done on this problem. This adds difficulty when 
developing a research framework for this problem due to the fact that there is a lack of 
underlying models. 
In the healthcare sector, a major cause of SKU proliferation is the physician’s preferences 
factor. The focus of this research is on investigating how healthcare providers manage physician 
preference items (PPIs) from a supply chain performance perspective. PPIs are costly 
medical/surgical items, such as hip and knee implants, cardiac stents, mechanical devices…etc., 
that are selected/preferred by the physician to use for a specific patient and procedure. Due to 
preference in selecting PPIs, these items are not standardized. Standardized items are those 
which organizations have on stock or purchase when necessary and are used by the entire 
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organization. They can be modeled with traditional inventory policies since ordering quantities 
and time can be decided from the forecasting models and demand patterns; obviously we wish to 
have all items standardized. Some examples of these items are: injections, gloves, stethoscopes 
… etc., dealing with these items is not the interest of this research. 
On the other hand, PPIs are difficult to manage and cannot be easily modeled as in the 
standard items with conventional theory; because the demand is affected by another factor which 
is physicians’ preference. Physician preference is the major obstacle standing in the way of 
standardizing these items, that is a healthcare organization can standardize stock and choose low 
cost, efficient items, if physician’s preference is ignored. However, failure to satisfy physicians’ 
preferences implies the threat of physicians leaving the organization, or unsatisfied physicians 
who may become unmotivated. Some examples of PPIs are heart valves, orthopedic and 
cardiovascular implants. 
PPIs exist in a variety of treatment areas: neurosurgery, urology, vascular, oncology, plastic 
surgery, ophthalmology, and most widely in orthopedics and cardiovascular. Within each area of 
treatment, they are classified into more specialized categories according to their purpose of use, 
and for each purpose there are many items (brands) for the same item type which are functionally 
equivalent but have different features, or in other words are produced by different manufacturers. 
For instance, orthopedic implants can be classified into many categories according to use such 
as: Austin-Moore prosthesis (for fracture of the neck of femur), Baksi’s prosthesis (for elbow 
replacement) … etc. (List of orthopedic implants 2014). Within each category, there are many 
items available in the market from different manufacturers. In addition to being expensive, 
orthopedics and cardiovascular implants showed big jumps in prices (Jebson and Sweat 2010), 
therefore they dominate other categories and are a major concern.  
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In hospitals, more than 40% of expenses are attributed to supply chain activities in North 
America (Nachtmann and Pohl 2009), same result was also found by (Chow and Heaver 1994). 
Within supply chain costs, (DeJohn 2005) stated that a great deal of savings in hospitals is held 
in PPIs, which are supplies and expensive disposable items used in procedures. PPIs are selected 
by the physician and thus present management challenges for the supply system of a healthcare 
provider. The physician’s preferences cause the organization to hold more than one brand for the 
same item, and as a result, the total supply chain cost increases and efficiency decreases (in terms 
of labor utilization, space utilization, and fill rate). Why do physicians prefer different brands? 
Understanding the causes and factors affecting the preference may help in constructing directions 
to some potential solutions. The purpose is to characterize the problem, and propose a framework 
which the organization can follow to address areas that can be attributed to minimizing the PPIs 
and consequently increasing the efficiency of the supply chain. 
The remaining sections of this paper are structured as follows; first a literature review 
presents the work done on PPI and opinions about the topic. Then, an overview of how 
organizations deal with PPI issues is discussed. Then the methodology used in this research is 
discussed. The research objectives are stated and then the results are presented. 
 
2.2 Literature Review 
The PPI issue is a recent problem; hence the amount of work done on this problem is almost 
negligible. The following literature spans work done into two parts. The first describes literature 
from industry regarding the SKU proliferation problem caused by PPI. The second part describes 
example literature that has addressed parts of the problem and which may be used to better 
understand how the healthcare industry has addressed the problem. 
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Mentioning the problem from the practitioners’ point of view can give a very good insight 
about the elements of the problem and factors included in the items’ selection process from 
practical perspective. In (Siddel 2012), the rising cost of PPI is stated as one of the reasons for 
losses in hospitals. This provides evidence that the PPI issue is causing a problem for healthcare 
organizations. According to (Jebson and Sweat 2010) three factors mainly cause PPIs. The first 
factor is the continual pressure to use the newest technology from implant vendors. The second 
factor is the approach of one treatment for one disease that some medical doctors MDs are using. 
This is mainly because they may not be willing to expand the effort of learning a new 
technology, or they are comfortable with their current treatment. Finally, MDs usually do not 
necessarily consider financial matters in hospitals and/or they are not involved in this kind of 
analysis. Consequently, they may not realize the impacts of helping a hospital with cutting its 
costs.  
Also (Jebson and Sweat 2010) mentioned some factors that make physicians use a specific 
item (brand). The first factor is how convenient a physician is with utilizing specific instruments 
and implants during residency training, in other words the physician’s preference is developed 
during the early stages of their career. Another factor is the incentives a physician receives due to 
using a specific implant type. Third, a physician who is a member in the design or trials team 
tends to adopt that item. Within industry, it is common for physicians to work directly with 
companies, testing new items, and then to eventually adopt the item. The fourth factor is the 
vendor-physician relationship: physicians tend to order items from vendors based on a good 
relationship. Finally, physicians say that representatives add clinical educational value and 
expertise to routine and complex cases. In a survey of 200 orthopedic physicians, 96% indicated 
that the representative is essential for learning about the new item. 93% prefer to have the 
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representative inside the room during the surgery. Finally, 96% said the selection will be based 
on the better representative.  
Healthcare organizations aim to reduce spending on PPIs and work to pull the leverage from 
the vendor side to their side. With that being said, the review indicates that vendors have the 
advantage through their physician relationships. Consequently, significant savings in cost is not 
feasible without cooperation from physicians. 
Due to lack of technical knowledge about items by supply chain and materials management, 
hospitals are pushed to make purchasing decisions with little information about quality and cost. 
To better control this spend, two suggested practices by (Jebson and Sweat 2010) may help in 
reducing PPIs. The first practice is to prevent or minimize purchasing implants and expensive 
supplies from vendors by physicians directly. That is MDs commonly purchase implants directly 
from vendors and then charge the hospital. Second, to quantify the degree of PPIs effect on 
organization, a report that includes type of case, surgery dates, physician name, item name, 
quantity and list price may be shared with physicians to focus on most cost contributors. They 
also mentioned some implant management methods namely: consignment, demand matching, 
standardization, group purchasing, price ceiling, and pricing matrix. 
Factors considered by physicians when selecting PPIs are mostly cost unrelated according to 
(Montgomery and Schneller 2007) such as, experience with a specific product, their judgment of 
what is best for particular patient, and their relationship with the representative of the 
manufacturer. In a survey carried out by Premier (Siddel 2012), they found that the top three 
factors influencing PPI purchasing decisions are clinical outcomes, cost, and physician’s past 
experience with suppliers or device manufacturers.  
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Another survey to see if value analysis is effective or not showed that 79% of the respondents 
were positive about it. Value analysis (VA) is the “examination of each procurement item to 
ascertain its total cost of acquisition, maintenance, and usage over its useful life and, wherever 
feasible, to replace it with a more cost effective substitute” (Chavan 2013). As opposed to a 
simple technique, value analysis is considered to be a process; this is because it is both an 
organized approach to improving the profitability of product applications and it makes use of 
many different techniques for the purpose of achieving this objective. 
Value analysis practice is examined in the survey developed for this research to investigate if 
organizations are adopting it and if they think it is useful. At the very heart of the VA process 
review is the task to determine and eliminate item product features that add no true value to the 
patient but incur cost to the healthcare provider and patient (Rich and Holweg 2000).  According 
to the survey, three characteristics of the supply chain should exist in order to benefit from using 
VA. First is to have a skilled data analyst to support the process. Second is implementing the 
process to every PPI. Third is to provide value training on value analysis to members and 
contributors to the process. 
At the Mayo Clinic, a standard procedure methodology is followed during the process of 
contracting with suppliers for purchasing items as indicated by (Dudas and Widhalm 2012). The 
Mayo Clinic has restructured their approach to physician preference items, as it is the most 
difficult contracting category. The contract portfolio manager (CPM) is responsible for 
contracting with suppliers, and should be knowledgeable of the product category. The process 
should involve medical staff at key decisions points and follow a time line from contract 
planning to contract launch. The process of contracting for PPIs at Mayo clinic is a 9 – 12 
months period, depending on the complexity of the product. The CPM begins preparing six 
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weeks before starting the contracting initiative. During this time, the CPM collects, reviews and 
analyzes data from many sources, including literature for similar items, meetings with supplier, 
and feedback from physicians. A stakeholder team is formed of physicians from Mayo clinic’s 
three locations and the Mayo clinic health system to serve as technical experts to the CPM. The 
stakeholder team meets with the CPM four times during the planning process to provide clinical 
success factors, potential strategy of bid, analysis of bid, and final contract value. Acceptable 
quality and the outcome of products are ensured based on physician’s recommendations. 
Finally, the Mayo clinic delivers the plan to the supplier and defines the timeline for each 
stage of the process. As a result, the physicians have been satisfied and involved in the decision 
process, and the process helps them understand both product quality and cost. A similar approach 
was discussed by (Tyson 2010) with more emphasis on data analysis and team based techniques 
to bring down the costs. The first step is to review all cost related aspects of physician 
preference-related procedures, including device item cost and utilization, clinical outcomes and 
physician variations. The next step is to share the assessment with the leadership. Before 
reviewing clinical outcomes and cost data achieved from the assessment, a discussion among the 
staff, hospital leadership and the physician is necessary to obtain their buy-in. The team approach 
is an efficient strategy to identify the products that will deliver the best outcome for each patient. 
More formal academic work on this problem was done and published by (Rossetti and Liu 
2009). Two types of proliferation were defined namely: acceptance and adoption. The 
acceptance case is when the requested item is not carried by the system, whereas the adoption 
case occurs when another hospital in the system happens to have the requested item but not the 
one that requested it. The research falls under the simulation context, and the SKU problem was 
tackled with object oriented modeling using the JSL library developed by (M. D. Rossetti 2008). 
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The work showed that both cases affect the hospital supply chain performance, specifically, 
service level (demand fill rate) and cost. With fixed combined proliferation rate (acceptance + 
adoption), the fill rate increases when decreasing the acceptance rate (increasing the adoption 
rate). Total cost behaved differently showing a minimum value when both rates are equal. The 
reader can refer to (Liu 2008) for more details on this work. 
On the other hand, (Bayus and Putsis, Jr. 1999) studied the effect of new products’ 
introduction and products’ varieties from a marketing point of view. The target of the research 
was the personal computer industry. The researcher investigated the effect from the seller 
perspective. They proposed a three-equation simultaneous system that captures both the 
determinants and market outcomes from decisions of a product line in a company. While 
marketing is trying to measure the outcomes from introducing a new item and estimate profit 
margins from selling the item, the purpose of this research is to understand effects of introducing 
a new item and the cost of adopting it in a healthcare provider. Healthcare organizations want to 
adopt/drop items that minimize total cost associated. This research investigates the problem from 
two perspectives (physicians and supply chain professionals in healthcare) to first provide insight 
on the problem. Then to address areas and practices that can be investigated more to make 
progress in building solutions. 
Lack of research done on the PPI problem, especially solid mathematical modeling and even 
problem characterization with its attributes, is what triggered choosing the survey methodology. 
Justification and explanation of the methodology chosen in this study are found in the next 
section.  
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2.3 Method of Research 
To gain insight into factors and practices affecting PPIs selection and management processes 
from physicians and supply chain professionals’ perspectives, the survey method was employed. 
Due to limit in time and budget, just two interviews were conducted with two supply chain teams 
from two different main hospitals in the area of North West Arkansas. An understanding of the 
problem was developed to help in structuring the questions in the surveys. As a result of these 
interviews, researchers’ discussions and literature review, two different surveys were developed 
targeting two different populations namely, physicians and supply chain professionals. Both 
surveys were pretested for poorly worded questions, redundant questions, as well as missing 
questions by a physician, supply chain professional from the healthcare sector, graduate students, 
self-critiques and finally by the research committee. Responses to requests for feedback were 
considered in improving the survey, as well as refining questions to use language consistent with 
healthcare sector terminologies. The final survey instrument contained 25 questions for 
physicians, and 44 for supply chain professionals and were both administrated online. Specific 
surveys’ items were tailored to respondents; that is, conditional and skip logic was employed to 
show questions based on responses to previous items.  
 
Data Collection 
The survey was implemented and distributed electronically using the web-based tool from 
Qualtrics through University of Arkansas license (uark.qualtrics.com). It was released on June 
2014 and was available through June 2015. It was distributed to two hospitals in the North West 
Arkansas region, as well as to a list of randomly selected 4000 surgeons through a database 
company, and through agencies like AHRMM and SMI for the supply chain professionals’ 
survey. Individuals received an email that stated the purpose of the survey, how long it is 
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expected to take, contact information of researchers, and a link to take to the online survey. 
Respondents for the physicians survey were often surgeons (general, orthopedic, cardiovascular, 
and other specials), and for the supply chain survey were mainly vice presidents and directors 
(few managers and executives). 
 
Survey Sample 
Responses were received from 41 physicians and 47 supply chain professionals, and more 
than total 20 responses from physicians and 30 from SC which were deleted because no answers 
were provided, indicating the survey was opened and closed but not completed, and 7 responses 
from physicians and 8 from SC were also deleted as they partially answered the survey with very 
few questions. Final counts are 39 completed and 2 partially completed surveys from physicians, 
and 46 completed and 1 partially completed from SC. The median response time for the 
physicians’ survey was 7 minutes, mode was 5 minutes, and trimmed mean of 12 minutes. The 
median response time for the supply chain professionals’ survey was 10 minutes, mode of 8 
minutes, and trimmed mean of 15 minutes. Expected time was 5-10 minutes for the physicians’ 
survey and 10-15 minutes for the SC professionals’ survey. The lowest physicians question’s 
response rate was for the specialization question with 60%; this could be due to the fact that 
specialization is not easy to explain with one or two words. For the supply chain survey, the 
lowest response rates were for the questions asking about ABC classification practice (56%). 
This could be due to lack of knowledge about the practice or because the practice is not 
employed explicitly. 
These responses were received from a total of 16 states, with highest contribution from 
Arkansas, Missouri, and Ohio. Table  2.1 below shows a breakdown of Physicians’ based on 
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specialty, region, and gender with the corresponding breakdown reported by (Erikson, Jones and 
Tilton 2012). 
 
Table  2.1 Physicians’ Survey Respondents breakdown and comparison 
Characteristic Type Respondents’ n (%) Comparison % 
Specialty General surgery 10 (34.5) 3.3 
 
Orthopedic Surgery 5 (17.2) 2.5 
 
Cardiovascular Disease 2 (6.9) 2.7 
 
Hematology & Oncology 2 (6.9) 1.6 
 
Plastic Surgery 2 (6.9) 0.9 
 
Other 8 (27.6) 89 
State AR 15 (39.5) 0.7 
 
MO 5 (13.2) 1.9 
 
OH 4 (10.5) 3.8 
 
NY 2 (5.3) 8.5 
 
Other 12 (31.6) 85.1 
Sex Male 27 (71.1) 69.6 
  Female 11 (28.9) 30.4 
 
Except for the sex percentages, the survey response set shows a notable difference than the 
expected percentages according to active physicians in the US. The total estimated number of 
active physicians in the US as of 2012 is 799472; which explain the deviation due to the small 
sample collected. A possible explanation for the higher response rate from AR is the direct 
relationship of researchers with a local network of hospitals. 
Table  2.2 presents a breakdown of SC respondents’ healthcare organizations characteristics 
with a comparison to the actual percentages for US hospitals found in (National Center for 
Health Statistics 2011). 
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Table  2.2 SC professionals survey respondents’ breakdown and comparison 
Characteristic Type Respondents’ n (%) Comparison % 
Size of Organization 
(Number of beds) 
< 100 4 (9.8) 51.1 
100-300 6 (14.6) 32.8 
>300 31 (75.6) 16.1 
Size of Organization 
(Revenue) 
<$100M 6 (16.2) 
 $101M - $500M 5 (13.5) 
 $501M - $1B 5 (13.5) 
 >$1B 21 (56.8) 
 
Department's Annual 
Purchasing Budget 
<$5M 9 (20.9) 
 $5M - <$20M 9 (20.9) 
 $20M - <$50M 4 (9.3) 
 >$50M 21 (48.4)   
Organization setting 
National 9 (20) 
 Rural 10 (22.2) 35 
Suburban 13 (28.9) 
 Urban 8 (17.8) 
 Other (Small Community) 5 (11.1)   
 
 
Data Analysis 
The physicians’ survey contained 25 items which can be categorized as: demographic, 
preference characterization, role in the decision, and cost information. The supply chain 
professionals’ 44-item survey consisted of the categories: demographic, SKU and PPI influence, 
and a major component about practices in managing PPIs. Where appropriate, the “other” option 
was provided in a subset of both surveys’ questions giving respondents the opportunity to add 
text and clarify their response provided. The provided text in these “other” responses were 
analyzed and assigned to predefined categories when possible. Most questions were provided 
using a Likert scale of 1-7, where 4 was the midpoint or neutral.  
Observations of the two populations about interesting problem’s variables were reported 
using appropriate descriptive techniques like: frequency tables, bar charts, and measures of 
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central tendency and dispersion. Each survey’s responses were segmented where appropriate by 
specific responses’ or organization’s characteristics to recognize/capture any association that 
existed in how physicians and SC professionals manage PPI to these characteristics. Physicians’ 
survey responses were segmented where appropriate by available characteristics like years of 
experience (<2, 2-5, 6-10, 11-20, >20), organization’s setting (rural, suburban, urban), 
employment type (hospital employed, contracted physician group, community physician), gender 
(male, female), and compensation model (Per wRVU, percentage of net collections, percentage 
of practice, percentage of gross charges, per encounter, guaranteed base plus incentives). SC 
survey responses were also segmented by years of experience (<2, 2-5, 6-10, 11-20, >20), 
organization’s setting (rural, suburban, urban), job title (Executive, vice president, director), 
gender (male, female), and annual purchasing budget (<$500k, $500k-$1M ...) to identify any 
pattern that existed in how SC professionals are managing PPIs and how they think it should be 
managed to these characteristics. Organization’s size is a characteristic that may be considered 
for both surveys. Interesting variables could be tested for any expected relationship with other 
variables that may be expected to be a cause other than the mentioned characteristics. Similar 
variables in both surveys were investigated for any differences between the perspectives from the 
two populations. 
Appropriate inferential statistical tests were employed throughout the analysis to investigate 
interesting hypotheses. Statistical tests were selected based on the fact that the data in this 
research is basically ordinal or nominal, which implies the use of nonparametric techniques. 
However, when appropriate, Likert scale data type was treated as interval data for purposes of 
using parametric tests. Researchers have stated that it is acceptable to be considered as interval 
data (Rea and Parker 2005). This is a debatable issue, and according to the same source, there are 
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three assumptions that should be made in order to consider a Likert scale as interval data. In this 
research these assumptions were adopted. For example, median or mode are used with ordinal 
data, however, mean was calculated sometimes from Likert scale data. Manipulating scaled 
responses (ex, Likert scale) as interval data has become accepted because the costs associated 
with overlooking these technicalities are far outweighed by the power of information obtained 
(Rea and Parker 2005). Appropriate nonparametric tests were employed to analyze data and 
investigate any significant result. It is known, nonparametric tests are more robust than 
corresponding parametric ones, however they lack the power (making type II error) when sample 
size <15. However, nonparametric tests become as powerful as the parametric tests when sample 
size is higher than 15 which is the case in this research. Consequently, it is an advantage in this 
research to use nonparametric tests, since the sample size is >15. 
A one-way χ2 test was used for many questions to identify if sizes of categories (number of 
responses in each category) are statistically different within the same question. One-sample sign 
test was also used to test if the median scored is statistically significantly different than the 
neutral score. Contingency tables were used along with a two-way χ2 analysis, to verify any 
relationship between two interesting variables by determining if the association/dependence 
between these two variables is statistically significant. Specifically, patterns were investigated 
for variables by characteristics which were mentioned earlier. Cramer’s V is a measure of the 
strength if any association found by the χ2, which was calculated for each association that was 
found to be statistically significant. Due to the small sample size, a major part of response 
categories received fewer responses than required to make expected count values for each cell of 
the contingency table, fall above generally accepted threshold values. A Likert scale 1-7 was 
used in most questions in both surveys, consequently, response categories of scale 1, 2 and 3 
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were combined together, and 5, 6, and 7 were combined together to eliminate the problem. Also 
for this reason, all “other” responses that did not fall in well-defined categories were excluded 
from this analysis. A 95% confidence level was adopted in the analysis; it represents a 
reasonable balance between the risks associated with type I & II errors and that makes it fairly 
well accepted by researchers (Rea and Parker 2005). Each contingency table included 
corresponding χ2 values with their associated p values. Since α=0.05, p values of less than 0.05 
implies a statistically significant relationship between the two variables.  
Chi-square test is built for nominal data, it identifies significance in data when observed 
values differ sufficiently from expected ones. It does not tell anything about any trend behavior 
the data may have when dealing with categorical data. When the data is categorical and trends 
being analyzed, as mostly in this research, Gamma (γ) is a more appropriate test (Rea and Parker 
2005). Gamma is the measure of association strength, like Cramer’s V in the χ2 case, and a z 
score calculated from γ is the significance test. A Gamma test was performed along with the χ2 
for every contingency table where a significant relationship was detected; this will give more 
support for any conclusion. 
The Mann-Whitney U-test was used to compare rankings of both populations for common 
questions between the two populations. The Kruskal-Wallis test, the nonparametric test analogue 
to the one-way independent measures ANOVA (parametric test), was also used to compare 
groups’ medians for a specific variable within the same population. The one-way ANOVA itself 
was also used whenever the Kruskal-Wallis test was used. 
 
2.4 Survey Research Findings 
Results for selected items like demographic, factors affecting physicians’ preference, 
physicians perspective of the decision process, supply chain professionals’ perspective, and SC 
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best practices potentially affect the management of PPIs items are discussed. Items are discussed 
for each population separately, except where there were common questions/variables for both; 
the results will be compared and discussed directly. 
 
Demographics 
The physicians’ demographic information collected included specialization, healthcare 
provider type, compensation model, size of organization, years of experience, gender, 
employment type, and organization’s settings. Most common specializations of those who 
responded are orthopedic surgery, general surgery, and plastic surgery. Of the total physicians 
who responded, 71% were males and 29% females. Compensation model types of responded 
physicians in along with years of experience are indicated in Table  2.3. Of the total physicians, 
56% have experience more than 20 years, and 89% have experience of 11 years or more. This 
result is particularly good since more experienced physicians probably have faced more issues 
and used more items, and they are more likely to give a more realistic input. Physicians with 
compensation model “Guaranteed base plus incentives” and “Per wRVU (work relative value 
units)” make up 51.4% and 23.1% of respondent, respectively. 
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Table  2.3 Compensation model and years of experience 
  Compensation model   
Years of 
Experience 
Per wRVU (per 
work relative 
value units) 
Percentage of 
net collections 
Percentage of 
practice “bottom 
line” 
Per 
encounter 
Guaranteed base 
plus incentive n (%) 
<2 1 0 0 0 0 1 (2.6) 
2-5 0 1 0 0 2 3 (7.7) 
6-10 0 0 0 0 0 0 (0.0) 
11-20 6 1 1 1 4 13 (33.3) 
>20 2 1 4 1 14 22 (56.4) 
n (%) 9 (23.1) 3 (7.7) 5 (12.8) 2 (5.1) 20 (51.3)   
 
 
Breakdown of organizations’ settings and employment types is shown in Table  2.4. 
Physicians from organizations located in urban areas contributed most to the questionnaire with 
59% of total responses. Participants from other areas are close in number of responses. 
Hospitals’ employed and community physicians were the major employment types for 
physicians, with 51.3% and 23.1%, respectively. 
 
Table  2.4 Organizations' settings and employment model 
  Organization's Settings 
Employment Type 
National Rural Suburban Urban Other (Small Community) n (%) 
Hospital Employed 3 3 2 11 1 20 (51.3) 
Contracted physician group 0 0 0 3 0 3 (7.7) 
Community physician 1 1 4 3 0 9 (23.1) 
Other (Academic and 
Private practice) 1 0 0 6 0 7 (17.9) 
n (%) 5 (12.8) 4 (10.3) 6 (15.4) 23 (59.0) 1 (2.6) 39 (100.0) 
 
Regarding the healthcare provider type, academic institution was mentioned 18 times, 
hospital/medical center was mentioned 22 times, acute care facility 5 times, health 
system/Network (IDS/IDN) 5 times, and Military/VA/Government affiliated 3 times. In terms of 
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organization’s size, most common (47%) number of beds was (301-600), while number of 
employees reported was for the category (301-600 ~ >1500) with 31%.  
The supply chain professionals’ demographic information collected included type of 
healthcare provider, size of organization, years of experience, job title, gender, department’s 
annual purchasing budget, and organization’s setting. Regarding the healthcare provider type, 
hospital/medical center was mentioned 19 times, acute care facility 12 times, academic 
institution was mentioned 8 times, and health system/Network (IDS/IDN) 23 times. Size of 
organization question included 4 drop down menus: number of beds, annual revenue, number of 
employees, and percentage of spend on PPIs.  A breakdown of number of employees by number 
of beds, and percentage of spend on PPI items by annual revenue are shown in Table  2.5.  
 
Table  2.5 Breakdown of number of employees by number of beds and % of spend on PPI items 
by annual revenue 
 
From the first part, it is obvious that the SC professionals from the very big healthcare 
organizations contributed more to the input. This put the importance of this problem in the top 
tier issues and big scale problems of large size healthcare organizations. With regard to the spend 
on PPI items, more than 35% said their spend on PPI items is more than 30% of total spend. 
Such a result by its own establishes the importance of this problem and justifies the big concern 
and interest in this issue by healthcare organizations. 
Male respondents were 70% of the total respondents, while females were 30%. Respondents’ 
job titles showed that 89% have a director position or higher, with 45% of total respondents are 
Number 
of beds
1-99 100-499 500-1500 >1500 n (%)
Annual 
Revenue
<10% 10%-20% 21%-30% 31%-40% >40% n (%)
< 100 1 1 2 0 4 (9.8) <$100M 1 0 2 3 0 6 (16.2)
100-300 0 3 2 1 6 (14.6) $101M - $500M 1 1 1 2 0 5 (13.5)
301-600 0 1 0 8 9 (21.9) $501M - $1B 0 1 1 1 2 5 (13.5)
601-1000 0 0 0 4 4 (9.8) >$1B 2 7 7 3 2 21 (56.8)
>1000 0 0 0 18 18 (43.9)
n (%) 1 (2.4) 5 (12.2) 4 (9.8) 31 (75.6) 41 (100) n (%) 4 (10.8) 9 (24.3) 11 (29.8) 9 (24.3) 4 (10.8) 37 (100)
Number of employees Percentage of spend on PPI items
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directors and 39% vice presidents; this gives a more validity to responses since that these are the 
kind of stakeholders who are generally involved in the decision process. Department’s annual 
purchasing budget was greater than $50M for 49% of total respondents. More than 81% have 
experience in the healthcare industry of or more than 11 years, 50% of total responses indicated 
they have experience of 20 years or more. This demographic info is supportive, since we can rely 
on the fact that respondents have enough experience to recognize the SKU problem and also 
have faced the issue of PPIs. More results and graphs from both surveys, which were not 
discussed in the body of this chapter can be found in Appendix E: Surveys’ Extra Results and 
Analysis. 
 Physicians Perspective 2.4.1
A table that summarize the results from all individual questions showing median, low score 
and high score percentages, and both the one-sample sign and one-way 𝜒2 tests is shown in 
Appendix E.1: Physicians. 
 
Preference characterization/behavior 
Information collected regarding physicians’ preference behavior included awareness of the 
term PPI, willingness to use available brands in stock other than the preferred, permission to 
order preferred brand, factors affecting physicians’ preference, willingness to use functionally 
equivalent item which comes from a different manufacturer, and reasons that make a physician 
switch to another brand. 
When asked how aware you are of the term PPI, on a scale of 1-7, around 73% of physicians 
indicated that they are aware with 38% are highly aware, the median score was 5. A one-sample 
sign test was performed with null hypothesis H0 that median equals 4 (The neutral score), versus 
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H1 that the median is greater than 4. The resulting p-value was 0.001; H0 was rejected in favor of 
H1, this means that the calculated median is significantly greater than 4, which supports the 
conclusion that physicians have some feelings of awareness. A one-way χ2 test was also 
performed to check if data obtained is not uniformly distributed and representing the population. 
The H0 is that the distribution of categories is uniform, versus H1 not uniformly distributed. The 
resulting p-value was 0.00, H0 was rejected in favor of H1, the awareness level is not uniformly 
distributed across the population, this could mean that results were not obtained by chance, and 
there is a little skewness of awareness level toward highly aware. The same two tests will be 
done on each question, and the results will be mentioned in a shorten format. A breakdown of the 
awareness of physicians in the term PPIs by related characteristics is shown in Table  2.6 below. 
The awareness (dependent variable) was supposed to be in rows and the characteristics 
(independent variables) were supposed to be in columns, but both were swapped for formatting 
purposes. The same contingency table setup will be followed in all following analysis for 
consistency. The results indicate that awareness of the term PPI does not depend on any of these 
characteristics. 
Table  2.6 Awareness of the term PPI by physicians' characteristics 
 
Total
Characteristic Categories
Per wRVU 2 (22.2) 0 (0) 7 (77.8) 9 χ2 = 10.47 df=10, p= 0.40
% of net collections 0 (0) 0 (0) 3 (100) 3 Cramer's V = NA
% of practice "bottom line" 1 (20) 0 (0) 4 (80) 5
% of gross charges 0 0 0 0
Per encounter 0 (0) 1 (50) 1 (50) 2
Guaranteed base plus incentive 5 (25) 1 (5) 14 (70) 20
Total 8 2 29 39
< 2, 2 - 5, 6-10 3 (75) 0 (0) 1 (25) 4 χ2 = 8.34 df=4, p= 0.08 γ = 0.49
11-20 2 (15.4) 1 (7.7) 10 (76.9) 13 Cramer's V = NA Z = 0.88
> 20 3 (13.6) 1 (4.5) 18 (81.8) 22 No Association
Total 8 2 29 39
Male 4 (14.8) 1 (3.7) 22 (81.5) 27 χ2 = 3.33 df=4, p= 0.50
Female 4 36.4) 1 (9.1) 6 (54.5) 11 Cramer's V = NA
Prefer to not answer 0 (0) 0 (0) 1 (100) 1
Total 8 2 29 39
Hospital employed 4 (20) 1 (5) 15 (75) 20 χ2 = 3.56 df=4, p= 0.47
Contracted physician group 2 (66.7) 0 (0) 1 (33.3) 3 Cramer's V = NA
Community physician 2 (22.2) 1 (11.1) 6 (66.7) 9
Total 8 2 22 32
National 1 (20) 1 (20) 3 (60) 5 χ2 = 2.92 df=6, p= 0.82
Rural 1 (25) 0 (0) 3 (75) 4 Cramer's V = NA
Suburban 1 (16.7) 0 (0) 5 (83.3) 6
Urban 5 (21.7) 1 (4.3) 17 (73.9) 23
Total 8 2 28 38
No Association
No Association
No Association
χ2 Analysis Gamma Analysis (If applicable)
Compensation model
Neutral 4
n (%)
5, 6, 7 Highly aware
n (%)
Not aware 1, 2, 3
n (%)
No Association
No Association
Years of experience
Gender
Employment type
Organization's setting?
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On the SC side, when they were asked about their awareness in the PPI term, 100% of SC 
professionals indicated that they are aware with 94% are fully aware. The one-sample sign test 
gave a p-value of 0.00, and one-way χ2 test also gave a p-value of 0.00, this means that SC 
professionals are highly aware of the term and the data represents the population. The SC 
professionals’ awareness of the term was found to have no association with any of the 
characteristics mentioned earlier. 
Both populations have strong feelings toward awareness of the term, however a Mann-
Whitney U-test showed that the ranks from the two populations are statistically significantly 
different with p = 0.00 and Z=-4.719. Since the sample size is greater than 20, MW U-test 
follows a z distribution; and for the two-tail test, H0 is rejected if Z < -Zα/2 or Z > Zα/2. The H0 
that there is no difference was rejected in favor of the H1. Higher awareness within physicians’ 
population was expected as the term was thought to be more related to clinical staff than SC. 
However, a higher awareness within SC professionals’ community was observed; this makes 
more sense that this is essentially a SC issue and its ramifications directly affect the SC 
performance within the organization. Physicians focus more on getting items and do not 
necessarily consider the effects of their decision on SC performance. 
Regarding physicians’ willingness (Q2) to use available items in stock even if it is not their 
preferred brands, 59% indicated that they are willing to use available items. A one-sample sign 
test gave a p-value of 0.00, and a one-way χ2 test also gave a p-value of 0.00. This indicates that 
the median is statistically significantly greater than 4 and the data is significant, which mean that 
physicians have noticeable willingness to adopt available items in stock. A breakdown of 
physicians’ willingness to use available items by related characteristics is show in Table  2.7 
below. The results show that physician’s willingness to use available items in stock only depends 
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on how many years the physician has worked. Strong association was recognized by the gamma 
analysis, and since γ is positive, this means that the more experienced the physician is, the more 
he/she is willing to use whatever items are available in stock. Physician’s skills gained through 
experience increase their ability to use other non-preferred items and adapt to the item with 
minimal effort. Organizations may want to pay more attention to training physicians to better 
manage PPIs, and consequently more effectively moving to standardized items. Figure  2.1below 
shows a bar stack chart for the physicians’ willingness versus experience. 
 
Table  2.7 Physicians' willingness to use available items by physicians' characteristics 
 
 
Total
Characteristic Categories
Per wRVU 3 (33.3) 2 (22.2) 4 (44.4) 9 χ2 = 16.18 df=10, p= 0.09
% of net collections 0 (0) 2 (66.7) 1 (33.3) 3 Cramer's V = NA
% of practice "bottom line" 0 (0) 3 (60) 2 (40) 5
% of gross charges 0 0 0 0
Per encounter 1 (50) 0 (0) 1 (50) 2
Guaranteed base plus incentive 0 (0) 5 (25) 15 (75) 20
Total 4 12 23 39
< 2, 2 - 5, 6-10 1 (25) 2 (50) 1 (25) 4 χ2 = 9.34 df=4, p= 0.05 γ = 0.68
11-20 3 (23.1) 5 (38.5) 5 (38.5) 13 Cramer's V = 0.346 Z = 1.98
> 20 0 (0) 5 (22.7) 17 (77.3) 22 Strong Association
Total 4 12 23 39
Male 4 (14.8) 7 (25.9) 16 (59.3) 27 χ2 = 4.28 df=4, p= 0.37
Female 0 (0) 4 (36.4) 7 (63.6) 11 Cramer's V = NA
Prefer to not answer 0 (0) 1 (100) 0 (0) 1
Total 4 12 23 39
Hospital employed 1 (5) 5 (25) 14 (70) 20 χ2 = 1.99 df=4, p= 0.74
Contracted physician group 0 (0) 1 (33.3) 2 (66.7) 3 Cramer's V = NA
Community physician 1 (11.1) 4 (44.4) 4 (44.4) 9
Total 2 10 20 32
National 2 (40) 1 (20) 2 (40) 5 χ2 = 7.36 df=6, p= 0.29
Rural 0 (0) 2 (50) 2 (50) 4 Cramer's V = NA
Suburban 0 (0) 3 (50) 3 (50) 6
Urban
2 (8.7) 6 (26.1) 15 (65.2) 23
Total 4 12 22 38
No Association
No Association
Compensation model
Not willing 1, 2, 3
χ2 Analysis Gamma Analysis (If applicable)
n (%)
No Association
Moderate Association
No Association
Neutral 4
n (%)
5, 6, 7 Very willing
n (%)
Years of experience
Gender
Employment type
Organization's setting?
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Figure  2.1 Willingness of physicians to use available items in stock versus experience 
 
When asked if they are permitted to order whatever they want if the item in stock is not their 
preferred brand, 83% said they are sometimes permitted to order, while 10% said they are not 
permitted and 7% said yes. Both one-sample sign and one-way χ2 tests gave p-values of 0.00, 
which means that the result is statistically significant and indeed the majority is partially allowed 
to order their preferred brands. No association of ordering permission with any characteristic was 
recognized by the two-way χ2. 
A breakdown of physicians’ willingness to use available items in stock by two variables, 
namely awareness of the PPI term and ordering permission is shown in Table  2.8 below. Results 
show that there is not an association with the physicians’ level of awareness in the term, while 
there is a relatively strong association according to Cramer’s V, with the ordering permission. 
When limitation on what physicians are permitted to order takes place, they will be more willing 
to use available items. 
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Table  2.8 Willingness to use available items in stock by permission to order and years of 
experience 
 
A key goal for this research was to determine the factors that affect physician’s preference. 
When asked, physicians rated factors as shown in Figure  2.2 below. Items’ effectiveness and 
previous experience are the highest rated factors, and other factors mentioned were ease of 
application and long term availability. The Kruskal-Wallis (K-W) test, a nonparametric test, was 
performed to investigate if the differences among the groups’ medians are statistically 
significant. Null and alternative hypothesis are H0: the population medians are all equal, and H1: 
the medians are not all equal. The test statistic (H) had a p-value of 0.000, both unadjusted and 
adjusted for ties, providing sufficient statistical support to reject H0 in favor of H1, and 
concluding that there is at least one statistical significant difference among factors. The sample 
medians for the five factors affecting physician’s item selection preference were calculated and 
shown on Figure  2.2. A box-plot for the same results is included below in Figure  2.3. 
The z-value for “knowledge of item cost” factor is -0.77, the smallest absolute z-value, which 
indicates that the average rank for this factor differed least from the average rank for all 
observations. With the lowest z-value of -7.69, the average rank for “relationship with sales 
representative” was lower than the average rank for all other factors. With a z-value of 5.76, the 
average rank for “Item’s effectiveness” factor was higher than the mean rank for all factors. 
Assuming that the data can be manipulated with parametric tests as discussed earlier, ANOVA 
was also performed and showed that there is statistical evidence (p=0.00) of at least one 
Total
Characteristic Categories
Not aware 1,2,3 2 (20) 4 (40) 4 (40) 10 χ2 = 5.88 df=4, p= 0.21 γ = 0.43
Neutral 4 1 (50) 0 (0) 1 (50) 2 Cramer's V = NA Z = 0.76
Highly aware 5,6,7 2 (6.3) 9 (28.1) 21 (65.6) 32 No Association
Total 5 13 26 44
Yes 2 (66.7) 1 (33.3) 0 (0) 3 χ2 = 17.6 df=4, p= 0.00
No 2 (40) 0 (0) 3 (60) 5 Cramer's V = 0.447
Sometimes 1 (2.8) 12 (33.3) 23 (63.9) 36
Total 5 13 26 44
Gamma Analysis (If applicable)
n (%) n (%) n (%)
Awarness of PPI term
No Association
Ordering permission
Relatively Strong Association
Not willing 1, 2, 3 Neutral 4 5, 6, 7 Very willing
χ2 Analysis
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significant difference among factors’ means,  which is consistent with the result from the K-W 
test. In other research, factors affecting and considered in the PPI selection decision process by 
physicians and other stakeholders as well, are analyzed in detail. The purpose is to develop a 
decision framework to improve the item’s selection process. 
 
 
Figure  2.2 Factors that affect physician's selection (preference) 
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Figure  2.3 Box-plot of factors that affect physician's selection (preference) 
 
All factors were analyzed using one-sample sign test and one-way χ2 test, both tests gave p-
values <0.05 for all factors except the χ2 for the “Item’s manufacturer reputation” factor. Factors’ 
medians are statistically significantly deviated from the neutral, which means all factors are 
important except the “Relationship with sales representative” which is not important. Scoring for 
all factors is significant and non-uniformly distributed except for the “Item’s manufacturer 
reputation” which indicates a uniform distribution among rankings; it could be unrepresentative 
of the true population or the physicians are not agreeing on this direction. A breakdown of all 
factors by all characteristics were conducted and results indicated that there is no association 
between any of the factors with any of the characteristics, except for the “Item’s cost knowledge” 
with the years of experience.  The following table, Table  2.9, is a breakdown of the “Knowledge 
of item’s cost” factor by years of experience. The χ2 indicates that there is a moderate 
association, which means a more experienced physician may consider the item’s cost 
significantly more important in his decisions than a lower experienced physician. This specific 
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result is consistent with the one obtained in Table  2.7, where more experienced physicians are 
more willing to use whatever is available in stock. 
 
Table  2.9 Factors affecting physician's preference (knowledge of item’s cost) by experience 
 
Another survey item (Q8) collected information on physicians’ willingness to substitute an 
item from stock which is not their preferred brand but functionally equivalent. This is similar to 
the item in Table  2.7, but that item was general while this item added the word “functionally 
equivalent”. Of the total 40 respondents who answered this question, 90% indicated that they are 
very willing to substitute their preferred brand, 2.5% said not, and 7.5% were neutral. A one-
sample sign test and one-way χ2 test both gave p-value of 0.00. This indicates that the results are 
significant and not uniformly distributed, and that the median score is statistically significantly 
greater than 4. This result is consistent with the one in question 2, except that physicians became 
more willing to use another brand given it is functionally equivalent. A Mann-Whitney U-test 
was performed to investigate if there is a difference between the ranks of the two items. The 
resulting test statistic U=457.5, Z=-3.43, and p-value=0.00 provide enough statistical evidence to 
reject H0 and accept H1, which means that there is a difference between the ranks. In other 
words, a physician became more willing to substitute his/her preferred brand once he is 
convinced that it is functionally equivalent. According to the two-way χ2 analysis, physician’s 
willingness to use another functionally equivalent brand is moderately associated with the 
physician’s experience. 
Total
Characteristic Categories
< 2, 2 - 5, 6-10 0 (0) 0 (0) 4 (100) 4 χ2 = 10.46 df=4, p= 0.03 γ = 0.38
11-20 2 (15.4) 6 (46.2) 5 (38.5) 13 Cramer's V = 0.366 Z = 0.61
> 20 0 (0) 4 (18.2) 18 (81.8) 22 No Association
Total 2 10 27 39
Not important 
1,2,3
Neutral 4 5,6,7 Very 
important χ2 Analysis Gamma Analysis (If applicable)
n (%) n (%) n (%)
Years of experience
Moderate Association
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A follow-up item collected information on how willing physicians are to permanently drop a 
brand and adopt another one. A significant portion (70.7%) said they are highly willing, when 
19.5% were unsure (neutral) and (9.8%) were not willing to drop their preferred brand. This 
result supports the findings from the previous results found above in this research in that 
physicians are more than willing to drop their preferred brand. A one-sample sign test and one-
way χ2 test gave p-values of 0.00 and 0.04, respectively. This confirms that the willingness level 
is not uniformly distributed or in other words the results were not obtained by chance, and the 
score median is significantly greater than 4. The breakdown contingency table and χ2 analysis 
showed that there is no association between the physicians’ willingness to drop their preferred 
brand and any of the characteristics. 
Examining item 4, on rating factors’ importance for physicians when selecting an item, 
another item was asked to collect information on reasons that would cause physician switching to 
another brand. The available options were (easier to use, more features, being produced by a 
reputable manufacturer, safer for patient, cheaper, and expected to give better results for the 
patient). Scores’ means for all factors are shown below in Figure  2.4. As expected, patient’s 
related aspects are the most important followed by the ease of use. Respondents also mentioned 
product support as an important factor in encouraging the physician to switch. The Kruskal-
Wallis (K-W) test was performed and the resulting test statistic (H) had a p-value of 0.000, both 
unadjusted and adjusted for ties, providing sufficient statistical support to reject H0 in favor of 
H1, and concluded that there is at least one statistical significant difference among factors.  
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Figure  2.4 Factors that would make a physician to switch to another brand 
 
The z-value for the easiness of use factor was 1.08, the smallest absolute z-value, which 
indicates that the average rank for this factor differed least from the average rank for all 
observations. With the lowest z-value of -6.39, the average rank for “Being produced by a 
reputable manufacturer” was lower than the average rank for all other factors. With a z-value of 
5.2, the average rank for “Expected to give better results for the patient” factor was higher than 
the mean rank for all factors. Assuming that the data can be manipulated with parametric tests as 
discussed earlier, ANOVA was also performed and showed that there is statistical evidence 
(p=0.00) of at least one significant difference among factors’ means  which is consistent with the 
results from the K-W test. All factors were analyzed using the one-sample sign test, the p-value 
was <0.05 for all except for “Being produced by a reputable manufacturer”. This indicates that 
all reasons could contribute to make the physician switch except knowing that it is from a 
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reputable manufacturer with score’s median at neutral. This result is actually consistent with the 
previous indications found above in this research in that the manufacturer reputation being not 
important to physicians. A one-way χ2 test was also conducted and gave p-values <0.05 for all 
factors which indicates that results were significant and were not obtained by chance. Two-way 
χ2 analysis of the contingency tables of all factors by all characteristics indicated that there is no 
association between any of the factors with any of the characteristics. This means that physicians 
agree on the importance pattern of these factors when considering switching to another brand. 
Another item was included in the questionnaire to learn to what extent physicians consider 
patients’ preference when selecting the right item. When asked how important the patient’s 
preference is to you in deciding which item will be used directly on the patient, 32.5% said it is 
very important, 42.5% said it is not important, and 25% were neutral. A one-sample sign test and 
one-way χ2 test resulted in p-values>0.05, which indicates that the importance levels are 
uniformly distributed and the median actually equals 4. The unimportance of patient’s preference 
for physicians could come from the physician’s experience and knowledge of what is more 
appropriate for the patient. Patient’s opinion is important for those extra features and life quality 
issues with the item. A breakdown of patient’s opinion importance to physicians when selecting 
their preferred items by question 10 (reasons that make a physician switch – specifically the 
reason “being produced by a reputable manufacturer”) is shown in Table  2.10 below. A moderate 
association was recognized by the χ2 analysis. This means that for those who said patient’s 
preference is not important, manufacturer reputation is important when selecting the item.  This 
could mean that when physicians totally depend on their opinion, it is more likely that they are 
affected by manufacturer reputation factor. Yet, gamma analysis has indicated that there is no 
association between the two aspects. 
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Table  2.10 Reason for a physician to switch (Being produced by a reputable manufacturer) by 
patient's preference 
 
 
Role in decision 
Information collected regarding the physicians perspective of their role in the organization’s 
decision included how knowledgeable the physician was about how the selection process takes 
place, physician’s perceived ability to influence the decision, and their opinion about important 
factors that are considered by the organization when making the decision. 
When asked how knowledgeable they are about how the organization decides to select the 
item, 53.7% of respondents said they are knowledgeable, 29.3% said they are not, and 17.1% 
were neutral (unsure). The median score was 4 and a one-sample sign test confirmed this result 
by giving a p-value of 0.12. Physicians in general think they are not knowledgeable enough on 
the decision process. A one-way χ2 test indicated that the results are not significant and 
uniformly distributed. The breakdown of physicians’ knowledge level with physicians’ 
characteristics did not show any significant association, and the only close association was with 
experience with a p-value of 0.06. 
When asked about their ability to influence the decision to stock and use an item, 48.8% of 
physicians indicates that they are highly able to influence the decision, 26.8% said they are not, 
and 24.4% are not sure (neutral). Both one-sample sign and one-way χ2 tests gave p-values>0.05, 
which indicates that the data is uniformly distributed across the population and the score median 
is actually 4. A χ2 and γ analyses were conducted to determine whether the physicians’ ability to 
influence the decision depends on physicians’ characteristics. The results, presented in 
Total
Characteristic Categories
Not important 1,2,3 7 (41.2) 0 (0) 10 (58.8) 17 χ2 = 12.08 df=4, p= 0.02 γ = -0.30
Nuetral 4 2 (20) 4 (40) 4 (40) 10 Cramer's V = 0.389 Z = -0.50
Very important 5,6,7 8 (61.5) 1 (7.7) 4 (30.8) 13
Total 17 5 18 40
No Association
Not important 
1, 2, 3
Neutral 4
5, 6, 7 Very 
important χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
Patient's preference 
importance to 
physicians decision Moderate Association
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Table  2.11, indicate that there is association with two characteristics, which are experience and 
employment type. A relatively strong association with physician’s experience was recognized, 
the more experience the physician has, the more able he/she is in influencing the organization 
decision in item’s selection decision, this result is especially important. 
 
Table  2.11 Physicians ability to influence the organization's decision by different characteristics 
 
 
The importance of this result comes from the previous finding that a more experienced 
physicians is more willing to use whatever is available in stock and more willing to switch to 
another brand. this suggests that solutions to the PPI issue are more likely to be addressed if the 
organization focuses on influencing highly experienced physicians’ preference since they are the 
more influential on the organization’s decision, yet more flexible. Another moderate association 
was found with the employment type. Community physicians seem to be more able to influence 
the decision. A breakdown of physicians’ ability to influence the selection decision by their 
knowledge of the decision process is shown in Table  2.12. Obviously, a strong relationship was 
Total
Characteristic Categories
Per wRVU 2 (22.2) 2 (22.2) 5 (55.6) 9 χ2 = 4.06 df=10, p= 0.94
% of net collections 1 (33.3) 1 (33.3) 1 (33.3) 3 Cramer's V = NA
% of practice "bottom line" 0 (0) 1 (20) 4 (80) 5
% of gross charges 0 0 0 0
Per encounter 1 (50) 0 (0) 1 (50) 2
Guaranteed base plus incentive 7 (35) 4 (20) 9 45) 20
Total 11 8 20 39
< 2, 2 - 5, 6-10 4 (100) 0 (0) 0 (0) 4 χ2 = 14.89 df=4, p= 0.00 γ = 0.64
11-20 5 (38.5) 2 (15.4) 6 (46.2) 13 Cramer's V = 0.437 Z = 1.85
> 20 2 (9.1) 6 (27.3) 14 (63.6) 22
Total 11 8 20 39
Male 7 (25.9) 5 (18.5) 15 (55.6) 27 χ2 = 2.13 df=4, p= 0.71
Female 4 (36.4) 3 (27.3) 4 (36.4) 11 Cramer's V = NA
Prefer to not answer 0 (0) 0 (0) 1 (100) 1
Total 11 8 20 39
Hospital employed 9 (45) 3 (15) 8 (40) 20 χ2 = 9.37 df=4, p= 0.05
Contracted physician group 0 (0) 2 (66.7) 1 (33.3) 3 Cramer's V = 0.383
Community physician 1 (11.1) 1 (11.1) 7 (77.8) 9
Total 10 6 16 32
National 3 (60) 0 (0) 2 (40) 5 χ2 = 7.57 df=6, p= 0.27
Rural 0 (0) 2 (50) 2 (50) 4 Cramer's V = NA
Suburban 2 (33.3) 0 (0) 4 (66.7) 6
Urban 6 (26.1) 6 (26.1) 11 (47.8) 23
Total 11 8 19 38
No Association
Gamma Analysis (If 
applicable)
n (%) n (%) n (%)
Compensation 
model
Years of 
experience
Relatively Strong Association
Gender
No Association
No Association
Low ability 
1, 2, 3
Neutral 4 5, 6, 7 High 
ability χ2 Analysis
Employment type
Moderate Association
Organization's 
setting? No Association
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recognized by the tests, χ2 and γ, meaning that the more knowledgeable the physician, the more 
the physician may influence the decision. 
 
Table  2.12 Physicians ability to influence the decision by their knowledge of the decision process 
 
The third item in this category asked physicians to rate a list of factors according to their 
importance in influencing the organization’s item selection decision. Factors and mean score for 
each are shown in Figure  2.5. Total cost was the dominant factor according to physicians, 
followed by patient’s outcome, then they consider it as an administration decision, and 
physician’s preference came at 4th place with manufacturer reputation and required storage space 
as being not important. A one-sample sign test gave a p-value of <0.05 for all factors which 
confirms that scores’ medians are statistically significantly deviated from the neutral. A one-way 
χ2 test also gave a p-value <0.05 for all factors, this means that scoring on factors is not 
uniformly distributed and the results are significant. 
Total
Characteristic Categories
Not knowledgeable 1,2,3 6 (50) 5 (41.7) 1 (8.3) 12 χ2 = 14.42 df=4, p= 0.01 γ = 0.70
Neutral 4 3 (42.9) 1 (14.3) 3 (42.9) 7 Cramer's V = 0.419 Z = 2.49
Very knowledgeable 5,6,7 2 (9.1) 4 (18.2) 16 (72.7) 22
Total 11 10 20 41
Strong Association
Physicians 
knowledge of how 
the organization 
decides to select Relatively Strong Association
Low ability 
1, 2, 3
Neutral 4
5, 6, 7 High 
ability χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
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Figure  2.5 Factors influencing organization's decision from physicians' perspective 
 
 
A χ2 analysis was conducted to determine whether the factors influencing the organization’s 
selection decision depend on any of the physicians’ characteristics. The only association 
according to α = 0.05 significance level is between the “administration decision” factor and 
physicians employment type characteristic as shown in Table  2.13 below. Relatively strong 
association was found, and community physicians think that item’s selection is an administration 
decision. Community physicians do not really do major treatments or surgeries and generally are 
hired by government, and most probably they are neither included in the decision process nor 
have the need to work with PPIs. This explains their opinion and at the same time could not be 
adopted. 
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Table  2.13 Importance of "Adminstration decision" factor to the organization's decision by 
employment type 
 
 
The difference among groups (factors) was tested using K-W test. The test statistic (H) had a 
p-value of 0.000, both unadjusted and adjusted for ties, providing sufficient statistical support to 
reject H0 in favor of H1, and concluded that there is at least one statistical significant difference 
among factors. The z-value for “Physician’s preference” factor is -0.20, the smallest absolute z-
value, which indicates that the average rank for this factor differed least from the average rank 
for all observations. With the lowest z-value of -5.23, the average rank for “Required storage 
space” was lower than the average rank for all other factors. With a z-value of 5.84, the average 
rank for “Total Cost” factor was higher than the mean rank for all factors. Parametric test 
ANOVA was also performed and showed that there is statistical evidence (p=0.00) of at least one 
significant difference among factors’ means, which is consistent with the result from K-W. 
This same question was asked (Q5) to the SC group and results are as shown in Figure  2.6, 
they rated “patient outcome” as highly important, followed by “physicians’ preference”, and 
“total cost”. The other three factors namely, “manufacturer reputation”, “required storage space” 
and “admiration decision” were not important. One-sample sign test gave a p-value of 0.00 for 
all factors with H1 as greater than 4 for the first three factors, and less than 4 for the other three 
factors, which confirms that scores’ medians are statistically significantly deviated from the 
neutral. A one-way χ2 test also gave a p-value of 0.00 for all factors, this means that scoring on 
factors is not uniformly distributed and the results are significant. A χ2 analysis was performed to 
Total
Characteristic Categories
Hospital employed 6 (31.6) 7 (36.8) 6 (31.6) 19 χ2 = 11.23 df=4, p= 0.02
Contracted physician group 2 (66.7) 0 (0) 1 (33.3) 3 Cramer's V = 0.426
Community physician 0 (0) 1 (11.1) 8 (88.9) 9
Total 8 8 15 31
Gamma Analysis (If 
applicable)
n (%) n (%) n (%)
Low 
importance 
1, 2, 3
Neutral 4
5, 6, 7 Very 
important χ2 Analysis
Employment 
type
Relatively Strong Association
 40 
 
determine whether the factors influencing the organization’s selection decision depend on any of 
the SC characteristics. No association was recognized with any of the characteristics.  
 
 
Figure  2.6 Factors influencing organization's decision from SC perspective 
 
The difference among groups (factors) was tested using K-W test. The test statistic (H) had a 
p-value of 0.000, both unadjusted and adjusted for ties, providing sufficient statistical support to 
reject H0 in favor of H1, and concluded that there is at least one statistical significant difference 
among factors. The z-value for “Total cost” factor is 3.46, the smallest absolute z-value, which 
indicates that the average rank for this factor differed least from the average rank for all 
observations. With the lowest z-value of -5.90, the average rank for “Administration Decision” 
was lower than the average rank for all other factors. With a z-value of 7.09, the average rank for 
“Patient outcome” factor was higher than the mean rank for all factors. The one-way ANOVA 
was also performed and showed that there is statistical evidence (p=0.00) of at least one 
significant difference among factors’ means, which is consistent with the result from K-W. 
Mann-Whitney U-test was performed on each factor for the two groups (SC and physicians) 
and results are shown below in Table  2.14. There is not enough statistical evidence to reject null 
 41 
 
hypothesis and conclude that rankings of the populations are different for the “patient outcome”, 
“manufacturer reputation”, and “required storage space”. This means that they are both agreeing 
on the importance of the patient outcome and unimportance of the other two. On the other hand, 
ranks from the two populations are statistically significantly different for “physicians’ 
preference” for which the SC professionals think it is more influential than what physicians 
themselves think. SC professionals could be more perceptive to this since they have a big picture 
of the whole ordering process and more awareness of total cost, while physicians underestimated 
their preference influence. Ranks are also statistically significantly different for “total cost” 
factor, where for physicians it is more important than what SC professionals think. Again, 
physicians think that total cost is more important than their preference, while SC who purchases 
items said that physicians’ preference is usually taken into consideration more than the cost 
which could be true since physicians are not totally aware of the total cost. The last factor 
“administration decision” has also shown a difference between the two groups’ ranks with 
physicians rating it as an important factor while SC did not. 
 
Table  2.14 Mann-Whitney U-test results on factors influencing organization’s decision, for the 
two populations 
Factor Z - value P-value Decision and conclusion 
Physicians’ preference -3.24 0.00 Reject H0. There is a difference 
Total cost -2.69 0.00 Reject H0. There is a difference 
Patient outcome -1.62 0.11 Fail to reject H0. There is no difference 
Manufacturer reputation -0.35 0.73 Fail to reject H0. There is no difference 
Required storage space -0.30 0.76 Fail to reject H0. There is no difference 
Administration decision -4.35 0.00 Reject H0. There is a difference 
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Cost information 
Information collected regarding cost information included physicians’ awareness of items’ 
costs, costs’ ranges of procedures they perform, their willingness to substitute an item in each 
range, percentage of PPIs from the items they use, costs of these PPIs. 
When asked how knowledgeable they are about actual costs of items they use, 48.8% said 
they are highly aware, 29.3% said they are not, and 22% were neither which could mean that 
they are aware of some items but not all, or roughly aware. A one-sample sign test gave a p-
value of 0.22 which indicates that the mean is not different than the neutral 4. A one-way χ2 test 
also gave 0.32 which means that scores’ categories are uniformly distributed and results could be 
not representative of the population. This could be due to the fact that data was based mainly on 
few healthcare organizations and did not include others who might have different policies. A 
relatively strong association was determined by the two-way χ2 between physicians’ knowledge 
level with items cost and their experience level, as shown in Table  2.15. It makes sense to be 
more aware of items cost when having more experience.  
 
Table  2.15 Physicians' awareness of items' actual costs 
 
  
The same question, awareness of the actual costs of items, was asked to the SC group. Of the 
total SC respondents, 100% indicated they are highly aware of the items’ cost, which is an 
expected result. The score median is 7 and the one-sample sign test confirmed this result with a 
p-value of 0.00, also the one-way χ2 gave a p-value of 0.00 indicating significance of data. The 
Total
Characteristic Categories
< 2, 2 - 5, 6-10 4 (100) 0 (0) 0 (0) 4 χ2 = 17.88 df=4, p= 0.00 γ = 0.47
11-20 1 (7.7) 6 (46.2) 6 (46.2) 13 Cramer's V = 0.479 Z = 1.01
> 20 5 (22.7) 3 (13.6) 14 (63.6) 22
Total 10 9 20 39
No Association
Gamma Analysis (If 
applicable)χ
2 Analysis
5, 6, 7 Very 
important
Neutral 4
Low 
importance 
1, 2, 3
Years of 
experience
Relatively Strong Association
n (%)n (%)n (%)
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two-way χ2 analysis indicated that SC awareness of items’ cost does not depend on any of the 
characteristics.  The two subjects were compared for their awareness of actual items’ cost, the 
Mann-Whitney U-test showed that the ranks from the two populations are statistically 
significantly different with p = 0.00 and Z=-6.6. The H0 that there is no difference was rejected 
in favor of the H1. Higher awareness within SC professionals’ community was determined, this is 
because they directly issuing orders and negotiate prices with vendors. 
When asked about the cost range of the procedures/surgeries that the physicians perform 
(Q13), 32% of total respondents perform procedures with cost greater than $10,000. The 
Physicians’ willingness to substitute an equivalent item when performing a procedure in each of 
different cost categories was asked in a separate item, in Q14. The two-way χ2 and γ tests were 
performed, and the resulting analysis showed an association between the first cost category 
(<$1,000) and the physicians’ experience. A relatively strong relationship and a very strong 
relationship were determined by both, the χ2 and γ, respectively as shown in Table  2.16. A 
possible explanation for this is that these kinds of surgeries are done by less experienced 
physicians as well as by highly experienced physicians. Highly experienced physicians, in 
contrast to less experienced physicians, may not really care about PPIs when doing low cost 
surgeries as when they do expensive surgeries. The K-W test was performed, and the test statistic 
(H) had a p-value of 0.90 and 0.89, both unadjusted and adjusted for ties, respectively. Hence, 
there was not enough statistical evidence to reject H0, which means that there was no difference 
among groups’ medians for willingness to substitute items. The physicians’ willingness to 
substitute an item was initially thought to have some sort of a relationship with the cost range of 
procedures the physician works on. The reason behind this hypothesis was the assumption that 
the physician will have more restrictions on his preference when doing big value procedures. 
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However, they showed equal willingness, which is higher than neutral, across the different cost 
ranges. One-way ANOVA was also performed and came with a p-value of 0.966, which 
confirms the result from the K-W test. 
 
Table  2.16 Willingness of physicians to substitute an equivalent item in the <$1,000 surgeries 
category by experience 
 
  
A question about percentages from all items that are considered as PPIs was asked to 
physicians to have an idea about the size of the problem. More than 93% of physicians use items 
that can be classified as PPIs. This is consistent with the previous result of ordering permission, 
when just 10% said they are not permitted while the rest say they do. A pie-chart showing 
percentages of physicians who utilize items that fall in the category of PPIs for each PPIs 
percentage category is shown below in Figure  2.7. 
Total
Characteristic Categories
< 2, 2 - 5, 6-10 1 (50) 0 (0) 1 (50) 2 χ2 = 9.75 df=4, p= 0.04 γ = 0.82
11-20 1 (16.7) 3 (50) 2 (33.3) 6 Cramer's V = 0.57 Z = 2.20
> 20 0 (0) 0 (0) 7 (100) 7
Total 2 3 10 15
Not willing 
1, 2, 3
Neutral 4
5, 6, 7 Very 
willing χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
Very Strong association
Years of 
experience
Relatively Strong Association
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Figure  2.7 Breakdown of PPIs percentages from total items the physicians who utilize in their 
procedures 
The median is (25%-50%) and the one-way sign test confirms this result with a p-value of 
0.5. The one-way χ2 test showed that the categories are not uniformly distributed. Overall 
weighted average of PPIs is 39.1% of total items. Regarding the costs of these PPIs items, the 
physicians were asked about their PPIs cost’s characteristics and 90% of them indicated that it 
falls in one of the three categories (low, medium, or high) while 10% said it is not applicable. Of 
the total responses, 13% indicated a high cost category while 64% said it is in the medium cost 
category. With more than 77% of PPIs being medium expensive to very expensive, this issue is 
certainly of concern for healthcare organizations.  
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 Supply Chain Professionals’ Perspective 2.4.2
A table that summarize the results from all individual questions showing median, low score 
and high score percentages, and both the one-sample sign and one-way χ2 tests is shown in 
Appendix E.2: Supply Chain Professionals. 
 
SKU and PPI Influence 
Information collected regarding SC professionals’ knowledge about SKU and PPI terms and 
effects included awareness of the term SKU, possible cause for the SKU proliferation, awareness 
of the PPI term, awareness of the actual items’ cost, and their opinion about important factors 
that are considered by the organization when making the decision. The last three items were 
discussed within the context of physicians’ perspective as they were common questions to both 
populations. 
When asked about their awareness of the term SKU proliferation, on a scale of 1-7, 91.5% of 
the SC professionals indicated that they are highly aware, and the median was 7. The one-sample 
sign test was performed and the resulting p-value was 0.00, H0 was rejected in favor of H1, 
concluding that the calculated median is significantly greater than 4 which support the 
conclusion that SC professionals are actually aware of the SKU proliferation concept. The one-
way χ2 test gave a p-value of 0.00; H0 was rejected in favor of H1. Both results conclude that the 
results are significant. A breakdown of the SC awareness in the term SKU proliferation by SC 
characteristics did not recognize any association between the awareness and any of these 
characteristic. 
To learn more about what SC professionals think about what causes the SKU proliferation 
problem, they were asked to rank three possible factors (PPIs, growing size with limited space, 
unpredicted schedules of needed items) which are thought to be main potential reasons for the 
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SKU proliferation, results are shown in Figure  2.8. Despite the effect of big size organizations 
and forecasting on managing SKUs, SC professionals indicated that PPIs is the major reason for 
SKU proliferation with a score median of 6, while the unpredicted schedules of needed items 
came second with a score of 5, and finally the growing size with a score of 4. All factors were 
analyzed using one-sample sign test and one-way χ2 test, both tests gave p-values <0.05 for all 
causes. Causes for proliferation scores’ medians are statistically significantly deviated from the 
neutral; this confirms that both PPIs and unpredicted schedules are relatively important causes 
while the growing size is not. Also, scoring for all causes is significant and non-uniformly 
distributed. A breakdown of the three causes by all characteristics was conducted and results 
indicated that there is no association between causes and any of the characteristics; this tells that 
the SC group actually agrees on this ranking. 
 
 
Figure  2.8 Causes of SKU proliferation according to SC professionals 
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The K-W test was performed, the test statistic (H) had a p-value of 0.000, both unadjusted 
and adjusted for ties, providing sufficient statistical support to reject H0 in favor of H1, and 
concluding that there is at least one statistical significant difference among SKU proliferation 
causes’ medians. The z-value for the “unpredicted schedules of needed items” cause is -1.19, the 
smallest absolute z-value, which indicates that the average rank for this cause differed least from 
the average rank for all observations. The average rank for “Growing size with limited space” 
was lower than the average rank for the other two. Finally, with a z-value of 7.06, the average 
rank for the “PPI” cause was higher than the mean rank for all causes. The one-way ANOVA 
confirmed the results from the K-W. 
Other causes for the SKU proliferation mentioned by respondents were: direct sales 
representative influence with physicians, variation in practice, lack of driving commitment on 
choices, new clinical technologies, and backorders/unavailability. These other reasons mentioned 
by SC professionals are mainly part of the PPIs. When the sales representative affects the 
physician’s opinion, the item will become a PPI. New technology is another example of PPI. 
 
Supply chain practices 
This is the major body of the SC survey, where it captures in general three aspects of many 
practices in the supply chain context. Information collected about SC practices included the 
awareness of SC professionals about each practice, the extent to which this practice is 
implemented in the organization, and potential impact of implementing it. Practices investigated 
were sharing item’s cost and total supply cost, spend analysis, capitated pricing, monitoring 
spending of individual physicians, ABC classification, cross-functional teams, and finally value 
analysis. These practices were identified from literature, see ( (Wright 2006), (Alguire 2016), 
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(Baty, et al. 2014)), feedback from professionals who reviewed the survey before conducting it, 
as well as from the researchers experience and knowledge of supply chain. The survey attempted 
to understand f these practices are effective or not, and which one can be recommended as a best 
practice for SC within healthcare organizations. 
When asked to what extent they share item cost and total supply cost with physicians, over 
76% of the SC professionals indicated they highly share item’s cost with physicians and near 
12% said they do not, while near 23% said they do share the total supply cost and more than 59% 
they do not. The median score of sharing the item’s cost is 6 while for the total supply cost it is 
3. A one-sample sign test gave a p-value of <0.05 for both costs which confirms that scores’ 
medians are statistically significantly deviated from the neutral. A one-way χ2 test also gave a p-
value of 0.00 for the item’s cost and a p-value of 0.18 for the total supply cost. This means that 
scoring on sharing item’s cost is not uniformly distributed and the results are significant, while a 
uniformly distributed scoring on sharing the total supply cost was detected meaning that the SC 
professionals are indefinite. A χ2 analysis was conducted to determine whether sharing any of the 
two costs depends on any of the SC characteristics; no association was detected. 
Mann-Whitney U-test showed that the ranks from the two cost types are statistically 
significantly different with p = 0.00 and Z=-4.8. The H0 that there is no difference was rejected 
in favor of the H1. It could be assumed that they do not know the total cost information, or it is 
too much detail to share the total supply cost with physicians. However, it is important to learn 
what SC professionals think about the potential impact of sharing each of these costs. Two 
separate questions were asked to them about their perspective of the perceived potential impact 
of sharing item’s cost and total supply cost with physicians. Of the total responses, 92% and 72% 
think that sharing item cost and total supply cost, respectively, have high potential impact. The 
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one-sample sign test and χ2 tests gave p-values of 0.00 for both questions, which means that the 
results are significant. The two-way χ2 analysis showed that there is no association with any of 
the characteristics for both variables. 
Results for potential impact of sharing item cost were filtered by those who share it and those 
who do not, Mann-Whitney U-test gave a z value of -0.77 and associated p-value of 0.44, which 
means there is no significant statistical difference between the two rankings and all believe that 
sharing item cost has high potential impact on managing PPIs. Same was done on the perceived 
potential impact of sharing total supply cost with physicians, and all SC professionals either they 
share it or not, they think it has a high potential impact on managing the PPIs, z value of -1.08 
and p-value of 0.28. Since just 23% are sharing the total supply cost, it becomes clear that 
healthcare organizations need to adopt this practice and activate the sharing channel with 
physicians, especially for the total supply cost. 
The second practice being discussed is the spend analysis. Over 95% of the total respondents 
indicated that they are highly aware of this practice and none said they are not. The one-sample 
sign test and one-way χ2 test both gave p-value of 0.00, which indicates that scoring is 
significant and the median is statistically significantly deviated from the neutral. A χ2 analysis 
was conducted to determine whether SC professionals’ awareness of spend analysis practice 
depends on any of the SC characteristics; no association was detected. In another question when 
they were asked about implementing spend analysis on their PPIs, with a score median of 6, 85% 
of the total respondents indicated that they always do. The one-sample sign and one-way χ2 tests 
both gave p-values of 0.00, this validates the significance of the results that healthcare 
organizations perform spend analysis on their PPIs. A two-way χ2 analysis was performed to 
investigate any association between applying spend analysis on PPIs and any of 
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characterizations. A very strong positive association between applying spend analysis practice 
within the department’s annual purchasing budget was detected by the gamma test. The same 
result was detected by the χ2 as shown in Table  2.17 . Clearly, when the department’s purchasing 
budget increases, the organization pays more attention to analyze spending on PPIs for more 
savings opportunities.  
Table  2.17 Applying spend analysis practice by healthcare characterstics 
 
  
A following question about frequency of conducting spend analysis on their PPIs relative to 
other items was asked for those who said they do spend analysis. of total respondents, 64% said 
they perform spend analysis on their PPIs more than other regular items, while near 21% said 
they do it the same, and 15% less than other items. The 64% indicates that PPIs is indeed an 
issue and potential savings could be made by focusing more on PPIs than on other standardized 
items. Frequency of performing a spend analysis on PPIs relative to other items does not depend 
on any of the healthcare organization’s characteristics according to the two-way χ2. Another two-
way χ2 analysis was performed to investigate any association between frequency of performing 
spend analysis on PPIs relative to other items and the previous two variables (awareness of the 
practice and if they perform it on their PPIs). A moderate association was determined by the χ2 
with the SC professionals’ awareness of the practice, and a strong association with whether they 
perform spend analysis on their PPIs or not was detected by both χ2 and gamma. Results are 
shown in Table  2.18. This means that with increased awareness among SC professionals the 
practice, they will perform it more on their PPIs, also if they do it on their PPIs, they will do it 
Total
Characteristic Categories
<$5M 0 (0) 4 (44.4) 5 (55.6) 9 χ2 = 14.70 df=6, p= 0.02 γ = 0.76
$5M - <$20M 1 (11.1) 1 (11.1) 7 (77.8) 9 Cramer's V = 0.413 Z = 2.34
$20M - <$50M 0 (0) 1 (25) 3 (75) 4
>$50M 0 (0) 0 (0) 21 (100) 21
Total 1 6 36 43
Gamma Analysis (If 
applicable)
n (%) n (%) n (%)
χ2 Analysis
Not at all 
1, 2, 3
Neutral 4
5, 6, 7 
Always
Very Strong positive 
association
Department's annual 
purchasing budget
Relatively Strong Association
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more on PPIs than on other items. This provides evidence that they have realized the good 
impact on managing PPIs using this practice. This argument is telling healthcare organizations 
increase awareness of this practice and encourage SC to perform it on their PPIs as an advice 
from peers. 
 
Table  2.18 Frequency of applying spend analysis on PPIs relative to other items by awareness 
and performing the practice 
 
 
A validation and support or vice versa of the above argument could be obtained by asking SC 
professionals directly about their perceived potential impact of this practice on managing PPIs. 
More than 89% of the total respondents indicated that spend analysis has a high potential impact 
on managing PPIs, while just 2% said it does not and 8.5% were in between.  The score median 
is 6, and both the one-sample sign and one-way χ2 tests gave p-values of 0.00, indicating 
significant results. A χ2 analysis was conducted, a relatively strong association of the perceived 
potential impact was determined with the department’s annual purchasing budget. The higher the 
department’s purchasing budget, the higher the perceived potential impact as seen by SC 
professionals. Negative very strong association of the perceived potential impact with the job 
title was found by the γ analysis. Higher job titles believe more in this practice.  Another χ2 
analysis determined that a moderate association exist between the perceived potential impact of 
spend analysis on managing PPIs and the frequency of performing spend analysis on PPIs. Those 
who are conducting the spend analysis on their PPIs more than regular items have more faith in 
Total
Independent Variable Categories
Not aware 1,2,3 0 0 0 0 χ2 = 11.94 df=4, p= 0.02 γ = 1.00
Neutral 4 2 (100) 0 (0) 0 (0) 2 Cramer's V = 0.356 Z = N/A
Highly aware 5,6,7 5 (11.1) 10 (22.2) 30 (66.7) 45
Total 7 10 30 47
Not at all 1,2,3 0 (0) 0 (0) 1 (100) 1 χ2 = 25.93 df=4, p= 0.00 γ = 0.74
Neutral 4 5 (83.3) 0 (0) 1 (16.7) 6 Cramer's V = 0.525 Z = 2.01
Always 5,6,7 2 (5) 10 (25) 28 (70) 40
Total 7 10 30 47
Q10. To what extent 
do you perform spend 
analysis on your PPIs? Strong positive AssociationRelatively Strong Association
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
Q9. To what extent are 
you aware of spend 
analysis practices? Moderate Association No Association
Less The same More
χ2 Analysis
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its potential impact on managing PPIs. Actually, they will not spend the time and effort on doing 
this practice if they did not find it fruitful. 
To look more in the process of spend analysis, SC professionals were asked about sharing 
spend analysis data with physicians, 74.5% said they do share the data with physicians while 
10.6% do not and 14.9% were in between. The one-sample sign and one-way χ2 tests both gave 
p-value of 0.00 indicating significance of results. A two-way χ2 analysis showed that perceived 
potential impact of spend analysis practice has a relationship with whether spend analysis data is 
shared with the physicians or not, as shown in Table  2.19. Those who share the spend analyses 
data with physicians, have more faith in the potential impact of this practice. No association 
between level of sharing spend analysis data with physicians with any of the characteristics was 
captured. In another question, SC professionals were asked about if they think the spend analysis 
data should be shared with physicians or not, 95.7% indicated that it should be shared. One-
sample sign test and one-way χ2 test gave p-values of 0.00 which indicates that data is 
significant. No association with any of the SC characteristics was recognized for this question. 
 
Table  2.19 Perceived potential impact of spend analysis by sharing spend analysis data with 
physicians 
 
 
 
The third practice was looked at is the capitated pricing. When asked about awareness of the 
practice, more than 91% indicated they are aware while the rest were divided between unaware 
and neutral. Both the one-sample sign and one-way χ2 tests gave 0.00 for the p-values, indicating 
Total
Characteristic Categories
Not at all 1,2,3 1 (20) 0 (0) 4 (80) 5 χ2 = 9.18 df=4, p= 0.05 γ = 0.37
Nuetral 4 0 (0) 1 (14.3) 6 (85.7) 7 Cramer's V = 0.313 Z = 0.37
Always 5,6,7 0 (0) 3 (8.6) 32 (91.4) 35 No Association
Total 1 4 42 47
Q13. Sharing spend 
analysis data with 
physicians Moderate Association
No impact 
1, 2, 3
Neutral 4 5, 6, 7 High 
impact χ2 Analysis
Gamma Analysis (If 
applicable)
n (%) n (%) n (%)
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that data is significant and further investigation for following questions can be trusted. No 
association with any of the healthcare organization characteristics was recognized. In another 
question, they were asked on the frequency of implementing capitated pricing on PPIs relative to 
regular items, and near 70% said they use it more on PPI than on other items, while 21.7% use it 
with the same frequency. No association of the frequency of applying capitated pricing with any 
of the healthcare organization characteristics was recognized. To learn more about the benefit of 
using this practice, SC professionals were asked about the potential of utilizing capitated pricing 
on controlling PPIs.  Of total respondents, 73.9% indicated a high potential impact of using 
capitated pricing on controlling PPIs, while17.4% neutral 8.7% no impact. Both the one-sample 
sign and one-way χ2 tests gave 0.00 for the p-values, indicating that data is significant. No 
association with any of the healthcare organization was recognized. 
A χ2 and gamma analysis were performed to determine if SC professionals perceived 
potential impact of using capitated pricing depends on awareness and/or frequency of use. The 
results, presented in Table  2.20, indicate that the perceived potential impact of using capitated 
pricing practice on controlling PPIs depend on both the awareness of the practice and frequency 
of use. A moderate association with the awareness was recognized by the χ2, which mean that the 
more awareness the SC professionals have, the more understanding of it capabilities and 
therefore the more appreciation of its potential impact.  
Table  2.20 Potential impact of using capitated pricing on controlling PPIs by awareness and 
frequency of use 
 
 
Total
Characteristic Categories
Not aware 1,2,3 0 (0) 0 (0) 2 (100) 2 χ2 = 10.50 df=4, p= 0.03 γ = 0.33
Nuetral 4 0 (0) 2 (100) 0 (0) 2 Cramer's V = 0.338 Z = 0.29
Highly aware 5,6,7 4 (9.5) 6 (14.3) 32 (76.2) 42 No Association
Total 4 8 34 46
Less 1 (25) 2 (50) 1 (25) 4 χ2 = 11.24 df=4, p= 0.02 γ = 0.74
The same 2 (20) 3 (30) 5 (50) 10 Cramer's V = 0.35 Z = 2.35
More 1 (3.1) 3 (9.4) 28 (87.5) 32
Total 4 8 34 46
No Impact 
1, 2, 3
Neutral 4
5, 6, 7 High 
Impact χ2 Analysis
Frequency of using 
capitated pricing on 
PPIs relative to Strong Positive AssociationModerate Association
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
Awareness of 
capitated pricing
Moderate Association
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Potential impact of using capitated pricing also depends on the frequency of using it, as 
captured by both tests with the gamma analysis indicating it as strong association. The average 
and median scores of potential impact for the frequency of use categories (less, the same, more) 
are: (3.5, 4.6, and 5.7) and (4, 4.5, and 6), respectively. The K-W test was performed and the 
resulting test statistic (H) had a p-value of 0.01, both unadjusted and adjusted for ties, providing 
sufficient statistical support to reject H0 in favor of H1, and concluded that there is at least one 
statistical significant difference among the categories. The z-value for “the same” category was 
1.76, the smallest absolute z-value, which indicates that the average rank for this group differed 
least from the average rank for all observations. With a z-value of -2.18, the average rank for 
“less” category was lower than the average rank for “the same” and “more” categories. With a z-
value of 2.91, the average rank for “more” category was higher than the mean rank for the other 
two groups. ANOVA was also performed and resulted in a p-value of 0.01 which confirms the 
same result of the K-W. Those who practice capitated pricing on their PPIs more than regular 
items have indicated a more potential impact of the practice on controlling PPIs. Increasing 
awareness and frequency of use on this practice is recommended for healthcare organizations. 
Spending by individual physicians could be a sign on how much the physician use PPIs. 
When SC professionals were asked about monitoring individual physicians spending when 
making decisions regarding PPIs, 71.7% said they do, while 17.4% do not, and 10.9% in 
between. Results are significant according to the one-sample sign and one-way χ2 tests. A χ2 
analysis was performed to determine if there is any association between monitoring spending of 
individual physicians and the perceived potential of utilizing the capitated pricing on controlling 
PPIs. A relatively strong association was determined, meaning that those who monitor individual 
spending see a potential impact on controlling their PPIs. 
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Another related question was if physicians’ spending is compared to budgeted amounts. Of 
total respondents, 45.6% said they do, 34.8% do not, and 19.6% were neutral. The score median 
is 4 (neutral) which was confirmed by the one-sample sign test with a p-value of 0.51. Also the 
one-way χ2 gave a p-value of 0.73 indicating a uniform distributed scoring across the scale. 
Organizations in general do not set up budgets for their physicians to refer to when monitoring 
individual spending. Setting budgets is not easy due to the nature of service and variability in 
forecasting. One last question on this practice was if the organizations compare physicians to 
each other on their spending habits, 70% said they do, while 15.2% do not. This is seen as 
benchmarking with performance measure as the lowest spending relative to amount worked 
(revenue generated). The score median was 5, and both the one-sample sign and one-way χ2 tests 
gave p-value of 0.00. A χ2 analysis showed an association between comparing physicians to each 
other and job title of the respondents as shown in Table  2.21. The moderate association shows 
that higher positions said they do compare physicians on their spending habits, this means we 
can confidently say that this is actually done. More importantly, it indicates that this practice is 
done on higher management levels and healthcare organizations do watch physicians on their 
spending and compare them to each other in a step to evaluate their performance. 
Table  2.21 Comparing physicians to each other on their spending habits by job title 
 
 
The fourth practice which was investigated is ABC classification. When asked about their 
awareness of the ABC practice, more than 82% said they are aware and 11% are not. The score 
median was 7 and both the one-sample sign and one-way χ2 tests gave p-values of less than 0.05. 
Total
Characteristic Categories
Executive (CEO, CFO, CIO, President) 0 (0) 1 (50) 1 (50) 2 χ2 = 14.06 df=6, p= 0.03 γ = -0.29
Vice president 0 (0) 3 (17.6) 14 (82.4) 17 Cramer's V = 0.4 Z = -0.45
Director 7 (35) 1 (5) 12 (60) 20 No Association
Manager 0 (0) 2 (40) 3 (60) 5
Total 7 7 30 44
Job Title
Moderate Association
Not at all 
1, 2, 3
Neutral 4 5, 6, 7 
Always χ2 Analysis
Gamma Analysis (If 
applicable)
n (%) n (%) n (%)
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The frequency of conducting an ABC classification was asked in next question with options 
(Never, daily, weekly, monthly, and yearly). More than 70% do it at least yearly, half indicated 
they do it yearly, while 29% have never done it, see Figure  2.9 below. 
 
Figure  2.9 Frequency of performing ABC classification 
 
 
In two separate questions, SC professionals were asked if they use ABC classification based 
on value and usage. Proportions of those who said they use, do not use, and in-between were 
34.4%, 34.4%, and 31.2% for the value, respectively. While based on usage proportions were 
39.4%, 30.4%, and 21.2%, respectively. Score median is 4 for both which is confirmed by the 
one-sample sign test, and obviously both distributions seem to be uniform, which is confirmed 
by one-way χ2 tests. When asked if they share ABC classification data with physicians, just 16% 
said they do, and 71% do not share it. It seems to be much detail to share with physicians who 
might not have the time look at. The one-sample sign test and one-way χ2 test gave p-values less 
than 0.05. When asked if ABC classification should be shared with physicians or not, 56% said it 
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should be. The score median was 5, and the one-sample sign test confirmed this with p-value of 
0.04. Scoring distribution is uniformly distributed according to the one-way χ2 with p-value 0.13. 
When asked about their perceived potential impact of utilizing ABC classification on 
controlling PPIs, 44.4% said it does have potential in controlling PPIs, while 37.8% said it does 
not. The one-sample sign and one-way χ2 tests both gave p-values of 0.74 and 0.07, respectively. 
This indicates that the median score is actually 4 and results are uniformly distributed. The SC 
professionals seem to not have much trust in this practice as an effective way to control PPIs. A 
breakdown of the perceived potential impact by using ABC classification based on value and 
based on usage, sharing ABC classification data with physicians, and if the data should be shared 
or not showed is shown in Table  2.22 below. The χ2 analysis shows a moderate association with 
utilizing ABC classification based on value and usage.  
 
Table  2.22 Percieved potential impact of utilizing ABC classification on controlling PPIs by 
actual using it and data sharing 
 
 
Total
Characteristic Categories
Not at all 1,2,3 7 (63.6) 2 (18.2) 2 (18.2) 11 χ2 = 10.07 df=4, p= 0.04 γ = 0.62
Nuetral 4 1 (10) 2 (20) 7 (70) 10 Cramer's V = 0.397 Z = 1.62
Always 5,6,7 2 (18.2) 1 (9.1) 8 (72.7) 11 No Association
Total 10 5 17 32
Not at all 1,2,3 8 (61.5) 1 (7.7) 4 (30.8) 13 χ2 = 9.76 df=4, p= 0.04 γ = 0.56
Nuetral 4 1 (14.3) 1 (14.3) 5 (71.4) 7 Cramer's V = 0.391 Z = 1.32
Always 5,6,7 1 (8.3) 3 (25) 8 (66.7) 12 No Association
Total 10 5 17 32
Not at all 1,2,3 10 (45.5) 2 (9.1) 10 (45.5) 22 χ2 = 6.21 df=4, p= 0.18 γ = 0.65
Nuetral 4 0 (0) 1 (25) 3 (75) 4 Cramer's V = NA Z = 1.41
Always 5,6,7 0 (0) 1 (20) 4 (80) 5 No Association
Total 10 4 17 31
Not at all 1,2,3 6 (75) 1 (12.5) 1 (12.5) 8 χ2 = 13.72 df=4, p= 0.01 γ = 0.78
Nuetral 4 2 (33.3) 2 (33.3) 2 (33.3) 6 Cramer's V = 0.463 Z = 2.91
Always 5,6,7 2 (11.1) 2 (11.1) 14 (77.8) 18
Total 10 5 17 32
The extent of utilizing 
ABC classification on 
PPIs based on value. Moderate Association
The extent of utilizing 
ABC classification on 
PPIs based on usage. Moderate Association
The extent of sharing 
ABC classification 
data with physicians. No Association
To what extent ABC 
classification data 
should be shared 
with physicians. Relatively Strong Association Very strong association
No Impact 
1, 2, 3
Neutral 4
5, 6, 7 High 
Impact χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
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Another very strong association with their opinion of sharing the data with physicians was 
recognized by the gamma analysis, as well as by the χ2. Those who believe the data should be 
shared also believe in the potential of ABC classification as a good practice in controlling PPIs. 
Interestingly, 56% of them are vice presidents and 39% are directors, the original job titles 
percentages were 39% for vice president and 45% for directors. Believing in this practice from 
top level management will point out its effectiveness. 
The fifth practice is cross-functional teams, as it is assumed to be utilized especially for the 
PPIs. When asked about utilizing it in their organizations, 71.7% of the SC professionals said it 
is utilized, while 17.4% said it is not. The score median was 6, and the one-sample sign test gave 
a p-value of 0.00 which confirms this result. Also the one-way χ2 test gave a p-value of 0.00 
indicating significance of the results. A χ2 analysis shown below in Table  2.23, indicates that 
utilizing cross-functional teams depends on years of experience and department’s purchasing 
budget. Dependence on experience could be because respondents with low experience are 
actually not included in the process and consequently may not be aware of it. On the other hand, 
the higher the purchasing budget is, the more they utilize this practice, which is expected. This is 
due to the need for more structured and organization of selection’s decisions, due to the 
sensitivity of small margins on the big scale of purchasing. 
 
Table  2.23 Utilizing cross-functional teams by experience and purchasing budget 
 
Total
Characteristic Categories
< 2, 2 - 5, 6-10 0 (0) 3 (33.3) 6 (66.7) 9 χ2 = 10.60 df=4, p= 0.03 γ = 0.25
11-20 5 (35.7) 1 (7.1) 8 (57.1) 14 Cramer's V = 0.339 Z = 0.35
> 20 3 (13) 1 (4.3) 19 (82.6) 23 No Association
Total 8 5 33 46
<$5M 1 (11.1) 1 (11.1) 7 (77.8) 9 χ2 = 15.50 df=6, p= 0.02 γ = 0.44
$5M - <$20M 5 (55.6) 1 (11.1) 3 (33.3) 9 Cramer's V = 0.425 Z = 0.84
$20M - <$50M 1 (25) 0 (0) 3 (75) 4
>$50M 0 (0) 2 (9.5) 19 (90.5) 21
Total 7 4 32 43
Years of experience
Moderate Association
Department's annual 
purchasing budget
Relatively Strong Association No Association
Not at all 
1, 2, 3
Neutral 4
5, 6, 7 
Always χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
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When asked if the procurement (supply chain) department is represented in the cross-
functional team, 87.5% said they are highly represented, while12.5% said the representation is 
not significant. When they were asked if the physicians are represented, 68.3% said they are, 
while 31.7% said they are not effectively represented. A χ2 analysis showed that representing 
physicians in the cross-functional teams depends on the purchasing budget, results in Table  2.24. 
The strong association means that physicians are more represented in cross-functional teams 
within bigger organizations.  
 
Table  2.24 Representing physicians in cross-fucntional teams by purchasing budget 
 
 
When asked whether they discuss PPIs in cross-functional team meetings or not, 75.6% said 
they do discuss PPIs while 12.2% said they rarely do. The score median was 6, and the one-
sample sign test gave a p-value of 0.00 confirming the result. The one-way χ2 also gave a p-
value of 0.00.  A very strong association with purchasing budget was recognized by the γ 
analysis as shown in Table  2.25 below. Two points could be learned from this; the first is that 
PPIs are discussed within healthcare organizations which may permit negotiations over the 
selection process. Second point is that more focusing on PPIs is found in bigger healthcare 
organizations, this means that PPIs inevitably have high potential of savings and cross-functional 
team is an effective way of doing so. 
Total
Characteristic Categories
<$5M 2 (25) 4 (50) 2 (25) 8 χ2 = 14.79 df=6, p= 0.02 γ = 0.74
$5M - <$20M 1 (20) 2 (40) 2 (40) 5 Cramer's V = 0.441 Z = 2.42
$20M - <$50M 0 (0) 0 (0) 4 (100) 4
>$50M 0 (0) 3 (14.3) 18 (85.7) 21
Total 3 9 26 38
Department's annual 
purchasing budget
Relatively Strong Association Strong Association
Not at all 
1, 2, 3
Neutral 4 5, 6, 7 
Always χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
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Table  2.25 Discussing PPIs in cross-functional team meetings by purchasing budget 
 
 
To validate this conclusion, they were asked about their perceived potential impact of 
utilizing cross-functional team meetings on controlling PPIs, 85% said it is effective practice 
while just 8.7% said it is not. Score median was 6, and both the one-sample sign and χ2 tests 
gave p-values of 0.00, indicating significant results. A very strong association was determined by 
the γ analysis. Those who actually utilized cross-functional teams in their organizations found it 
an effective practice in controlling PPIs and improving the selection process. 
 
Table  2.26 Perceived potential impact of utilizing cross-functional teams on controlling PPIs by 
using it 
 
 
Results of the χ2 analysis, represented in Table  2.27, indicate the perceived potential impact 
of utilizing cross-functional teams on controlling PPIs depends on two of organization’s 
characteristics, purchasing budget and organization’s settings. Bigger organizations seem to be 
more receptive to this practice and consequently found it effective. 
 
 
Total
Characteristic Categories
<$5M 4 (50) 0 (0) 4 (50) 8 χ2 = 23.22 df=6, p= 0.00 γ = 0.76
$5M - <$20M 0 (0) 2 (40) 3 (60) 5 Cramer's V = 0.553 Z = 2.43
$20M - <$50M 0 (0) 1 (25) 3 (75) 4
>$50M 0 (0) 1 (4.8) 20 (95.2) 21
Total 4 4 30 38
Department's annual 
purchasing budget
Relatively Strong Association Very Strong Association
Not at all 
1, 2, 3
Neutral 4
5, 6, 7 
Always χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
Total
Characteristic Categories
Not at all 1,2,3 4 (50) 1 (12.5) 3 (37.5) 8 χ2 = 33.56 df=4, p= 0.00 γ = 0.95
Nuetral 4 0 (0) 2 (40) 3 (60) 5 Cramer's V = 0.604 Z = 7.38
Always 5,6,7 0 (0) 0 (0) 33 (100) 33
Total 4 3 39 46
Utilizing cross-
fucntional teams
Strong Association Very Strong Association
No Impact 
1, 2, 3
Neutral 4 5, 6, 7 High 
Impact χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
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Table  2.27 Perceived potential impact of utilizing cross-functional teams on controlling PPIs by 
organization’s characteristics 
 
  
The sixth and last practice investigated is the value analysis or process. When asked how 
aware they are of the value analysis process, all of the responses (100%) indicated that they are 
highly aware. This could be due to the versatile use of this process in healthcare organizations as 
well as other kind of organizations to assess the value of items and processes. When asked about 
the extent to which physicians are included in the value analysis process, 65.2% indicated that 
physicians are included in the process while 28.3% said they are not and remaining were in-
between. The median score was 5, and the one-sample sign test confirmed this result with a p-
value of 0.01 which provides statistical evidence that the median is greater than 4. The one-way 
χ2 test gave a p-value of 0.04 which indicates significance of data. A χ2 analysis was performed 
to determine if including the physicians in the value analysis process has any association with 
any of the characteristics.  
The results, shown in Table  2.28, indicate the only association with department’s annual 
purchasing budget, χ2 determined it as relatively strong and γ confirmed the dependence with 
strong relationship. The healthcare organizations with more purchasing budgets seem to insist 
more on including physicians in the process. This could be due to the benefits they see from this 
process. 
Total
Characteristic Categories
<$5M 1 (11.1) 1 (11.1) 7 (77.8) 9 χ2 = 15.40 df=6, p= 0.02 γ = 0.66
$5M - <$20M 3 (33.3) 2 (22.2) 4 (44.4) 9 Cramer's V = 0.423 Z = 1.62
$20M - <$50M 0 (0) 0 (0) 4 (100) 4
>$50M 0 (0) 0 (0) 21 (100) 21
Total 4 3 36 43
National 0 (0) 0 (0) 9 (100) 9 χ2 = 12.62 df=6, p= 0.05
Rural 3 (30) 1 (10) 6 (60) 10 Cramer's V = 0.397
Suburban 0 (0) 2 (15.4) 11 (84.6) 13
Urban 0 (0) 0 (0) 8 (100) 8
Total 3 3 34 40
Organization's 
setting?
Moderate Association
Department's 
annual purchasing 
budget
Relatively Strong Association No association
Not at all 
1, 2, 3
Neutral 4
5, 6, 7 
Always χ2 Analysis
Gamma Analysis 
(If applicable)n (%) n (%) n (%)
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Table  2.28 Including physicians in the value analysis process by department's annual purchasing 
budget 
 
 
 
One more piece of the puzzle is to learn about their perceived potential impact of utilizing 
value analysis on controlling PPIs. When asked this question, 89% indicated a high potential 
impact of this practice on controlling the PPIs, while just 6.7% disagreed. This result is expected 
due to the wide use and knowledge of this practice in all other sectors. No association was 
determined by the χ2 analysis with characteristics. A χ2 analysis was performed to determine if 
the perceived potential impact depends on whether physicians are included in the value analysis 
process. The results, shown in Table  2.29, indicate a moderate association was recognized by the 
χ2 analysis but no association was determined by the γ analysis. 
 
Table  2.29 Perceived potential impact of value analysis process on controlling PPIs by including 
physicians in the process 
 
 
 
Those who include their physicians in the value analysis process realize more the potential 
impact of this practice on controlling PPIs. The value analysis practice is the inspiration of 
another research where a decision making framework based on multi-criteria decision making 
techniques will be developed. 
Total
Characteristic Categories
<$5M 6 (66.7) 0 (0) 3 (33.3) 9 χ2 = 17.02 df=6, p= 0.01 γ = 0.71
$5M - <$20M 4 (44.4) 1 (11.1) 4 (44.4) 9 Cramer's V = 0.445 Z = 2.41
$20M - <$50M 0 (0) 0 (0) 4 (100) 4
>$50M 1 (4.8) 2 (9.5) 18 (85.7) 21
Total 11 3 29 43
Department's 
annual purchasing 
budget
Relatively Strong Association Strong Association
Not at all 
1, 2, 3
Neutral 4
5, 6, 7 
Always χ2 Analysis
Gamma Analysis (If 
applicable)n (%) n (%) n (%)
Total
Characteristic Categories
Not at all 1,2,3 3 (23.1) 0 (0) 10 (76.9) 13 χ2 = 14.23 df=4, p= 0.01 γ = 0.70
Nuetral 4 0 (0) 1 (33.3) 2 (66.7) 3 Cramer's V = 0.398 Z = 1.47
Always 5,6,7 0 (0) 1 (3.4) 28 (96.6) 29
Total 3 2 40 45
Including physicians 
in the process of 
value analysis Moderate Association No Association
No Impact 
1, 2, 3
Neutral 4
5, 6, 7 High 
Impact χ2 Analysis
Gamma Analysis (If 
applicable)
n (%) n (%) n (%)
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Last question within the practices’ items was an open question which requested respondents 
to provide any additional practices they think are important but were not included in the survey. 
Here are what they provided after shortening text to meaningful names and removing redundant. 
A summary of key hypotheses with the tests used and conclusions are summarized in 
Table  2.30 below. 
Table  2.30 Summary of key hypotheses with tests used and the conclusions  
Hypothesis Test Used Conclusion 
Physicians are aware of the term PPI One-Sign Yes 
Physician awareness of the term PPI depends on 
characteristics 
Two-way 
χ2 
No association 
Physicians are more aware of the term than SC Mann-
Whitney U 
No, SC are more aware 
Physicians are not willing to use available non-
preferred items 
One-Sign No, they are willing 
Physicians willingness to use non-preferred items 
depends on characteristics 
Two-way 
χ2 
Yes, on years of experience 
Physicians are permitted to order their preferred 
items 
One-Sign Yes 
Physicians permission to order their preferred 
brands depends on characteristics 
Two-way 
χ2 
No association 
Physicians who are aware of the PPI term, are more 
willing to use available items in stock 
Two-way 
χ2 
No association 
Ordering permission affects physicians' willingness 
to use available items in stock 
Two-way 
χ2 
Yes, those who are not permitted are more 
willing to use available items in stock 
Factors significance affecting physician preference One-Sign, 
Kruskal-
Wallis 
"Item effectiveness" and "previous 
experience with the item" are the most 
important 
Factors significance affecting physician preference 
depends on characteristics 
Two-way 
χ2 
Yes, on years of experience 
Patient's preference is important to the physician 
when selecting the item 
One-Sign No, it is not important 
Physicians are knowledgeable on how the 
organization make decision 
One-Sign No, they are not aware 
Physicians have high ability to influence the 
decision to select an item 
One-Sign No, they are not highly able 
physicians' ability to influence the organization’s 
decision depends on characteristics 
Two-way 
χ2 
Yes, on years of experience 
Physicians are aware of the items actual costs One-Sign They are neither aware nor not aware 
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Table 2.30 Summary of key hypotheses with tests used and the conclusions (Cont.) 
Hypothesis Test Used Conclusion 
Physicians willingness to substitute an equivalent 
item is less within the high cost surgeries 
Kruskal-
Wallis 
No, they have the same willingness among 
all cost categories 
SC professionals think the physicians preference is 
a major contributor to the SKU proliferation 
problem 
One-sign, 
Kruskal-
Wallis 
Yes, it is affecting and significantly more 
than other factors 
SC professionals believe that sharing item cost with 
physicians will have potential impact on controlling 
PPIs 
One-Sign Yes, it significantly has a potential impact 
on controlling PPIs 
SC professionals perform spend analysis on their 
PPIs 
One-Sign Yes 
Performing spend analysis on PPIs depends on 
characterizations 
Two-way 
χ2 
Yes, depends on department's annual 
purchasing budget 
SC professionals perform spend analysis on their 
PPIs more than regular items 
One-sign Yes, they do it more on PPIs 
SC professionals believe that performing spend 
analysis will have potential impact on controlling 
PPIs 
One-Sign Yes, it has potential impact 
SC professionals are highly aware of the capitated 
pricing practice 
One-sign Yes, they are aware 
SC professionals believe that performing capitated 
pricing will have potential impact on controlling 
PPIs 
One-Sign Yes, it has potential impact 
SC professionals perceived potential impact of 
capitated pricing depends on the frequency of 
performing the practice 
Two-way 
χ2 
Yes, those who do it more frequently 
believe more in this practice as a good 
practice for managing PPIs 
SC professionals are aware of the ABC 
classification practice 
One-Sign Yes, they are aware 
SC professionals believe that performing ABC 
classification will have potential impact on 
controlling PPIs 
One-Sign No, it does not help with controlling PPIs, 
it is not a good practice for this purpose 
SC professionals are aware of the value analysis 
practice 
One-Sign Yes, they are aware 
SC professionals believe that performing value 
analysis will have potential impact on controlling 
PPIs 
One-Sign Yes, it helps controlling PPIs 
 
2.5 Discussion 
Physician preference items management aspects included in both, physicians and SC 
professionals surveys and summarized in this article included preference characterization, 
decision process, and practices that could have impact. Where appropriate, physicians’ survey 
responses were segmented according to years of experience (<2, 2-5, 6-10, 11-20, >20), 
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organization’s setting (rural, suburban, urban), employment type (hospital employed, contracted 
physician group, community physician), and compensation model (Per wRVU, percentage of net 
collections, percentage of practice, percentage of gross charges, per encounter, guaranteed base 
plus incentives). While SC survey responses were also segmented by years of experience (<2, 2-
5, 6-10, 11-20, >20), organization’s setting (rural, suburban, urban), job title (Executive, vice 
president, director), and annual purchasing budget (<$500k, $500k-$1M ...). χ2 analysis was 
performed to identify any patterns that exist in how both physicians and SC professionals are 
looking to the problem and driving factors. 
In general, there is common awareness of the problem, but more within SC professionals. 
Awareness of the term PPI is higher within the SC; this indicates its effect on the SC 
performance and defines it as a SC term rather as a medical term. Physicians showed a high 
willingness to use available items in stock, which seemed to be higher for highly experienced 
physicians. Just to be willing to use available items in stock means they are willing to use 
standardized items and minimize the number of items used for the same purpose. Physicians’ 
ability to use non-preferred items increases with their skills gained through experience. 
Organizations should focus on more experienced physicians to standardize items since they are 
more willing to use any brand due to their skills and experience. As 83% of physicians said they 
are sometimes permitted to order whatever they want, this confirms that PPIs is an issue. 
However, when limitation on what physicians are permitted to order takes place, they will be 
more willing to use available items. 
Physicians also showed willingness (90%) to substitute an item from stock which is not their 
preferred brand but functionally equivalent. This result is consistent with the previous one, 
except that physicians became more willing to use another brand given it is functionally 
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equivalent. More experienced physicians are more willing to use another functionally equivalent 
brand. Even when they asked, 71% are very willing to permanently drop a brand and adopt 
another one. Healthcare organizations should focus on experienced physicians to adopt 
standardized items, and at the same time provide sufficient illustrations on items showing which 
are functionally equivalent. 
The two factors that most affect physician’s preference are Items’ effectiveness and previous 
experience. Physicians will choose items that they have experience with, and which they think 
are more effective. Healthcare organization may want to invest more in training physicians on 
the items they would like to lean toward, and also provide brief evaluation of items effectiveness. 
Another aspect to consider is the item’s cost, as physicians’ knowledge with items’ cost depends 
on experience, a more experienced physician may consider the item’s cost significantly more 
important in his decisions than a lower experienced physician. Reasons that would cause 
physician switching to another brand are patient’s related aspects followed by the ease of use. If 
a physician learned that this item is better for the patient’s outcome, he/she will adopt it as 
expected. Also, if it is easier to use, the physician will adopt it. 
Physicians do not consider patients’ preference when selecting the right item. Interestingly, 
those who said patient’s preference is not important indicated that manufacturer reputation is 
important when selecting the item. An explanation for this could be that physicians, who do not 
consider patient’s preference, trust manufacturer reputation more since patients could be unaware 
of what is available. 
Physicians are not totally knowledgeable about how the organization makes the decision. 
Around half of physicians are able to influence the decision of selection, and this depends on 
physicians’ experience. More experienced physicians are more able to influence the decision, yet 
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they are more flexible to use available items. Healthcare organizations should focus on 
encouraging experienced physicians to standardize items and enhance this by incentive systems; 
the return of this system could be used to train low experienced physicians and clinical staff to 
do better jobs. 
Total cost is the dominant factor in influencing the organizations’ item selection decision 
according to physicians. They considered administration to make decisions based on cost, then 
patients’ outcome and finally physicians’ preference. Physicians may complain about the central 
decision by administrators on brands. This may cause physicians to feel excluded, which is a 
negative impression that should be changed. Including physicians in the decision process and 
appreciating their input always, having them in cross functional teams, actively participate in 
value analysis teams would have effective outcomes. It is not just about changing their attitude 
toward being valuable to the decision process, it will make them feel the pressure and appreciate 
more the effort done to select the best items that could create the balance between all 
stakeholders. SC professionals were asked the same question, they agreed with physicians on the 
patient’s outcome as an important factor, however, they said physician preference is the second 
important factor and total cost came third. The result concluded from SC professionals input that 
patient outcome and physician preference were most important factors, is basically what was 
expected in this research. Since, no one disagreed that patient outcome is the first priority, it can 
be said that physicians’ preference is the most important factor. Both physicians and SC 
professionals said that total cost and physician preference are two important factors to the 
organization decision; however, they indicated different rankings. The SC professionals 
indicated higher rankings for the physicians’ preference than what physicians themselves said, 
and lower rankings on the total cost than what the physicians indicated. 
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Less than half were aware of the actual items’ costs, which depends on physicians’ 
experience. The SC professionals were asked the same question, all of them are highly aware of 
the items’ actual costs. SC professionals are more aware than physicians as expected. Educating 
physicians about cost of items they use is thought to be beneficial in encouraging physicians to 
think more before requesting any item. On the other hand, physicians’ willingness to substitute 
an item was expected to depend on the cost range of surgeries. In other words, a physician will 
stick to his/her choices when performing high cost surgeries. However, it was found that 
physicians’ willingness to substitute an item does not depend on the cost range of surgeries 
physicians do. 
Majority (93%) of physicians use items that can be classified as PPIs. Of the total amount of 
items used in healthcare organizations, 39.1% are considered PPIs. 
SC professionals are highly aware of the term SKU proliferation. They indicated PPIs as the 
major cause of the SKU proliferation issue, while unpredictable schedules for needed items as 
second important and growing size came last. With physician preference being first cause of this 
problem, it is highly needed to improve the selection process to reduce number of items. In other 
research, factors affecting and considered in the PPI selection decision process by physicians and 
other stakeholders as well, are analyzed in detail. The purpose is to develop a decision 
framework to improve the item’s selection process. 
The main body of the SC survey was about practices that could help in managing PPIs. The 
first practice was sharing items’ costs and total cost with physicians. Mostly, they share the 
items’ costs with physicians but not total cost. Of total respondents, 92% think that sharing item 
cost has high potential impact on controlling PPIs, either they actually share it or not. For the 
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total cost, 72% think it would impact controlling PPIs. Since just 23% share total supply cost, 
healthcare organizations should start sharing total supply cost with physicians. 
Second practice is spend analysis, where majority of SC indicated high awareness and 
utilizing of this practice on their PPIs. Utilizing spend analysis was found to depend on annual 
purchasing budget; the higher the budget, the more focus on spend analysis on PPIs. This is 
because of the potential savings in PPIs and noticeable effect when purchasing size is big. Of 
total respondents, 64% said they perform spend analysis on their PPIs more than regular items, 
while 21% are doing it the same frequency. Highly aware SC professionals are more likely to 
perform spend analysis practices on their PPIs, and if they do it on their PPIs, they will do it 
more than other standardized items. This means that SC professionals will realize the importance 
of this practice and its impact on managing PPIs as they learn more about it, and when they 
actually try it on their PPIs. 89% indicated that spend analysis has a high potential impact on 
managing PPIs. The higher the annual purchasing budget, the more they believe in the spend 
analysis practice potential impact on controlling PPIs. Those who perform spend analysis 
practice on PPIs more than other items, believe more in the practice potential impact, actually 
they will not do it more if they do not believe in it. It is highly recommended that healthcare 
organizations start educating their SC professionals about this practice and encourage them to 
apply it on their PPIs more frequently than regular items. Three quarters of SC professionals 
share spend analysis data with physicians. Analysis showed that those who share spend analysis 
data, see the potential impact of it on controlling PPIs. This is evidence that spend analysis data 
should be shared with physicians, which is confirmed by the 96% who said that data should be 
shared. 
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Third practice is capitated pricing, majority (91%) were aware of this practice. about 70% 
use it on their PPIs more than other items, while 21% use it the same frequency. Three quarters 
indicated high potential impact of this practice on controlling PPIs, while 17% were neutral. 
Higher awareness of this practice implies higher perceived potential impact on controlling PPIs, 
which comes from the understanding of its capabilities. A stronger association of capitated 
pricing perceived potential impact with its frequency of use was recognized, indicating that when 
using capitated pricing more, its impact will be more noticeable. It could be also vice versa, 
which means organizations do this practice more since they believe in its impact. Either way, it is 
recommended to adopt capitated practice as a good practice within healthcare organizations. 
Individual’s spending is monitored by most of healthcare organizations, and those who do so 
indicated a higher potential impact of the capitated pricing. However, most of them do not 
compare individual spending to a budgeted amount. This could be due to difficulty in setting up 
a budget because of the healthcare service nature. Most healthcare organizations compare 
physicians to each other on their spending habits, and this was indicated more by higher 
management levels, meaning that they do so to watch physicians’ performance. Physicians 
should pay more attention to their selections and wisely choose the most effective items. 
The fourth practice was ABC classification, majority are highly aware of this practice, and 
more than 70% do it either daily, or weekly, or monthly or yearly. Either based on value or 
usage, ABC classification data is not shared with physicians by 71% of respondents. However, 
56% said that it should be shared. In general, they were not sure of the potential impact for ABC 
classification on controlling PPIs. However, those who do the practice either based on value or 
usage, believe more in this practice. Vice presidents and directors seem to be the most 
enthusiastic for this practice as they believe ABC data should be shared with physicians, and also 
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they believe in this practice as an effective practice in controlling PPIs. This practice is seen by 
higher management level as an effective practice, and this could be because they are able to 
capture physicians’ behavior when such data is shared with them. 
Cross functional team is the fifth practice, and it is utilized by more than two thirds of 
healthcare organizations. The higher the purchasing budgets the more they utilize this practice. 
This is due to the need for more structured and organization of selection’s decisions, due to the 
sensitivity of small margins on the big scale of purchasing. One third said that physicians are not 
represented in cross functional teams, and this actually depends on how big the organization is, 
with smaller organizations have less representation of physicians in their cross functional teams. 
More than three quarters discuss PPIs in the cross functional teams, and this percentage depends 
on purchasing budget. Bigger healthcare organizations adopt cross functional teams more than 
smaller organizations, and they also discuss PPIs more; this highlights the savings potential in 
PPIs. The majority indicated that this practice has high potential impact on controlling PPIs. 
Bigger organizations seem to be more receptive to this practice and consequently found it 
effective. 
Value analysis is the sixth practice investigated. All were aware of this practice and indicated 
that just 65% of the physicians are included in the process. Healthcare organizations with higher 
purchasing budget effectively include physicians in this process. Almost all indicated that value 
analysis has high potential impact on controlling PPIs. Interestingly, those who included their 
physicians in the value analysis process, realize more the potential impact of this practice on 
controlling PPIs. 
For future work and research, a distinction could be made between the tools and items that 
are used in treating patients, and the replacement devices that will be in use directly by the 
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patient after the treatment. Cutting tools are an example of the first group, and heart stent is an 
example of the second group. The reason for separating them in two groups is due to the 
difference in objectives for each; consequently the kind of questions asked should be tailored 
according the objective investigated. For instance, a device that will be used directly by the 
patient may be affected by the opinion of the patient, which means asking questions regarding 
this point. In this research, the objective was to have a comprehensive understanding on both 
PPIs categories. 
Another future work is to redo the survey reflecting on common language with physicians 
and SC professionals. The survey could be improved by developing additional hypothesis 
learned from this one. We recognized that we are limited because of the sample size. This work 
could be considered as initial results that would indicate what a bigger sample would need to be 
in order to have improved confidence in the results. 
One more work for future, is to investigate more on the recommended practices from this 
work. This could be done by working with hospitals to implement these practices and evaluate 
the effect on performance. 
In a separate question (Q37), SC professionals were asked about any additional practices they 
think should be considered.  
One of the practices recommended was to make teams for physicians led by physicians 
themselves to review clinical and cost data for specialty items. The purpose is to encourage 
physician to use an already contracted product or perhaps one other doctors are using rather than 
bringing in something a representative is marketing. Physicians will need to present clinical 
evidence to their peers on why they must use a certain item, which direct the process towards 
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reviewing clinical data and outcomes and stressing clinical acceptability rather than just a 
personal preference. 
Another practice that was recommended was to limit sales representative access to surgical 
suites and their relationships with physicians. This direction actually helps in achieving the 
clinical evidence discussions mentioned above. 
They also suggested using an incentive system to encourage implementing and continue 
using agreed upon items. One example is to put a portion of savings from using standard items 
into an extra educational fund, that is to provide education the staff would not otherwise have 
had access to, or research, or capital investment. Another example is to reward physicians 
financially for choosing vendors that increase contract compliance. 
Another practice that was recommended is the integration of cost, quality, and outcomes in 
the value analysis process, to provide an analysis of patient impact and financial impact. 
Actually, this is a fundamental concept in the framework proposed in another research the 
authors are working on (Shbool and Rossetti 2016). The model captures all these elements 
mathematically and provides the necessary analysis of the different outcomes elements tradeoffs 
in terms of preferred selection value versus cost. 
Actual usage of products at the point of use and integrating the information with clinical 
systems was also recommended. The idea is to get outcomes so that they can do a more thorough 
and evidence-based comparative-effectiveness analysis across similar products. This will also be 
used to understand impact on outcomes like (readmission rates, reimbursement for related 
procedures, infection rates, surgical times, etc.). The usage and clinical data will also be used in 
variation analysis by physicians to drive standardization. In this way, physicians’ preference will 
 75 
 
not be sufficient justification for utilizing products, and the performance of those who are getting 
better outcomes at lower costs will be the benchmark. 
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3 Chapter 3: Physician Preference Items – A Decision Making Framework 
 
Abstract 
Physicians’ preference items contribute to 61% of total supply expenditure (Schneller and 
Smeltzer 2006). (Shbool and Rossetti 2016) found that 39.1% of total items in healthcare 
organization are PPIs. Stock keeping unit (SKU) proliferation is an issue for healthcare 
organizations, of which PPIs is a major contributor to the problem. Item’s selection process is 
done based on value analysis at best, which (value analysis) is done through discussions by a 
cross functional team on the candidate items. This process is highly subjective.  This work uses 
Multiple-objective decision analysis (MODA) to develop a mathematical structured framework 
for the PPIs selection decision process. This paper offers three contributions: characterization of 
the PPI selection problem by defining the criteria used in evaluating alternatives, implementing a 
multi-criteria decision making (MCDM) methodology to develop a framework for the decision 
that can be used in practice, and an illustration of the framework through a case study to evaluate 
the framework effectiveness. 
3.1 Introduction 
Effective and efficient selection of medical items and supplies within healthcare providers 
can lead to better management of inventory within the organization’s supply chain, and reduced 
total cost. During the last decades, the healthcare sector has advanced enormously regarding 
treatment processes, technology, devices and medical items/supplies. However, this puts the 
supply chain of healthcare providers under pressure due to the overwhelming number of items. 
The focus of this research is on functionally equivalent items which are introduced by 
competitors. In the retail sector this is called stock keeping unit (SKU) proliferation and is 
caused by holding different brands for the same item. SKU proliferation can be defined as the 
increasing of the variety and the number of functionally equivalent items that are stocked by 
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inventory management systems in response to marketing, acquisitions, sales incentives, and lack 
of life cycle controls. 
In the healthcare sector, SKU proliferation is a problem for the supply chain and might be 
attributed to many reasons of which physician preference items (PPIs) is the major contributor. 
PPIs are costly medical/surgical items, such as hip and knee implants, cardiac stents, mechanical 
devices…etc., that are selected/preferred by the physician to use for a specific patient and 
procedure/treatment. PPIs exist in most of treatment areas such as: orthopedics, cardiovascular, 
plastic surgery … etc., and within each area they are classified according to the purpose of use 
into further categories. In each category (same purpose) there are many items (brands) for the 
same item type, they are functionally equivalent but may come with different features since they 
are produced by different manufacturers. Some examples of PPIs are heart valves, orthopedic 
and cardiovascular implants. For instance, orthopedic implants can be classified into many 
categories according to use such as: Austin-Moore prosthesis (for fracture of the neck of femur), 
Baksi’s prosthesis (for elbow replacement) … etc. (List of orthopedic implants 2014). Within 
each category, there are many items available in the market from different manufacturers. 
It is difficult to reduce labor cost which is the largest expense in a typical hospital according 
to (Schoen, et al. 2010), so the focus has turned to the reduction of supplies, which represent the 
second largest expense (Moon 2004). A major portion of medical items and supplies in hospitals 
is actually in the form of PPIs (DeJohn 2005). According to (Chow and Heaver 1994), 40% of 
expenses in hospitals is due to supply chain activities, and according to (Schneller and Smeltzer 
2006), PPIs make up to 61% of total supply expenditure. 
Regularly stocked items are those adopted by the organization, stocked in the warehouse and 
ordered from suppliers on a regular basis without the need for a special approval from the 
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organization administration. These items can be managed with conventional inventory theory by 
using forecast models, traditional inventory policies, and optimization techniques. On the other 
hand, PPIs are often considered specialized items from a supply chain perspective. PPIs are more 
difficult to manage, and involve aspects beyond engineering, which can be attributed to factors 
affecting the selection process such as the physicians’ preference.  
Because PPIs may not be regularly stocked, a request by the physician should be placed to 
secure the item by materials management. From the perspective of this research, the problem 
mainly involves two kinds of decisions to be made based on some criteria. The first decision is, 
if a new item (technology) has been introduced, does the organization need to adopt it or not? 
The second decision is, for an existing item, is it better for the organization to not stock the item 
and replace it with another more efficient one based on its effect on the supply chain? In other 
words, should a regular item be used instead of a set of equivalent PPIs? For both decisions, the 
essential question is: Which item should be considered the standard one in a small set of items?  
Currently, healthcare organizations collect information about items, then cross-functional 
teams consisting of clinicians, supply chain professionals, value analysis professionals, and 
healthcare administrators discuss the items and then decide which item to purchase. This process 
is called value analysis by some organizations. Value analysis teams meet and discussions about 
items will take place.  One of the examples on how healthcare organizations are doing the value 
analysis is included in Appendix F.1: Value Analysis Example. When making a new item’s 
request, this form requires the value analysis team members to score on four areas, namely: 
financial, quality, impact, and clinical evidence on a scale from 1 to 10 except for the impact, 
which is from 2 to 20. If an item scored a total of 25, it is rejected. This method seems to use 
similar concepts to what is proposed in this work, yet it is less rigorous and has major technical 
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drawbacks. It does not consider all criteria when evaluating items, it does not have the ability to 
show all items in one picture, it does not have the ability to re-evaluate existing items, and even 
more technical issues related to combining multiple criteria. 
Due to the lack of quantitative evaluation of item’s value versus its cost, decision makers will 
not see the consequences of their decision on supply chain performance and the organization’s 
financial situation. This process is sub-optimal for two major reasons: first, criteria considered in 
the decision process are not clearly weighted, and second, no value-cost tradeoff is shown, 
consequently, decisions will be very subjective. For these reasons, a framework that considers 
putting this value analysis context within a more sound mathematical structure that captures 
criteria weights and the sensitivity of these weights is a contribution of this paper. Figure  3.1 
below is a schematic view of how the MODA framework aligns with the value analysis. 
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Figure  3.1 Value analysis and MODA relationship 
 
This process involves stakeholders, criteria/factors, and alternatives to choose from. Hence, it 
can be seen as a group decision making process with multi-criteria. Multi-criteria decision 
making (MCDM) is a sub-discipline of operations research, it is defined as taking/judging an 
action or a choice based on two or more standards/criteria/factors, which mostly will be 
conflicting (Belton and Stewart 2003). Group decision making is challenging due to different 
perspectives and judgments by stakeholders. Decision making is based on trade-offs between 
different outcomes, where trade-offs are actually based on values (valuable things for the 
decision maker). The presence of different attributes that are not measurable/incommensurable is 
what makes MCDM essentially not easy to solve (Triantaphyllou, et al. 1998). 
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MCDM methodology adopted in this research was the multiple-objective decision analysis 
(MODA) with the purpose of building a framework for the PPI selection decision process. The 
MODA method is actually based on measurable value theory, which is discussed in (Dyer and 
Sarin 1979). Details of the procedure, such as swing weights and value function assessments, is 
based on the Simple Multi-attribute Rating Technique using Swings (SMARTS). Further details 
of the SMARTS procedure can be found in (Edwards and Barron 1994), and (Von Winterfeldt 
and Edwards 1986). The goal is to implement the framework on a selection process through a 
case study in a healthcare organization and evaluate the framework’s effectiveness by the users 
themselves.  
Due to the fact that the PPI problem is a healthcare related issue, which has not been 
structured yet, we consider two important issues before attempting to implement the MODA 
approach. The first critical issue is the nature of the problem. The second issue is the 
unavailability of a structured problem’s definition. Being a health related problem actually 
implies the complicated relationship between all elements and overlap between stakeholders’ 
desires. The nature of factors and stakeholders contributing to the selection process imposes 
difficulty to the problem and make it more challenging. Measuring physicians’ preferences is a 
challenge, as well as how to combine all objectives into a meaningful indicator. Physicians’ 
preference is difficult to measure, and to not satisfy it increases the risk of physicians leaving the 
organization or being less motivated. In this research, physician preference was expressed in 
terms of objectives considered by physicians when building their preference. Unavailability of 
the problem’s characterization means that the criteria considered by all related stakeholders are 
not well defined. Eliciting criteria was the most time consuming stage in this research, and the 
most critical step in building the objectives structure. 
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According to (Triantaphyllou, et al. 1998), MCDM has three unique characteristics which 
are: presence of multiple qualitative and conflicting criteria, multi-dimensional criteria (different 
units of measurement), and the existence of different alternatives. The stakeholders generate 
conflicting objectives that should be considered. For example, supply chain professionals desire 
to minimize the number of different items, and to have regular stock managed at the lowest cost. 
On the other hand a physician’s main objective is satisfying their preferences with highest 
effective items that are easier to use. See Appendix F.2: Stakeholders and Objectives Definitions 
for full list of stakeholders, their desires, objectives and definitions. This tradeoff between 
maximizing supply chain performance and maximizing preferences should be consolidated in 
some way taking into account factors affecting decisions and the consequences of those 
decisions. A good selection decision should be made to increase inventory utilization and 
maximize dollar value as well as to keep a high service level. 
To proceed with this problem investigation, it is necessary first to understand three essential 
elements: How the selection process is being made and who is involved? What are the major 
factors affecting the selection process? How are these factors weighted for alternatives from the 
perspectives of stakeholders involved? These questions will be answered and explained in the 
methodology section.  
The remaining sections of this article are organized as follows; section  3.2 contains literature 
review related to PPI and MCDM. Details of the methodology used in this work can be found in 
section  3.3, which explains the approach and the model developed qualitatively and 
quantitatively. The case study conducted is shown in section  3.4, which includes the process of 
scoring alternatives, analyzing the results, sensitivity analysis. The feedback on the framework 
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effectiveness from users is presented and analyzed in  3.5. Finally, conclusions are presented in 
section  3.6. 
3.2 Literature Review 
Very limited work has been done on the PPI topic and majority of it is in the form of non-
technical reports, which present opinions and experiences of people in the field. The lack of 
modeling on this problem suggests the need for further investigation. It is stated by (Chow and 
Heaver 1994) that more than 40% of expenses in hospitals are attributed to supply chain 
activities. The same result was found later by (Nachtmann and Pohl 2009). Within supply chain 
costs, (DeJohn 2005) indicated that PPIs make-up a great deal of these costs, (Schneller and 
Smeltzer 2006) stated that PPIs make up to 61% of total supply expenditure. According to 
(Siddel 2012), one of the reasons for losses in hospitals is the PPIs, and this is an indication that 
PPIs is a problem for healthcare providers. 
(Jebson and Sweat 2010) discussed factors causing PPIs, as well as factors that make 
physicians use a specific item (brand). Persistent pressure by implant vendors to use the newest 
technology, the approach of one treatment for one disease that followed by some medical doctors 
MDs, and the fact that MDs usually do not take into account financial matters of their hospitals 
are three factors that cause PPIs. Factors that make a physician prefers a specific brand are: how 
experienced a physician is with utilizing the item during residency training, the incentives a 
physician receives due to using a specific implant type, being a member in the design or trials 
team of that item, the good vendor-physician relationship, and finally availability of 
representatives as they add clinical educational value and expertise to routine and complex cases. 
The authors are also currently working on another research to examine the PPI problem from 
a different perspective (Shbool and Rossetti 2016). They developed a deeper understanding of 
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the role that PPIs play within the healthcare supply chain. Two surveys were developed to gather 
information about the management process from two points of view, physicians and supply chain 
professionals. Surveys’ results will help to understand the factors and significance of each in the 
selection process.   
A bibliometric analysis on MCDA researches in healthcare done by (Diaby, Campbell and 
Goeree 2013) showed a steady increase in number of publications on MCDA in healthcare over 
the years 1965-2011. Three research topics were analyzed namely clinical, health systems, and 
methods, and all of them experienced the increase in research volume. However, no literature 
was found that has adopted MCDM methodology or implemented any decision analysis 
technique into the PPIs selection problem. 
MCDM techniques have different capability with different features and characteristics. The 
use of a technique over another depends on the problems elements, and the result may not be an 
optimal choice, rather it improves the quality of the decision taken. A review of MCDM 
techniques and classification can be found in (Triantaphyllou, et al. 1998). A literature review 
performed by (Velasquez and Hester 2013) discussed common MCDM techniques, their 
applications, and strengths and weaknesses.  
A very popular problem in the supply chain space is the evaluation and selection of suppliers. 
The selection of a supplier is a similar problem to the item selection problem; in that it has an 
objective of selecting a supplier based on some criteria. In addition, the decision is done by a 
group of decision makers who have input into the process from different perspectives. Many 
research efforts have been done on this problem, (Agarwal, et al. 2011) reviewed the most 
common techniques used in literature for this purpose. In more than 60 articles, they found that 
the most common methods are DEA, mathematical programming (linear programming, integer 
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linear programming, integer non-linear programming, goal programming, and multi-objective 
programming), AHP, CBR, ANP, fuzzy set theory, SMART, genetic algorithm, and criteria 
based decision making methods (ELECTREE and PROMETHEE), with DEA as the most 
prominent one. Following the sense of methods’ combination mentioned above, many 
researchers proposed a decision framework for supplier selection based on a combination of two 
or more techniques. An integrated decision model was proposed by (Vijayvagy 2012) to select a 
supplier using a combination of AHP and TOPSIS. The model included 18 criteria set classified 
into 7 groups. A survey was distributed to 50 managers to capture their opinions about 
importance of selection criteria and suppliers performance. AHP was used to make a primary 
evaluation, and then TOPSIS was used to do a second round of evaluation. TOPSIS did not 
conclude with the same choice as AHP, and hence AHP was declared as a better method for 
supplier selection. 
Decisions can be made either individually or by a group, and in both contexts the purpose is 
to make a decision, that minimizes the possibility of after-decision regret by being satisfied that 
the decision considered all factors properly (Belton and Stewart 2003). Group decision is more 
sophisticated than individual decision making; because it should tackle in addition to the level of 
conflict between criteria, the conflict between stakeholders in deciding which criteria are 
relevant, and to what extent it is important.  
There is no right answer to the decision problem; decision is mainly built on subjectivity 
(Belton and Stewart 2003). Decision analysis is designed to help in managing subjectivity and 
integrating objectives with criteria into one frame to select/rank from available alternatives. 
Multi criteria decision making will not provide a cut point and objective decision which takes the 
decision making’s pain out. MCDM will guide the decision process, and provide more 
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transparent decision through focusing on trade-offs of different objectives and result in a more 
informed decision. We should also differentiate between decision makers, who are responsible 
for making the decision, and the facilitators or analysts, who work to guide and assist the DM in 
making the most appropriate decision. 
MODA ( (C. W. Kirkwood 1997), (Keeney and Raiffa 1976), (Parnell, et al. 2013)) has been 
applied to applications in areas like military, see (Trainor, et al. 2007) and (Ewing Jr., Tarantino 
and Parnell 2006), and resulted a good quality decisions. MODA was chosen in this research due 
to many reasons of which that it is designed to be consistent with the five rules formulated by 
(Howard 2007). The framework consists of applying MODA on the PPI selection problem, 
performing a case study with users in a healthcare organization, and finally evaluating the 
framework effectiveness by the users. 
The end result of the framework produces an assessment of the value of different alternatives 
versus cost for the assessed alternatives. This will facilitate the decision process by informing 
decision makers of the estimated value of their selection versus the cost tradeoffs. In other 
words, it is not about making a decision, rather the goal is to add a sustainable better process 
(framework) that can help making the selection decision many times. We believe this paper 
offers the following contributions: 
• Characterization of the PPI selection problem by defining the criteria used in evaluating 
alternatives 
• Providing a framework for implementing MCDM techniques on the PPI selection 
decision problem, 
• Evaluating the decision framework effectiveness and applicability through a case study 
 87 
 
• Putting the existing value analysis process in a structured mathematical sound process 
which has two advantages: measuring value and tradeoffs quantitatively, and assessing 
value before implementation  
 
3.3 Methodology: MODA Implementation 
The intended goal of this work is to offer a framework that can be used by value analysis 
teams to guide the decision process and add visibility to the decision process. Understanding this 
is important to PPIs assessment for two reasons. First, selected attributes must emerge from the 
value analysis context. Second, the methodology should support the decision makers’ ability to 
increase the value of selected items’ portfolio and interpret the results at any time. Thus our 
approach assessed the value of items versus cost independent of their current state (in stock, 
approved, new, etc.), which allows us to treat all items from the same point of view and giving 
each item the same chance of staying in use, phased out, or adopted. 
The methodology (MODA) in this work implemented a nonmonetary value function 
(Approach 1A), which is found in (Parnell, et al. 2013) and (Keeney and Raiffa 1976). MODA 
enables the quantification of values of different candidate alternatives (items) based on the 
criteria considered when making the decision. Criteria like: Item’s effectiveness, manufacturer’s 
lead time, etc. While the specific model and framework was developed specifically for the PPIs 
selection decision problem, the methodology could be applied to other similar problems in 
healthcare. For alternatives involving multiple yet conflicting objectives, one of the most 
appropriate techniques to determine value and analyzing those alternatives is MODA. 
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We developed a value model using MODA, which provides logical, transparent, and an 
unbiased structure to assess each alternative with a single numerical value. The main 5 parts of 
the model are: 
1. An objectives hierarchy (Value tree) that summarizes and organizes the objectives 
2. Metrics (value measures) that quantify each objective 
3. Range of each value measure, from worst performance point (acceptable or available) to 
best possible performance (ideal or achievable) 
4. Value functions that define value return to scale levels of value measures 
5. Swing weights that determine the relative value assessed from swinging on the full range 
of the different value measures 
The process of developing the framework is presented in Figure  3.2 . 
 
Figure  3.2 Process of MODA implementation 
 
MODA can evaluate alternatives using any of several mathematical functions. The most 
commonly used and simplest model is the additive value function, which assumes mutual 
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preferential independence as well as that value scales and swing weights should be assessed for 
the value measures (C. W. Kirkwood 1997). Our work involved several key stages: 
Qualitative PPI selection value model. We developed a qualitative PPI selection value model 
based on research from available literature and stakeholder analysis.  The value model includes 
criteria related to all involved stakeholders organized in 5 major top level objectives. We 
interviewed professionals from three major different healthcare organizations in the area, and 
two other remote organizations either in person, or virtually to define the PPI value model. 
Feedback was also collected using computer based forms. 
Quantitative PPI value model. The quantitative model was developed using the qualitative 
model to determine the value of a PPI. 
Items selection analysis. Analysis of preferred items to select was done within the case study. 
This includes value versus cost chart, value components charts, and sensitivity analysis. 
Supply chain professionals from the healthcare organizations participated as users of the 
model and also gave feedback on the model before and after using it. Physicians were key to the 
process; they contributed to the model development process by criticizing and fixing, adding, 
and removing items within the objectives hierarchy. They also provided valuable feedback on the 
model elements, and the framework evaluation. The authors played the major role in the 
modeling and analysis of the value model. 
 The Qualitative Model 3.3.1
Developing the PPI value model was accomplished by a number of steps: analysis of 
literature, conducting interviews of professionals in the field, analyzing stakeholders and their 
desires, translating these desires to objectives in a hierarchy value tree, and finally building the 
quantitative model using MODA which by itself is composed of 5 parts. 
 90 
 
Literature was reviewed to initiate understanding of the problem. It was understood from 
available literature that the problem is not straightforward, it is still based on opinion, and the 
whole process is very subjective. This helped to conceptualize the model. Medical and PPI 
terminology were also reviewed to develop a common language with healthcare. This facilitated 
the communication with SC professionals and physicians. 
Interviews with physicians and supply chain professionals were conducted and helped to 
develop understanding of the basic elements of the PPI value model. Insights from these 
interviews also helped in analyzing the stakeholders and their desires. 
Stakeholder analysis was done to supplement the information reviewed from literature.  We 
conducted stakeholders’ interviews with three local healthcare organizations. Results from those 
interviews provided further insights that were not found in the scant literature. It helped to 
capture the desires and objectives of stakeholders. We listed the five main stakeholders 
(Physicians, Nurses, patients, supply chain professionals, and the organization itself), and then 
defined desires and objectives for each stakeholder, see Appendix F.2: Stakeholders and 
Objectives Definitions. Finally, the objectives hierarchy (also known as value hierarchy) was 
built for the PPI selection problem.  
Table  3.1 demonstrates the PPI selection value qualitative model, which we define as 
objectives and sub-objectives. The first column contains the five first level objectives that 
support the overall objective of improving the control and effective use of PPI items within the 
healthcare supply chain. The second column shows sub-objectives under each of the five 
objectives. A pictorial representation of the qualitative value model is shown in Figure  3.3. The 
orange boxes indicate the first (top) level objectives; the light blue boxes indicate the sub-
objectives, while the yellow boxes indicate the value measures. The cost objective was not 
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included in the value hierarchy for two main reasons. First, the context of this problem is 
healthcare, which makes it different in terms of objectives attainment and priority for value over 
the cost. Second, treating cost separately and showing the amount of value added per each unit 
cost is useful for the decision makers to evaluate the best choice, as well as for using such 
analysis in portfolio analysis. 
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Table  3.1 PPI selection value qualitative model  
First Level 
Objectives Sub-objectives Value Measures Type of scale 
1. Maximize 
treatment 
effectiveness 
1.1 Prefer items with higher 
efficacy (during trials) 
Proportion of treatments that achieved 
the intended effect during ideal trials Natural 
1.2 Prefer items with higher 
effectiveness (during actual 
use) 
Proportion of treatments that achieved 
the intended effect during actual use Natural 
1.3 Prefer items with lower 
Side effects/risks Side effects type Constructed 
1.4 Prefer items for which 
physicians have more 
experience using 
Skill and experience Constructed (Multidimensional) 
1.5 Prefer items that have 
more distinguishing/unique 
features 
Amount of distinguishing features Constructed 
1.6 Prefer items that are safer 
(Higher reliability and less 
issues during use) 
Reliability Natural 
2. Improve patient's 
long term  outcome 
2.1 Prefer items that minimize 
patient's length of stay Total # of days stayed Natural 
2.2 Prefer items that 
maximize quality adjusted life 
years 
Expected years*Quality of living 
(QALY) Natural 
2.3 Prefer items that minimize 
infection rates Infection percentage Natural 
2.4 Prefer items that have 
longer expected working life Expected item's working life Constructed 
3. Maximize 
clinicians 
satisfaction 
(Physicians and 
nurses) 
3.1 Prefer items from 
manufacturers/suppliers that 
have higher ability to provide 
product support 
Ability to solve problems Constructed 
3.2 Prefer items from 
manufacturers that have 
higher willingness and ability 
to support product trials 
Testability Constructed 
3.3 Prefer items that have 
easier instructions for 
preparation and use 
Instructions difficulty level Constructed 
3.4 Prefer items that are 
actually easier to use Usage difficulty level Constructed 
3.5 Prefer items that minimize 
the time needed for additional 
training  
Time needed Constructed 
3.6 Prefer items that minimize 
the time needed for 
performing treatment 
Relative time Constructed 
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Table 3.1 PPI selection value qualitative model (Cont.) 
First Level 
Objectives Sub-objectives Value Measures 
Type of 
scale 
4. Maximize 
Organizational 
benefits 
4.1 Prefer items that maximize 
patient's acquisition Acquired patients rate Natural 
4.2 Prefer items that maximize the 
reimbursement associated with 
procedures 
Reimbursement rate Natural 
4.3 Prefer items that minimize 
readmission Readmission rate Natural 
4.4 Prefer items that maximize patient 
retention Retention rate Natural 
4.5 Prefer items that maximize 
attractiveness of profitable physicians 
Attractiveness of profitable 
physicians Constructed 
4.6 Prefer items that minimize the 
amount of associated medical 
lawsuits/claims 
amount of lawsuits Constructed 
5. Maximize 
supply chain 
performance 
5.1 Prefer items that are easier to 
handle and manage  Ease of handling Constructed 
5.2 Prefer items that have more 
flexibility in specifying the minimum 
order quantity 
Minimum order quantity allowed Constructed 
5.3 Prefer items from 
manufacturers/suppliers that have 
higher ability to meet urgent delivery 
requirements 
Ability of urgent delivery Constructed 
5.4 Prefer items that have more 
consistent lead-time reliability Lead-time coefficient of variation Constructed 
 
 
 94 
 
 
 
Figure  3.3 PPI objectives hierarchy 
 
Initially, the objectives hierarchy included 36 sub-objectives, but was reduced to 27 after 
getting initial feedback from both the experts (physicians and SC professionals participated). We 
asked for their feedback on how they feel about the importance of these criteria to the context of 
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the PPI problem. Another round of meetings and feedback on the objectives hierarchy was 
conducted with physicians working in the area of item selection. This feedback was very 
important and deeper than the first round for two reasons. First, it is from physicians who are 
working with items selection and value analysis, which makes this the most accurate and 
valuable feedback due to their knowledge in all elements of the problem. Second, the feedback 
was done after an educational meeting was conducted to explain the MODA methodology itself, 
and provided them with all required information about the PPI model including hierarchy, 
definitions, and value measures scales. The feedback form used to give feedback on the 
definitions of objectives and value measures is included in Appendix F.3: Objectives and Value 
Measures Review. The result was removing 4 objectives, fixing definitions of few objectives and 
value measures, and finally adding 3 objectives leaving the tree with a total of 26 objectives. 
The first objectives level is used to increase the hierarchy readability and traceability. Each 
of the first level objectives has a set of sub-objectives. The lower level objectives (sub-
objectives) are directly measured, and also can be called attributes, criteria, etc. For each sub-
objective, a value measure was assigned to assess how a PPI selection supports the sub-objective, 
and a value function was defined which quantifies the value of returns to scale on each value 
measure. 
The preferential independence was inspected by making sure none of the criteria/sub-
objectives has joint value function with any of the other criteria. This was assumed in this 
research since it is almost impossible to fully marginally measure all criteria with no effect on 
any of the rest. Overlap always exists, but there is a reason for not combining criteria together. 
For example, side effects and effectiveness have some overlap. However, side effects should not 
be a key factor in selecting an effective item for critical treatments, and can differentiate items 
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for non-critical treatments or similar items in terms of effectiveness. This allows differentiating 
between importance of effectiveness and side effects. For example, when the treatment is risky 
and crucial, both the physician and the patient do not care about side effects as much as they care 
about the patient's life! So, a low swing weight on side effects and high score on effectiveness 
can manage this possible dependence. When the treatment/item is not critical, close scores on 
treatment will allow differentiating the items based on side effects. 
 
 The Quantitative Model 3.3.2
After the qualitative model was developed, value measures were defined for all objectives, 
single-dimensional value functions were also specified to measure returns to scale. One of the 
value measures needed a two-dimensional value function to accommodate for the value 
dependence, and this is the physicians experience using the item. Weights were also assessed as 
described later. The required assumptions for the additive value model were also ensured to be 
satisfied. 
Value Measures 
A value measure/metric is “a quantitative scale that measures the value to the decision 
makers and stakeholders of the degree to which objectives are achieved” (Parnell, et al. 2013). 
Value measures specified for the PPI model objectives are shown in Figure  3.3 as the yellow 
boxes, and also in Table  3.1. Different levels (or scores) for each value measure were also 
defined to work as a rubric for the scores on the x-axis and the corresponding values on the value 
function. According to (C. W. Kirkwood 1997), value measures can be classified according to 
two dimensions: alignment with the objective either direct or proxy, and types of measures either 
natural or constructed, with both direct and natural being preferred from both dimensions. Of the 
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26 objectives in the PPI model, 10 were direct natural measures, where 16 were direct 
constructed with 15 being single-dimensional and 1 being a two-dimensional measure. The two-
dimensional constructed scale was introduced to account for the interaction between physician’s 
skill and years of experience in one value measure. 
The value measures constructed scales must pass the clairvoyance test (C. W. Kirkwood 
1997). The scales must be well defined and include all outcomes possible to satisfy this test’s 
requirements. We defined the scales for the PPI model considering all possible outcomes; as 
subject matter experts we reviewed and approved/improved the scales and their definitions with 
physicians who are working in item selection. For the natural scales, the definitions are 
straightforward. An example of a natural measure is the item efficacy value measure “proportion 
of treatments that achieved the intended effect during ideal trials”, which has levels of measure 
as % ranging from 20 to 100%. An example of a constructed one-dimensional value measure 
rubric is the item’s distinguishing features value measure “amount of distinguishing features”, 
for which we defined the score levels as shown in Table  3.2. The full list of value measures 
(natural and constructed) and their levels definitions are shown in Appendix F.4: Value Measures 
Scales. 
Table  3.2 Item distinguishing features value measure 
Prefer items that have more distinguishing/unique features 
Score Definition 
0 No distinguishing/unique features 
1 Few extra features 
2 Noticeable distinguishing/unique features 
 
A Value Function for Each Value Measure 
In this section, the value functions are described in terms of types and assessment. The 
mutual preferential independence assumption means that the preference order of a criterion does 
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not change with changes in the rank ordering of preferences of other criteria. In other words, the 
assessment of the value for an alternative on a specific value measure does not depend on any 
other value measure’s assessment. If the criteria {𝑋1, 𝑋2, … ,𝑋𝑛} are mutually preferentially 
independent, the value function 𝑣(𝑥1, 𝑥2, … , 𝑥𝑛) is additive (for n>3) as proved by (Keeney 
and Raiffa 1976). We worked in this research to ensure that the value difference of a criterion is 
independent of the remaining criteria. Hence, the PPI value for a selection𝑣(𝑥), can be captured 
with an additive measurable value function as 
𝑣(𝑥) =  �𝑤𝑖𝑣𝑖(𝑥𝑖),𝑛
𝑖=1
 
Where x is a vector of the set of value measures 
𝑣(𝑥) is the overall value of an alternative on all the set of value measures, x 
i is an index of the value measure, and n is the total number of value measures 
𝑥𝑖 is the alternative score, level on the x-axis, of the ith value measure 
𝑣𝑖(𝑥𝑖) = is the corresponding value on the y-axis of the ith value measure 
𝑤𝑖 is the swing weight of the ith value measure, and 
�𝑤𝑖
𝑛
𝑖=1
= 1. 
Value functions provide normalized unified scores on the y-axis (value of preference) 
corresponding to alternative scores on the x-axis (score levels on the measure scale) of the 
specific value measure. Each value measure has its own x-axis. Two methods were presented to 
assess value functions by (Keeney and Raiffa 1976) namely, Midvalue Splitting Technique and 
the Lock-Step Procedure, with the first being the most common in practice. Another two 
methods were presented by (C. W. Kirkwood 1997) and they are the piecewise linear function 
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and the exponential function. The basic concept behind the piecewise linear single dimensional 
value function is the relative value increment. That is, for the small set of possible evaluation 
measure scores, the relative value increments should be determined between each successive 
score.  
When the value measure can take on an infinite number of different measure levels, the 
exponential function approach is followed. It was proposed by (Kirkwood and Sarin 1980) as an 
extension to the Midvalue Splitting Technique when criterion meet certain conditions. For an 
evaluation measure x, there are two cases for the preferences trend, either monotonically 
increasing or monotonically decreasing. When preferences are monotonically increasing (that is, 
higher score levels of xi are preferred to lower score levels), then the exponential single 
dimensional value function 𝑣𝑖(𝑥𝑖) is 
𝑣𝑖(𝑥𝑖) =
⎩
⎪
⎨
⎪
⎧ 1 − exp [−(𝑥𝑖 − 𝑥𝑖𝐿)/𝜌𝑖]1 − exp [−(𝑥𝑖𝐻 − 𝑥𝑖𝐿)/𝜌𝑖] , 𝜌 ≠ 𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼
𝑥𝑖 − 𝑥𝑖
𝐿
𝑥𝑖
𝐻 − 𝑥𝑖
𝐿 ,                                             𝑜𝐼ℎ𝑒𝑒𝑤𝐼𝑒𝑒 
where 𝑥𝑖𝐿 and 𝑥𝑖𝐻 are the lowest and highest score levels of the specific value measure xi, 
respectively, and 𝜌𝑖 is the exponential value function constant. The shape of the function is 
determined by 𝜌𝑖 where negative values result in convex functions, and positive values result in 
concave functions. A similar exponential value function can be specified for the monotonically 
decreasing preferences case. The value resulted 𝑣𝑖(𝑥𝑖) from the previous exponential function 
ranges between 0 and 1, and if another scale is needed, a leader appropriate factor should be 
used. The unknown in this equation is 𝜌𝑖 which can be numerically determined. 
Any of the above mentioned methods need significant amount of time from available experts 
in the healthcare area. This was a very difficult task due to the unavailability of experts from the 
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field who are willing to spend the required time in answering the amount of questions needed to 
produce value functions for the 26 measures. Consequently, another approach was needed which 
depends more on the researchers effort and minimize extra needed input from experts. The group 
voting procedure in (Parnell, et al. 2013, 197-198) was followed to propose the preliminary set of 
value functions. The procedure steps are 
• Define the value measures and the x-axis carefully. This is critical step, as everything 
following depends on it. 
• Decide about the units of value, that is the range of the unified normalized value on 
the y-axis. Most common ranges are 0 – 1, 0 – 10, and 0 – 100. 
• Specify the range of each value measure; that is the range of score levels on the x-
axis. This is important since it affects the shape of the value function as well as the 
swing weights. 
• Assess the value functions using one of two techniques 
a. Assess the shape of the curve (convex, concave, S-shape … etc.) and then 
assess corresponding parameters, inflection points 
b. Assess points of value corresponding to scores on the x-axis and fit the curve 
• Get the experts to agree on the shape of the value functions and the justification for 
the returns to scale 
The value functions in this research were developed using this approach, and the authors did 
extensive research to build the single-dimensional value functions and provide rational for the 
proposed shapes and returns to scale. Expert’s opinion was captured to either support our 
proposed functions, or to provide justification for another curve shape. Each value measure has 
its own x-axis. All measures have a unified scale from 0 to 100 on the y-axis for the value curves 
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representing the potential value added from the PPI. Value functions corresponding to all value 
measures and their rationale in this research are summarized in Table  3.3, followed by two 
examples on the logic behind the value function shape for the item efficacy and side effects. 
Table  3.3 PPI Selection Single-Dimensional Value Functions 
Value Measures 
Min 
Acceptable 
Level 
Ideal 
Level 
Curve 
shape Rational 
Proportion of treatments that 
achieved the intended effect 
during ideal trials 
20 100 Convex Higher efficacy is more valuable 
Proportion of treatments that 
achieved the intended effect 
during actual use 
20 100 Convex Higher effectiveness is more valuable 
Side effects type 0 6 S-Curve 
Low side effects is more desirable, and 
decrement in value is slow until side effects hit 
the red zone, the value drops quickly 
Skill and experience 1 7 Linear Each increment in experience is equally valuable 
Amount of distinguishing 
features 0 2 Linear Each increment is equally valuable 
Reliability 0.6 1 S-Curve 
Higher reliability is more desirable, but initial 
increase in more likely to be required, then the 
increase in value is slower 
Total # of days stayed 0 5 Concave Lower number of days is more desired 
Expected years*Quality of 
living (QALY) 0.1 1 Convex Higher QALY is more desirable and valuable 
Infection percentage 0 100 Linear Each decrement is equally valuable 
Expected item's working life 1 5 Linear Each increment is equally valuable 
Ability to solve problems 1 5 Linear Each increment is equally valuable 
Testability 1 4 Concave Initial increase is more likely to be desired 
Instructions difficulty level 1 4 Convex Easier instructions is more valuable 
Usage difficulty level 1 3 Linear Each increment is equally valuable 
Time needed 1 4 Concave Shorter time needed for additional training is more valuable 
Relative time 1 3 Linear Each decrement is equally valuable 
Acquired patients rate 10 100 Linear Each increment is equally valuable 
Reimbursement rate 40 100 Linear Each increment is equally valuable 
Readmission rate 0 100 Linear Each decrement is equally valuable 
Retention rate 10 100 Linear Each increment is equally valuable 
Attractiveness of profitable 
physicians 1 3 Linear Each increment is equally valuable 
amount of lawsuits 1 3 Linear Each decrement is equally valuable 
Ease of handling 1 3 Linear Each increment is equally valuable 
Minimum order quantity 
allowed 1 3 Linear Each increment is equally valuable 
Ability of urgent delivery 1 4 Convex Higher ability for urgent delivery is more valuable 
Lead-time coefficient of 
variation 0 2 Linear Each decrement is equally valuable 
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Item efficacy 
• The definition of item’s efficacy is: the extent to which an item/drug/medical device 
has the ability to produce its intended beneficial effect (or therapeutic effect) in expert 
hands and under ideal circumstances. During trials, the effectiveness of an item is 
captured as number of times it achieved the intended effect. Relative to the total 
number of trials, the efficacy will be measured as rate of success during laboratory 
tests.  
• The range of any percentage is from 0 to 100, but the minimum acceptable is assumed 
as 20%, so the range of the “item efficacy” value measure would also be 20 – 100 as 
a %. 
• The value function was assessed as exponentially increasing; see below.  
 
 
Figure  3.4 Item efficacy value function 
 
• The justification for this shape is that the value added for each increment in efficacy 
is more desirable when moving up in the scale. Low scores will have less value 
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because an efficacy below a specific point is not wanted. After this deflection point, 
each increment in the score will have more value than the one before, or in other 
words a drop in the efficacy score will cost more (value) than a previous drop in 
efficacy to the left on the x-axis.  
• Illustration: assume we have three points on the x-axis (efficacy score): 𝑥1, 𝑥2, 𝑥3 
where 𝑥1 < 𝑥2 <  𝑥3 𝑎𝑒𝑒𝑎𝑎𝑒  𝑥1 = 20,  𝑥2 = 40,𝑎𝐼𝑎  𝑥3 = 50. The corresponding 
y-axis values (value or return) are: 𝐼1 = 0, 𝐼2 = 7,𝑎𝐼𝑎 𝐼3 = 13, respectively. The 
two consecutive jumps in item efficacy will be 𝑥2 −  𝑥1 = 20,𝑎𝐼𝑎 𝑥3 −  𝑥2 = 10 
with the two corresponding value increments 𝐼2 −  𝐼1 = 7 𝑎𝐼𝑎 𝐼3 −  𝐼2 = 6, 
respectively. The value increment to scale increment ratio can be calculated as 
𝑅1−2 = 𝑦2−𝑦1𝑥2−𝑥1 = 720 = 0.35  and 𝑅2−3 = 𝑦3−𝑦2𝑥3−𝑥2 = 610 = 0.6, then we can say that for 
this specific value function,  𝑅2−3 > 𝑅1−2. 
Side effects/risks 
• The definition of side effects/risks is: the possibility that an item/medical device could 
cause an unwanted or unexpected negative effect ranging from minor (e.g. dry 
mouth) to serious (e.g. bleeding or heart attack). Observed problems in clinical trials 
are called “adverse events”; they might or might not be related to the item/medical 
device under study. Once that relationship is discovered, the problem is called 
“adverse effect” or as commonly known “side effects” (Medicine Safety and You 
2011). When item has been used before, the total percentage of injury or death-related 
events over all events for the item is used to assess side effects/risks. 
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• There is not a natural measure for side effects. Thus, a constructed scale was initiated 
with 7 cases ranging from no side effects to serious with >60% death related events, 
see Table  3.4 for the side effects/risks value measure constructed scale definitions. 
 
Table  3.4 Side effects/risks value measure constructed scale 
Score Definition Value 
0 No side effects 100 
1 Minor side effects (Dry mouth, itching …) 95 
2 Major injuries nonlife threatening 80 
3 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
less than 20% 40 
4 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
>20% & <40% 15 
5 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
>40% & < 60% 5 
6 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
>60% 0 
 
• The value function was assessed as a decreasing s-curve, see Figure  3.5. 
 
Figure  3.5 Side effects value function 
 
• The justification for this is that a low side effect is more desirable, and the decrement 
in value is slow until the side effect hits the red zone, moving from case 2 to 3, the 
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value drops quickly. For life threatening side effects, the value is already very low, 
and the decrease progress becomes less significant. The value function is like 3 pieces 
together: concave, linear, and convex. 
• Illustration: for the “no side effects” case which scored 0, the value is 100, this means 
it is the highest possible (and ideal at the same time) preferred scenario. However, in 
practice this is almost not achievable, so a near optimal case (score 1) was created and 
was assigned a value of 95. The next side effect case involves major injuries; but 
nonlife threatening, so the value assigned was 85. The next side effects case (score 3) 
represents a serious life threatening scenario, so a major drop in value is expected at 
this point due to the life threatening risk. Remaining cases are life threatening with 
higher risk expressed as death related events, so the value will continue to decrease; 
but with a lower rate than the rate of entering this red zone. 
 
The model was implemented using a spreadsheet, and the calculations of alternative value 
were performed using a macro which passes the required scoring, and the value function list of 
values for both x and v(x) as input. The macro used was adopted from (C. W. Kirkwood 1997) 
which can be found in Appendix F.5: Excel Macros. It has two sub-functions, one uses a 
piecewise linear approximation, and the other one uses an exponential approximation. The 
piecewise linear function is used when the value measure has a small number of possible scoring 
levels. It uses linear equations to approximate the value. 
The exponential approximation is used for monotonically increasing/decreasing preferences. 
For any given score level (x), the function will approximate the value preference using the 
equation shown previously. The low and high scores are known from the value measure scale 
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definition, and the parameter ρ should be assessed using a third point on the value, usually the 
mid-value such that v(x) = 0.5. There is no close form solution, it should be solved numerically. 
Using goal seek, ρ can also be estimated such that the value is 0.5 for the specific x. 
 
Weights Assessment 
Swing weights can be defined as the degree of desire assessed (value increment) by swinging 
the score on each value measure from its least preferred level to its most preferred level. Swing 
weights depend on importance and range of variation of the value measure; they represent the 
increment in value that is added from the alternative by enhancing the score on that evaluation 
measure from its least preferred level to its best level. Each value measure should be assigned a 
swing weight, which assesses the value added by the alternative when scoring high on that value 
measure. Sum of normalized swing weights should be 1.  
Determination of swing weights is the last step in building the model, after which the model 
will be ready for scoring and evaluating the alternatives. The weights’ assessment process is 
basically subjective, and to satisfactorily assess weights, both the decision makers’ preferences 
(relative importance of the criterion/objective) and the range of the value measures should be 
considered. In general, it is difficult to reach a consensus on the weight assessment from a group 
of decision makers. There are many methods for assessing swing weights such as: Simple 
Multiattribute Rating Technique (SMART), Simple Multiattribute Rating Technique using 
Swings (SMARTS), Simple Multiattribute Rating Technique Exploiting Ranks (SMARTER), 
Analytical Hierarchy Process (AHP), and Value Increment. Another approach to assess weights 
which could be used with groups is the voting (ordinal then cardinal) (Parnell, et al. 2013). 
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In this research, the voting for groups (cardinal and ordinal) method described in Parnell et 
al. (2013) was used to determine the weights for the PPI model to illustrate the process. Once the 
range has been determined for each value measure, the voting for groups steps are: 
1. Vote. (Have each individual order value measures based on the measures’ importance 
and range.) 
2. If the groups did not agree on the order, discuss the differences. Have the “outliers” 
explain their rationales. 
3. Revote until the group come to a consensus on the order. 
4. Have each person to spread 100 points over the measures following the group’s 
ordinal ranking of the value measures. 
5. Average the weights and normalize to range 0-1, the sum should be one. 
6. Discuss if points assigned are significantly different. Have the “outliers” explain their 
rationales. 
7. Redo steps 4–6 until the group come to a consensus. 
For a real case study, the swing weights are to be determined using the value increment (C. 
W. Kirkwood 1997) method or swing weight matrix method (Parnell, et al. 2013). The swing 
weights also should be determined from the bottom to the top of the tree. In the illustrating 
example included in this work, voting was used to make it easy when explaining the 
methodology to the experts who participated in this process. Considering the first level of 
objectives shown in Figure  3.6, the voting approach was used to assess swing weights with 
professionals; results are shown in Table  3.5 below. 
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Figure  3.6 Top level objectives 
Table  3.5 Top level objectives’ swing weights 
Order First level objectives 
Points 
(100) Swing Weights 
1 Treatment Effectiveness 22 0.22 
2 Patient Long Term Outcome 22 0.22 
3 Clinicians Satisfaction 20.9 0.209 
4 Organizational Benefits 18.7 0.187 
5 Supply Chain Performance 16.4 0.164 
The swing weight for each of the top level objectives will be used to determine the subgroup 
contribution to the overall alternative value. Within each group of sub-objectives, swing weights 
should also be determined using the same procedure, and again the summation of the swing 
weights should be 1. For the first group “Treatment Effectiveness” shown in Figure  3.7 below, 
the resulting swing weights are shown in Table  3.6. Similarly, for the remaining 4 groups: 
“Patient long term outcome”, “Clinicians’ Satisfaction”, “Organization Benefits”, and “Supply 
Chain Performance”, the swing weights results are shown in Table  3.7, Table  3.8, Table  3.9, and 
Table  3.10, respectively. 
The normalized global swing weights can be calculated using the formula: 
𝑤𝑖 = 𝑓𝑖∑ 𝑓𝑖𝑛𝑖=1 ,        Where 
i = the ith value measure, 
n = total number of value measures, 
fi = swing weight assigned to a measure (in points) 
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Figure  3.7 Treatment's effectiveness objectives group 
 
Table  3.6 Treatment effectiveness objectives group swing weights 
Rank Treatment Effectiveness Points 
Swing 
Weights 
1 Item Effectiveness 18.1 0.181 
2 
Item Safety (Reliability and issues during 
use) 18 0.18 
3 Item Efficacy 17.1 0.171 
4 Side effects/risks 17.1 0.171 
5 Physician experience using the item 16.2 0.162 
6 Item distinguishing features 13.5 0.135 
 
Table  3.7 Patient long term outcome objectives group swing weights 
Rank Patient Long Term Outcome Points Swing Weights 
1 Patient length of stay 26.9 0.269 
2 Infection rates 26.9 0.269 
3 Quality-adjusted life years 25.4 0.254 
4 Item expected working life 20.8 0.208 
 
Table  3.8 Clinicians' satisfaction objectives group swing weights 
Rank Clinicians Satisfaction Points Swing Weights 
1 Supplier ability to support product trials 18.7 0.187 
2 Time needed for additional training 17.7 0.177 
3 Ease of instructions for preparation and use 16.7 0.167 
4 Ease of actual Use of the item 16.7 0.167 
5 Supplier ability to provide product support 15.6 0.156 
6 Time needed for performing treatment 14.6 0.146 
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Table  3.9 Organizational benefits objectives group swing weights 
Rank Organizational Benefits Points Swing Weights 
1 Readmission rates 19.6 0.196 
2 
Reimbursement rates associated with 
procedures 17.5 0.175 
3 
Amount of associated medical 
lawsuits/claims 17.5 0.175 
4 Patient retention 15.5 0.155 
5 Attractiveness of profitable physicians 15.5 0.155 
6 Patient acquisition rate 14.4 0.144 
 
Table  3.10 Supply chain performance objectives group swing weights 
Rank Supply Chain Performance Points Swing Weights 
1 Flexibility of minimum order quantity 35 0.35 
2 Suppliers' ability of urgent delivery 30 0.3 
3 Ease of item handling and management  20 0.2 
4 Lead-time reliability 15 0.15 
 
 
The overall value for each alternative was calculated using the following double summation 
to account for the two objectives hierarchy structure for the PPI model. 
��𝑤𝑖𝑖𝑣(𝑥𝑖)𝑛
𝑖=1
𝑙
𝑖=1
 
Where j is an index of the top level objectives, and l is the total number of top level 
objectives, which are five. 
3.4 Case Study 
 Scoring the Alternatives 3.4.1
Four alternatives for a specific item were scored on the 26 value measures by the decision 
team, scores are shown in Table  3.11 below with a theoretical ideal alternative having maximum 
possible scores on all value measures for comparison and verification purposes. 
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Table  3.11 PPI Scores on Each Value Measure 
Value Measures Stent A Stent B Stent C Stent D Ideal 
Proportion of treatments that achieved the 
intended effect during trials % 90 70 85 60 100 
Proportion of treatments that achieved the 
intended effect during actual use % 95 80 80 55 100 
Side effects type 1 2 2 1 0 
Skill and experience using the item 
(Multidimensional constructed) 2 5 6 7 1 
Amount of distinguishing features 2 0 2 1 2 
Reliability 0.7 0.8 0.6 0.75 1 
Total # of days stayed 1 2 3 4 0 
(# of years*life quality) 0.8 0.7 0.5 0.7 1 
Patients' infection % 10 40 30 70 0 
Expected Working life years (categories scale) 1 2 3 4 5 
Ability to solve problems 2 3 4 5 5 
Product trials availability 1 2 4 3 5 
Instructions difficulty level 2 3 1 4 4 
Usage difficulty level 1 2 3 1 4 
Time needed (non, short, medium, long) 2 3 1 4 4 
Relative Time (low, medium, high 3 2 1 2 3 
Acquired patients rate % 3 3 1 1 1 
Reimbursement rate % 3 2 4 1 5 
Readmission rate % 2 2 1 2 1 
Retention rate % 50 75 80 75 100 
Attractiveness of profitable physicians 80 90 60 85 100 
Amount of lawsuits/claims 30 25 50 40 0 
Ease of handling 90 85 70 80 100 
Minimum order quantity 3 2 2 1 3 
Ability for urgent delivery 3 3 2 2 1 
lead-time coefficient of variation 2 2 3 2 1 
 
Using the single-dimensional value functions previously built for the value measures and the 
scores given for each item, the single-dimensional value for each alternative item was calculated 
for each value measure. The value calculation for the ideal should always be 100, and this is used 
to verify mathematics as well as a guide to improvements of alternatives.  
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With all required information available, the quantitative measure of the total potential value 
for each item was calculated using the additive model. For each alternative item, the swing 
weight is multiplied by the value for each measure score, and total value is the sum across all 
value measures for each item. The scoring data was processed using a spreadsheet model to 
calculate the potential value for each alternative. 
 Analyzing the Results 3.4.2
A summary of alternatives scores on value measures and corresponding calculations 
including the single-dimensional values, swing weights, weighted values, and total values are 
summarized in Table  3.12. The total potential value versus cost is plotted and shown for all 
alternatives in Figure  3.8 below.  
 
Figure  3.8 PPI cost versus value 
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Table  3.12 PPI Total Value Calculations 
    Stent A Stent B Stent C Stent D Ideal 
Sub 
objecti
ve / 
Measur
e 
Swing 
Weig
ht 
 
Scor
e 
  
Single-
Dimension
al Value 
  
Value  
 
Scor
e 
  
Single-
Dimension
al Value 
 
Value 
 
Scor
e
 
Single-
Dimension
al Value 
 
Value 
 
Scor
e 
  
Single-
Dimension
al Value 
  
Value  
 
Scor
e 
  
Single-
Dimension
al Value 
  
Value  
 
1.1 0.037 90 70 2.6 70 32 1.2 85 59 2.2 60 23 0.8 100 100 3.8 
1.2 0.039 95 85 3.4 80 48 1.9 80 48 1.9 55 18 0.7 100 100 4.0 
1.3 0.037 1 95 3.6 2 80 3.0 2 80 3.0 1 95 3.6 0 100 3.8 
1.4 0.035 2 84 3.0 5 36 1.3 6 20 0.7 7 0 0.0 1 100 3.6 
1.5 0.029 2 100 3.0 0 0 0.0 2 100 3.0 1 50 1.5 2 100 3.0 
1.6 0.039 0.7 25 1.0 0.8 80 3.2 0.6 0 0.0 0.75 53 2.1 1 100 4.0 
2.1 0.059 1 95 5.6 2 80 4.7 3 60 3.6 4 30 1.8 0 100 5.9 
2.2 0.055 0.8 75 4.2 0.7 60 3.4 0.5 33 1.8 0.7 60 3.4 1 100 5.6 
2.3 0.059 10 90 5.3 40 60 3.6 30 70 4.1 70 30 1.8 0 100 5.9 
2.4 0.045 2 25 1.1 3 50 2.3 4 75 3.4 5 100 4.6 5 100 4.6 
3.1 0.032 1 0 0.0 2 25 0.8 4 75 2.4 3 50 1.6 5 100 3.3 
3.2 0.039 2 50 2.0 3 90 3.5 1 0 0.0 4 100 3.9 4 100 3.9 
3.3 0.034 2 25 0.9 3 55 1.9 1 0 0.0 4 100 3.5 4 100 3.5 
3.4 0.034 3 100 3.5 2 50 1.7 1 0 0.0 2 50 1.7 3 100 3.5 
3.5 0.037 3 50 1.8 3 50 1.8 1 100 3.7 1 100 3.7 1 100 3.7 
3.6 0.030 2 50 1.5 2 50 1.5 1 100 3.1 2 50 1.5 1 100 3.1 
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Table  3.12 PPI Total Value Calculations (Cont.) 
    Stent A Stent B Stent C Stent D Ideal 
Sub 
objecti
ve / 
Measur
e 
Swing 
Weig
ht 
 
Scor
e 
  
Single-
Dimension
al Value 
  
Value  
 
Scor
e 
  
Single-
Dimension
al Value 
 
Value 
 
Scor
e
 
Single-
Dimension
al Value 
 
Value 
 
Scor
e 
  
Single-
Dimension
al Value 
  
Value  
 
Scor
e 
  
Single-
Dimension
al Value 
  
Value  
 
4.1 0.026 50 44 1.2 75 71.5 1.9 80 77 2.1 75 72 1.9 100 100 2.7 
4.2 0.032 80 66 2.2 90 83 2.7 60 33 1.1 85 75 2.4 100 100 3.3 
4.3 0.036 30 70 2.6 25 75 2.7 50 50 1.8 40 60 2.2 0 100 3.7 
4.4 0.029 90 88 2.6 85 82.5 2.4 70 66 1.9 80 77 2.2 100 100 2.9 
4.5 0.029 3 100 2.9 2 50 1.4 2 50 1.4 1 0 0.0 3 100 2.9 
4.6 0.032 3 0 0.0 3 0 0.0 2 50 1.6 2 50 1.6 1 100 3.3 
5.1 0.032 2 50 1.6 2 50 1.6 3 100 3.3 2 50 1.6 3 100 3.3 
5.2 0.057 3 100 5.7 2 50 2.9 1 0 0.0 2 50 2.9 3 100 5.7 
5.3 0.049 3 50 2.5 2 25 1.2 1 0 0.0 2 25 1.2 4 100 4.9 
5.4 0.024 2 0 0.0 2 0 0.0 1 50 1.2 2 0 0.0 0 100 2.5 
  1.000   63.7   52.8   47.5   52.3   100.0 
 
 
 
𝑉𝐼𝐼𝐼𝐼1 = 𝑉𝐼𝐼𝐼𝐼2 = 𝑉𝐼𝐼𝐼𝐼3 = 𝑉𝐼𝐼𝐼𝐼4 = 𝑉𝐼𝐼𝐼𝐼𝑙 = 
 
 
115 
 
All sub-objectives in the PPI value tree are listed in the table by their heading number, which 
indicates the group’s (first level objectives) number and the sub-objective’s number in the list. 
Swing weights were also included for all value measures based on the sub-objectives level, in 
other words the weights were normalized based on the weight of the first level objectives. In 
addition, scores for each alternative on all value measures, the corresponding values, weighted 
values, and finally the total value were also calculated. 
Value versus cost plot helps the decision makers to identify the dominant and dominated 
alternatives and to see the potential value for each alternative if selected for the cost needed. In 
Figure  3.8 it can be seen that stents A and D dominate the other two alternatives. Hence, stents B 
and C, the dominated alternatives, are not recommended since the organization will be paying 
more money for less value compared with one of the dominant alternatives. This stage helps 
eliminate weak alternatives, and from this point on, analysists will focus on analyzing the 
dominant alternatives and look further into them with the decision makers. 
 
Figure  3.9 PPI total value components chart 
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Value component charts are used to show the contribution to total value for each value 
measure. Column stacked bar charts are used here to represent the value contribution for each 
alternative from each group of objectives (first level objectives) as whole, then another value 
component chart is shown for the sub-objectives in each group for further analysis. Figure  3.9 
shows the PPI total value components chart, the ideal alternative is shown for reference. 
Identifying what alternatives are doing best on which measures helps analyze the alternatives and 
creating a better alternative. Obviously, stent A is doing best on the “Treatment Effectiveness” 
group. Value components charts for all alternatives on each group are shown in Figure  3.10, 
Figure  3.11, Figure  3.12, Figure  3.13, and Figure  3.14. 
 
 
Figure  3.10 PPI “Treatment effectiveness” value components chart 
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Figure  3.11 PPI "Patient long term outcome" value components chart 
 
 
Figure  3.12 PPI “Clinicians satisfaction” value components chart 
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Figure  3.13 PPI “Organizational benefits” value components chart 
 
 
Figure  3.14 PPI “Supply chain performance” value components chart 
 
Focusing on the two best alternatives, a visual representation of the components of the 
difference in value between the two non-dominant alternatives is called a waterfall charts. A 
 
 
119 
 
waterfall chart for the PPI case is shown below in Figure  3.15. Stent D is better than Stent A for 
the clinician satisfaction group of objectives. However, stent A is better than stent D on the 
remaining four objectives groups. For example, it is seen that stent A has a 7.75 point advantage 
over stent D in treatment effectiveness. If stent A can be improved on the clinician satisfaction 
measure, then it is a better alternative. 
20 40 60 80
Stent D
Stent A 63.7
52.3
Clinician 
Satisfaction-6.3
Patient long 
term outcome
0.9
4.1
Organizational 
benefits
Treatment 
effectiveness 7.9
Value
Supply chain
4.8
 
Figure  3.15 PPI waterfall chart 
 
The best alternative can also be compared to the ideal in terms of value gaps. Value gaps are 
determined from the value components stacked bar charts, and are the delta between the two 
components. Value gaps help the analysts identifying potential areas for improving the 
alternative. 
 Sensitivity Analysis 3.4.3
Sensitivity analysis in MODA can be performed on any parameter such as swing weights, 
value curve shapes, and scores. The most common is the swing weights sensitivity. The 
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sensitivity was analyzed on the first objectives level, i.e. for each group as a whole, for example 
treatment effectiveness swing weight. When each swing weight of the five groups was varied, 
the remaining 4 swing weights were varied in the same proportion to ensure the swing weights 
sum to 1. The sensitivity analysis for the unnormalized swing weight assigned to treatment 
effectiveness is shown in Figure  3.16 below. The original swing weight assigned to the treatment 
effectiveness is 22, and varying it from 0 to 100 makes no difference on the best alternative, but 
when it is greater than 22, stent B becomes preferred in terms of value. Sensitivity of swing 
weights for the other groups “Patient long term outcome”, “Clinicians’ satisfaction”, 
“Organizational benefits”, and “Supply chain” are shown below in Figure  3.17, Figure  3.18, 
Figure  3.19, and Figure  3.20, respectively. 
 
Figure  3.16 PPI sensitivity analysis for treatment effectiveness unnormalized swing weight 
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Figure  3.17 PPI sensitivity analysis for patient long term outcome unnormalized swing weight 
 
 
Figure  3.18 PPI sensitivity analysis for clinician satisfaction unnormalized swing weight 
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Figure  3.19 PPI sensitivity analysis for organizational benefits unnormalized swing weight 
 
 
Figure  3.20 PPI sensitivity analysis for SC unnormalized swing weight 
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The sensitivity analysis for the unnormalized swing weight assigned to patient outcome is 
shown in Figure  3.17. It is obvious that the alternatives were not affected when changing the 
patient outcome swing weight. The same unresponsiveness to swing weight changing was for the 
organizational benefits Figure  3.19, and also for the SC performance as seen in Figure  3.20. 
However, the decision is sensitive to the clinician satisfaction swing weight as seen in 
Figure  3.18, such that for a swing weight greater than 50, stent D will become more valuable 
than stent A and consequently the dominant one since it is cheaper. 
3.5 Feedback and Evaluation 
Meetings, either actual or virtual, with experts on the PPI problem were carried out. The 
purpose was to explain the decision framework developed in this research including the 
methodology (MODA), as well as the PPI model elements. Four SC professionals and two 
physicians from 3 different organizations were interviewed.  
Based on the discussion during the meetings, we can conclude that all participants were 
receptive to the process and thought it is valuable. A document summarizing the framework was 
prepared specifically for this education process and shared with the experts as well as all 
required elements of the PPI model. The goal after explaining the methodology was to conduct a 
case study on few real items, and then evaluate the framework in terms of many factors, which 
will be discussed later. However, due to lack of time, a real case study was not conducted, and a 
notional example on 4 heart stents was created by the researchers for illustration. Participant’s 
initial reactions were captured during the meetings. In addition, participant evaluation of the 
framework and the process was collected through a feedback form that was sent to participants 
after showing the example with all results. The feedback form is included in Appendix F.6: 
Evaluation Feedback Questions. 
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The experts participated in giving input during the modeling process, education process, and 
all the way through to evaluating the framework.  The experts are all working directly in the 
items selection process and value analysis process within their organizations. A special note is to 
be made about the two physicians who participated in this process; this is because of their 
knowledge and experience which make them best fit for the evaluation and an asset for 
developing the model. Two of the participants are physicians: a plastic surgeon and 
neurosurgeon, with each having more than 15 years of experience.  Both are also leading value 
analysis programs in their organization, experienced in clinical and financial outcomes, 
standardizing quality of care, and facilitating physician engagement and the integration of value-
driven decision making within healthcare delivery systems. Thus, they have valuable experience 
as clinicians and they bring experience in value-driven decision making.   
It was possible to get evaluations from these two surgeons in addition to one SC professional 
at the time of writing this dissertation. All questions were asked on a scale of 1 to 5 Likert scale, 
where 1 means “I do not agree” and 5 means “I strongly agree”. The 15 questions were classified 
into 4 groups, namely: Degree the framework captures the PPI problem, time and ease of 
implementation, value added from this framework, if implementable in their companies. Average 
scorings on all items per group are shown in the bar chart in Figure  3.21. 
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Figure  3.21 Framework evaluation feedback 
 
The highest scores for the “degree the framework captures the PPI problems” and “value 
added from this framework”. The first one is very important as it serves as a potential indicator 
for the value of the model; it satisfied the participants in terms of capturing the problem and all 
objectives for involved stakeholders. This is by itself is a contribution; as it can be stated now 
that the basic PPI model has been built in this research and it is available for any future and 
further work. All previous work and non-academic discussions about the PPI problem were 
based on opinions and pure subjectivity. This model provides a rigorous methodology for 
incorporating subjective and objective factors and makes discussion involving these factors more 
effective.  In addition it is also rigorous and mathematically structured. The second evaluation 
item (Third bar on the chart) also supports the contributions made in this research.  There is a 
high potential value added to the value analysis process by the framework. This should 
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encourage healthcare organizations to consider adopting this methodology in order to increase 
the efficiency of their items selection process as well as adding value to their value analysis 
process. 
For the “Time and ease of implementation”, it is expected to have lower score; the model 
needs explanation and input is needed from stakeholders before any item value evaluation can 
take place. Items evaluation (scoring) itself requires input assessment on all of the 26 sub-
objectives. With that being said, this will not be always the case, since organizations will learn 
with time, can customize the framework, and automate portions of the evaluation process.  In the 
long run, it may be expected to be even easier than the pure discussions due to the fact that the 
framework more readily fosters the tracking and evaluation of decisions over time. For the last 
item “If they think it is implementable in their companies”, this is the nature for any new 
process. It is not easy to change and adopt new processes since people in general do not like to 
spend time learning new methods as well as the fear from the added layer of complexity. The last 
question in the evaluation feedback was an open question, and the following summarize the 
comments with minor changes to correct spelling and formatting. 
The SC professional said “Even though this is a university setting and our Physicians are 
scientists, there has not been a culture in the past of adding scientific theory to the Value 
Analysis process. In the past, decisions have been made "assumedly" under the need of the 
patient and (typically) with very little scrutiny. Implementation (though not impossible) would 
be very difficult due to what would be seen as additional layers of complexity and more 
"bureaucratic hoops" to jump through. In many cases, if systems are deemed too cumbersome, 
Physicians complain, and find ways around the system.” 
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Physicians said “I think any tool that lends objectivity to the value analysis process is a 
welcome addition. Value analysis in practical terms often gets slowed down by indecision and 
lack of momentum.” Also “This tool can potentially improve that and simplify the decision 
making analysis.” Finally, “I appreciate the fact that the developers sought clinician input to 
ascertain which were the most important aspects to consider in the various categories. I felt the 
criteria they selected were extremely thorough and represented a comprehensive thought process 
in evaluating products.” 
 One final note to mention is a comment that was made through one of the meetings that the 
power of physicians’ contribution to the decision will outweigh other people’s opinion. This 
concern is actually one of the major reasons for using such a methodology because it 
systematically includes the perspective of all stakeholders. This type of analysis will enable 
value analysts to show the consequences of any decision in terms of added value versus cost. 
Visibility of decisions and traceability are two major characteristics for the big picture shown in 
the output. 
3.6 Conclusions 
SKU proliferation can decrease the supply chain performance of healthcare organizations for 
many reasons. First, proliferation causes additional administrative cost to handle multiple item 
types, vendors and purchase orders. Second, SKU proliferation decreases the ability of the 
organization to pursue order size discounts. Third, SKU proliferation decreases the ability the 
organization to negotiate price because of the need to meet physician preference. Fourth, SKU 
proliferation can cause additional shipping and handling of items in stock because more item 
types must be ordered. A very good reason for having fewer items to manage is the stock out 
issue. That is with more items to manage and less quantities needed; there is higher probability 
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of stock out for particular items, which translates to poor service to patients. This may also hurt 
the reimbursement rates.  
The objective of the proposed framework is to add value to the current value analysis process 
by making more informative decisions to keep the highest value added items relative to cost. A 
magazine specifically devoted for value analysis and utilization management in healthcare is 
published quarterly (Yokl, et al. 2016). A review of the periodical indicated that much emphasis 
is being placed on this area for being a very critical practice in utilization management within 
healthcare. Articles also emphasize the need for adding software and more structured models to 
enhance and enrich the value analysis process. The mathematical modeling and structured 
MCDM methodology (MODA) used is expected to enhance the value analysis process. 
A PPI selection model was proposed, and a MCDM decision framework was developed 
based on MODA. The model was reviewed, and evaluated in terms of effectiveness and value 
added to the current value analysis process. The evaluation feedback received from experts as 
summarized in the previous section, shows a very positive perspective about the framework and 
a high perceived potential regarding its effectiveness. An emphasis should be made here that this 
framework separates the cost from all other non-cost related qualities, which was found as 
interesting and useful by the healthcare organizations. 
The framework is implemented via a tool that shows all of the calculations as well as outputs 
and sensitivity analysis. The framework was positively evaluated as a mathematical rigorous 
framework that enhances the objectivity of the decision process. Also, the process was seen as 
extremely thorough and comprehensive. 
One of the contributions of this work is that we built the first comprehensive PPI model. 
Another contribution is that MODA has never been applied to this problem. This framework 
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improves the value analysis process and adds value to the context of items selection. This 
framework has the potential (with some improvements) to be used commercially across 
healthcare organizations. 
Finally, in the following we discuss recommendations for future work. A difference between 
healthcare modeling and the modeling for other sectors is the need to address the ethical and 
criticality of this kind of service. Dealing with people and lives is definitely more sensitive than 
dealing with other sectors. Another difference is the complexity of the healthcare nature due to 
the many stakeholders involved, namely: patients, physicians, nurses, supply chain professionals, 
hospital’s administration, and insurance companies. This actually creates a variety of tradeoffs 
and overlapping between desires and objectives. 
A recommendation for healthcare organizations is to conduct value focused thinking (VFT) 
after analyzing the results and performing the sensitivity analysis; to improve the alternatives. 
This interactive process involves decision makers, stakeholders, experts, and decision analysists 
to look for alternatives that can create higher value. The VFT approach was created by (R. 
Keeney 1992). This framework should be reviewed frequently; to make sure weights as well as 
value functions represent the stakeholders’ preferences. 
As a future work, the authors are planning on applying a portfolio optimization modeling 
after the value versus cost analysis. The best value of selected items subjected to constraints like 
available budget and available space should be the focus of the optimization. Another work for 
the future is to develop a total cost of ownership (TCO) model for the PPI and to use it instead of 
the item’s purchase price. 
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As a future work, PPIs may be categorized into 3 different groups namely: tools, replacement 
devices, and consumables and a framework may be developed for each category. The rationale 
behind this is because items in these categories differ in terms of objectives and swing weights. 
A real case study is also planned to be conducted following this work. Also, models other 
than the additive may be applied and the framework performance investigated. 
Another work for future is to investigate the reliability of the value measures and incorporate 
this parameter in the model. Uncertainty of the value measure estimation could be a 
distinguishing factor in the decision. 
  
 
 
131 
 
4 References 
Agarwal, Prince, Manjari Sahai, Vaibhav Mishra, Monark Bag, and Vrijendra Singh. "A review 
of multi-criteria decision making techniques for supplier evaluation and selection." 
International Journal of Industrial Engineering Computations 2 (2011): 801-810. 
Alguire, Patrick C. Understanding Capitation. 2016. https://www.acponline.org/about-
acp/about-internal-medicine/career-paths/residency-career-counseling/understanding-
capitation (accessed May 2016). 
Bajaria, Hans J. "Difference between Reliability Testing and Durability Testing." Multiface, Inc. 
Multiface, Inc. 2000. http://www.multiface.com/RvsDTest.PDF (accessed September 16, 
2015). 
Baty, Jason, James McManus, Pehrson Matthew, and Daren Relph. Strategies for Managing 
Orthopedic Implant Costs. Article, Healthcare Financial Management Association, 2014, 
1-4. 
Bayus, Barry L., and William P. Putsis, Jr. "Product Proliferation: An Empirical Analysis of 
Product Line Determinants and Market Outcomes." Marketing Science (INFORMS) 18, 
no. 2 (1999): 137-153. 
Belton, Valerie, and Theodor J. Stewart. Multiple Criteria Decision Analysis: An Intigrated 
Approach. Massachusetts: Kluwer Academic Publishers, 2003. 
Chavan, Apurva J. "Value Engineering in Construction Industry." International Journal of 
Application or Innovation in Engineering & Management (IJAIEM) 2, no. 12 (December 
2013): 18-26. 
Chow, Garland, and Trevor D. Heaver. "Logistics in the Canadian Health Care Industry." 
Canadian Logist (Canadian Professional Logistics Institute) 1, no. 1 (December 1994): 
29-74. 
DeJohn, Paula. "The last frontier: saving on M.D. prefernce items." Hospital Materials 
Management 30, no. 6 (June 2005): 9-11. 
Diaby, Vakaramoko, Kaitryn Campbell, and Ron Goeree. "Multi-criteria decision analysis 
(MCDA) in health care: A bibliometric analysis." Operations Research for Health Care 
(Elsevier) 2 (2013): 20-24. 
Dudas, Joseph, and Susan Widhalm. "Will buyers ever call the shots?" Healthcare Purchasing 
News. May 2012. http://www.hpnonline.com/inside/2012-05/1205-pnp-dudas.html 
(accessed March 9, 2014). 
 
 
132 
 
Dyer, James S., and Rakesh K. Sarin. "Measurable Multiattribute Value Functions." Operations 
Research (Operations Research society of America) 27, no. 4 (August 1979): 810-822. 
Edwards, Ward, and F. Hutton Barron. "SMARTS and SMARTER: Improved Simple Methods 
for Multiattribute Utility Measurement." Organizational Behavior and Human Decision 
Processes (Academic Press, Inc.) 60 (1994): 306-325. 
Efficacy. April 16, 2015. https://en.wikipedia.org/wiki/Efficacy (accessed July 30, 2015). 
Erikson, Clese, Karen Jones, and Casey Tilton. 2012 Physicians Speciality Data Book. 
Databook, Center for Workforce studies, Washington, D.C.: Association of American 
Medical Colleges, 2012. 
Ewing Jr., Paul L., William Tarantino, and Gregory S. Parnell. "Use of decision analysis in the 
army base realignment and closure (BRAC) 2005 military value analysis." Decision 
Analysis (Informs) 3, no. 1 (March 2006): 33-49. 
Howard, Ronald A. "The foundations of decisions analysis revisited." In Advances in Decision 
Analysis: From Foundations to Applications, by Ward Edwards, Ralph F Miles Jr. and 
Detlof von Winterfeldt, 32-56. Cambridge: Cambridge University Press, 2007. 
Jebson, Leslie R, and Gregory T Sweat. "Implant standardization opportunities by preserving 
physician preference." AHRMM, 2010. 
Keeney, Ralph L., and Howard Raiffa. Decisions with multiple objectives: Preferences and value 
tradeoffs. New York: John Wiley & Sons, 1976. 
Keeney, Ralph. Value Focused Thinking: A Path to Creative Decision making. Cambridge, MA: 
Harvard University Press, 1992. 
Kirkwood, Craig W. Strategic Decision Making: Multiobjective Decision Analysis with 
Apreadsheets. Belmont, CA: Duxbury Press, 1997. 
Kirkwood, Craig, and Rakesh Sarin. "Preference Conditions for Multiattribute Value Functions." 
Operations Research 28, no. 1 (1980): 225-232. 
List of orthopedic implants. February 23, 2014. 
http://en.wikipedia.org/wiki/List_of_orthopedic_implants (accessed April 12, 2014). 
Liu, Yanchao. SKU Proloferation in Healthcare Supply chain. Master Thesis, Industrial 
Engineering, University of Arkansas, ProQuest, 2008. 
Marley, John. "Efficacy, effectiveness, efficiency." Australian Prescriber, December 2000. 
 
 
133 
 
"Medicine Safety and You." Pfizer. 2011. http://www.pfizer.com/files/health/medicine_safety/1-
1_Medicine_Safety_and_You.pdf (accessed September 14, 2015). 
Montgomery, Kathleen, and Eugene S. Schneller. "Hospitals' Strategies for Orchestrating 
Selection of Physician Preference Items." Milbank Quarterly (Blackwell Publishing Inc) 
85, no. 2 (2007): 307-335. 
Moon, Susanna. "Taking cost off supply shelf." Modern Healthcare (Crain Communications) 34, 
no. 47 (2004): 26-28. 
Nachtmann, Heather, and Edward A. Pohl. The state of healthcare logistics: cost and quality 
improvement. Survey, University of Arkansas, Fayetteville: Center for Innovation in 
Healthcare Logistics, 2009. 
National Center for Health Statistics. 2011. http://www.cdc.gov/nchs/data/hus/2011/116.pdf 
(accessed 2015). 
Parnell, Gregory, Terry Bresnick, Steven Tani, and Eric Johnson. Handbook of Decision 
Analysis. Hoboken, New Jersey: John Wiley & Sons, 2013. 
Phillips, Ceri, and Guy Thompson. "What is a QALY?" Vers. 2. University of Oxford - Medical 
Sciences Division. Hayward Group Ltd. 2009. 
http://www.medicine.ox.ac.uk/bandolier/painres/download/whatis/qaly.pdf (accessed 
January 2016). 
Rea, Louis M, and Richard A Parker. Designing and Constructing Survey Research: A 
Comprehensive Guide. San Francisco: John wiley & Sons, 2005. 
Rich, Nick, and Matthias Holweg. Value Analysis, Value Engineering. Report, Cardiff, United 
Kingdom: Lean Enterprise Research, 2000. 
Rossetti, Manuel D. "Java Simulation Library (JSL): An Open-Source Object-Oriented Library 
for Discrete-event Simulation in Java." International Journal of Simulation and Process 
Modelling (Inderscience Publishers) 4, no. 1 (2008): 69-87. 
Rossetti, Manuel, and Yanchao Liu. "Simulating SKU proliferation in a health care supply 
chain." Edited by M. D. Rossetti, R. R. Hill, B. Johansson, A. Dunkin and R. G. Ingalls. 
Proceedings of the 2009 Winter Simulation Conference. Austin, TX: Institute of 
Electrical and Electronic Engineers, 2009. 
Schneller, Eugene S., and Larry R. Smeltzer. Strategic Management of the Health Care Supply 
Chain. San Francisco, CA: Jossey-Bass, 2006. 
 
 
134 
 
Schoen, Cathy, Robin Osborn, David Squires, Michelle M. Doty, Roz Pierson, and Sandra 
Applebaum. "How Health Insurance Design Affects Access To Care And Costs, By 
Income, In Eleven Countries." Health Affairs 29, no. 12 (November 2010): 2323-2334. 
Shbool, Mohammad A., and Manuel Rossetti. "Essays in Physicians Preference Items and 
Inventory Management within the Healthcare Supply Chain." PhD Thesis, 2016. 
Shbool, Mohammad, E. Pohl, M. Rossetti, and V. Varghese. "Comparing Education and 
Training Requirements for Retail and Healthcare Supply Chain Professionals." The 
Proceedings of the 34th American Society of Engineering Management Conference. 
Minneapolis, MN, 2013. 
Siddel, Keith. "Hospitals losing on physician preference items." OR Manager, January 2012: 1-
2. 
Trainor, Timothy E., Gregory S. Parnell, Brigitte Kwinn, John Brence, Eric Tollefson, and Pat 
Downes. "The US Army Uses Decision Analysis in Designing Its US Installation 
Regions." Interfaces (Informs) 37, no. 3 (June 2007): 253-264. 
Triantaphyllou, E., B. Shu, S. Nieto Sanchez, and T. Ray. "Multi-Criteria Decision Making: An 
Operations Research Approach." Edited by J. G. Webster. Encyclopedia of Electrical and 
Electronics Engineering (John Wiley & Sons) 15 (1998): 175-186. 
Tyson, Patricia. "Extract BIG savings from physician preference items. Use a data-driven, team-
based approach to drive down costs." Materials Management In Health Care (Health 
Forum Inc) 19, no. 5 (May 2010): 23-25. 
Velasquez, Mark, and Patrick T. Hester. "An Analysis of Multi-Criteria Decision Making 
Methods." International Journal of Operations Research 10, no. 2 (2013): 56-66. 
Vijayvagy, Lokesh. "Decision framework for supplier selection through multi criteria evaluation 
models in supply chain." International Journal of Management and Innovation 4, no. 12 
(2012): 16-28. 
Von Winterfeldt, Detlof, and Ward Edwards. Decision Analysis and Behavioral Research. 
Cambridge, New York: Cambridge University Press, 1986. 
Wright, Dan. Performance measurement: A report by the hospital supply chain working group. 
Report, Ontario Ministry of Finance, OntarioBuys, Ontario: Queen's Printer for Ontario, 
2006. 
Yokl, Robert T., Robert W. Yokl, Beth Potter, and James Russell. Healthcare value analysis & 
utilization management magazine, 2016: 1-32. 
 
 
135 
 
 
Appendix A: Terms’ Definitions 
Physician preference items: costly medical/ surgical items, such as hip and knee implants, 
cardiac stents, mechanical devices…etc., that are selected by the physician to use for a 
specific patient and procedure, and they are not preferred by the healthcare management 
and still being selected by the physician 
 
SKU Proliferation: The increasing of the variety and the number of functionally equivalent items 
that are stocked by inventory management systems in response to marketing, acquisitions, 
sales incentives, and lack of life cycle controls 
 
Item: A specific brand from a specific manufacturer (stent A from supplier X. 
 
Item type: The class of the item for which it belongs (e.g. heart stent) 
 
Spend Analysis: is the process of analyzing expenditure data. The purpose of spend analysis is to 
find ways of reducing procurement costs, and monitoring compliance. 
 
Capitated Pricing: A model established that allows healthcare providers to purchase medical 
products and devices from a variety of original equipment manufacturers (OEMs) at set 
levels based on the level of the product. For example there may be 3 levels: Standard, High, 
and Premium. Each OEM will establish their products that fall into each of these categories 
by a certain set of characteristics that make these products “equal” from a clinical 
effectiveness point of view. Then the healthcare provider will pay each OEM the same 
amount for any product in each level. For example: $3500 for all Standards, $5000 for all 
High, and $7500 for all Premiums. The capitated pricing model also allows for OEMs to 
produce a special or “niche” product that does not fall into these categories if they can 
prove the clinical reasoning” 
http://wiki.answers.com/Q/What_is_capitated_pricing?#slide1 
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Appendix B: IRB Approval and Protocols 
Appendix B.1: IRB Approval 
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Appendix B.2: Survey Protocol 
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Appendix C: Surveys 
Appendix C.1: Physicians’ Survey 
Effect of Physician Preference Items (PPI) on the SKUs Proliferation in Healthcare 
Consent to Participate in a Research Study 
Principal Researcher: Mohammad Shbool 
Faculty Advisor: Dr. Manuel Rossetti 
 
INVITATION TO PARTICIPATE 
You are invited to participate in a research study about Physician Preference Items. You are 
being asked to participate in this study because you either a Physician or a Supply chain 
professional. 
 
WHAT YOU SHOULD KNOW ABOUT THE RESEARCH STUDY 
 
Who is the Principal Researcher? 
Mohammad Shbool, PhD. Candidate, 
(Contact information shown below) 
 
Who is the Faculty Advisor? 
Manuel Rossetti, Ph.D., P.E. 
(Contact information shown below) 
 
What is the purpose of this research study? 
The purpose of this study is to develop a deeper understanding of the role that physician 
preference items play within the healthcare supply chain. 
 
Who will participate in this study? 
We are expecting to have at most 200 physicians participating in this survey, and a 1000 
participants of supply chain professionals who work in the healthcare sector. 
 
What am I being asked to do? 
Your participation will require the following: 
Answering questions in the questionnaire to the best of your knowledge. 
 
What are the possible risks or discomforts? 
There are no anticipated risks to participating. 
 
What are the possible benefits of this study? 
There are no anticipated benefits to the participant. 
 
How long will the study last? 
The survey should take between 10-15 minutes of your time 
 
Will I receive compensation for my time and inconvenience if I choose to participate in this 
study? 
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No 
 
Will I have to pay for anything? 
No, there will be no cost associated with your participation. 
 
What are the options if I do not want to be in the study? 
If you do not want to be in this study, you may refuse to participate. Also, you may refuse to 
participate at any time during the study. My PhD degree will not be affected in any way if you 
refuse to participate. 
 
How will my confidentiality be protected? 
All information will be kept confidential to the extent allowed by applicable State and Federal 
law.   
All responses by individuals will remain anonymous. Individual participants will only 
be identified in the database with a pin number to eliminate the possibility of 
duplicate entries. Once the survey period is over, the linkages between the pin numbers and 
survey respondents will be eliminated. No questions are presented that will allow for the 
identification of an individual respondent.  Thus, the researchers will not be able to determine the 
identity of any respondents.  The responses will be analyzed and reported for physicians or 
supply chain professionals as a group.  Since individual responses are anonymous, 
individual names and that of their institution will never be associated with any particular 
findings. 
 
Will I know the results of the study? 
At the conclusion of the study you will have the right to request feedback about the results. You 
may contact the faculty advisor, Dr. Manuel Rossetti or Principal Researcher, Mohammad 
Shbool.  
 
What do I do if I have questions about the research study? 
You have the right to contact the Principal Researcher or Faculty Advisor as listed below for any 
concerns that you may have. 
 
Mohammad Shbool, PhD. Candidate, 
University of Arkansas  
Department of Industrial Engineering 
4207 Bell Engineering Center 
Fayetteville, AR 72701 
Phone:  
email:  
WWW:  
 
Manuel Rossetti, Ph.D., P.E. 
Professor and Associate Department Head 
University of Arkansas  
Department of Industrial Engineering 
4207 Bell Engineering Center 
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Fayetteville, AR 72701 
Phone: (479) 575-6756 
Fax: (479) 575-8431 
email: rossetti@uark.edu 
WWW: www.uark.edu/~rossetti 
 
You may also contact the University of Arkansas Research Compliance office listed below if you 
have questions about your rights as a participant, or to discuss any concerns about, or problems 
with the research. 
 
Ro Windwalker, CIP 
Institutional Review Board Coordinator 
Research Compliance 
University of Arkansas 
210 Administration 
Fayetteville, AR  72701-1201 
479-575-2208 
irb@uark.edu 
 
 
I have read the above statement and have been able to ask questions and express concerns, which 
have been satisfactorily responded to by the investigator. I understand the purpose of the study as 
well as the potential benefits and risks that are involved. I understand that participation is 
voluntary. I understand that significant new findings developed during this research will be 
shared with the participant. I understand that my completion of the survey indicates that I agree 
for my responses to be used in this research. I have been presented a copy of the consent form. 
 
______________________________________________________________________________ 
Q1. How aware are you of the term “physician preference item?" (Definition of “Physician 
preference items”: costly medical/ surgical items, such as hip and knee implants, cardiac stents, 
mechanical devices…etc., that are selected/preferred by the physician to use for a specific patient 
and procedure.) 
 Not aware 0 
 1 
 2 
 3 
 4 
 5 
 Highly aware 6 
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Q2. How willing are you to use an available item in stock even if it is not your preferred brand? 
 Not Willing 0 
 1  
 2  
 3  
 4  
 5  
 Very Willing 6 
 
Q3. If the item in stock is not your preferred brand, are you permitted to order whatever you 
want (your preferred brand)? (Brands are versions of an item and they are used for the same 
purpose, even though they might have different features) 
 Yes 
 No 
 Sometimes 
 
Q4. Please, rate the following factors according to their importance when you make an item 
selection decision. (Two factors can have the same rating if you think they are equivalent in 
importance.) 
 Not 
Important 
0 
1 2 3 4 5 Very 
Important 
6 
Previous 
experience 
using the 
item 
              
The 
effectiveness 
of the item 
              
Reputation of 
this item's 
manufacturer 
              
Relationship 
with sales 
representative 
              
Knowledge 
of item cost               
Other (Please 
specify and 
rate) 
              
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Q5. How knowledgeable are you about how the organization decides to select items? 
 Not-knowledgeable 0 
 1  
 2  
 3  
 4  
 5  
 Knowledgeable 6 
 
Q6. Please rate your ability to influence the decision to stock and use an item 
 Low 0 
 1  
 2  
 3  
 4  
 5  
 High 6 
 
Q7. Please, rate the following factors according to their importance in influencing your 
organization’s decision to stock and use a specific item. (Two factors can have the same rating if 
you think they are equivalent in importance.) 
 0 1 2 3 4 5 6 
Physician’s 
preference               
Total cost               
Patient 
outcome               
Manufacturer 
reputation               
Required 
storage space               
Administration 
decision               
Other (Please 
specify and 
rate) 
              
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Q8. Given that you have a preference for a particular brand, how willing are you to substitute an 
item from stock that is functionally equivalent but comes from a different manufacturer or 
brand? 
 Not Willing 0 
 1  
 2  
 3  
 4  
 5  
 Very Willing 6 
 
Q9. How willing are you to drop a brand and adopt another one? 
 Not Willing 0 
 1  
 2  
 3  
 4  
 5  
 Very Willing 6 
 
Q10. What are the reasons that would make you switch to another brand?  (Please rate the 
selected ones according to priority) 
 0 1 2 3 4 5 6 
Easier to use               
More 
features               
Being 
produced by 
a reputable 
manufacturer 
              
Safer for 
patient               
Cheaper               
Expected to 
give better 
results for 
the patient 
              
Other (List 
any other 
reason and 
rate it) 
              
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Q11. Please rate your awareness of the actual costs of items that you are requesting or using on 
your patients. 
 Not aware (No awareness of $ value)  0 
 1  
 2  
 3  
 4  
 5  
 Highly aware (know the exact $ value) 6 
 
Q12. When an item will be directly used on a patient, how important is the patient’s preference 
to you in deciding which item to use? 
 Not Important 0 
 1  
 2  
 3  
 4  
 5  
 Very Important 6 
 
Q13. What is the cost range of the procedures/surgeries/operations that you perform? (Check all 
categories that apply) 
  
 $1,000 - $5,000 
 $5,001 - $10,000 
 $10,001 - $20,000 
 $20,001 - $50,000 
 $50,001 - $100,000 
 >$100,000 
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Answer If “Q13. What is the cost range of the procedures/surgeries/operations that you perform? 
(Check all categories that apply)” Selected Choice Is Not Empty” 
Q14. In previous question, you were asked about the cost range of operations you perform, 
please rate your willingness to substitute an equivalent item when performing a procedure in 
each selected category). 
 0 1 2 3 4 5 6 
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... < 
$1,000 Is Selected 
< $1,000 
              
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... $1,000 
- $5,000 Is Selected 
$1,000 - $5,000 
              
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... $5,001 
- $10,000 Is Selected 
$5,001 - $10,000 
              
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... 
              
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$10,001 - $20,000 Is Selected 
$10,001 - $20,000 
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... 
$20,001 - $50,000 Is Selected 
$20,001 - $50,000 
              
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... 
$50,001 - $100,000 Is Selected 
$50,001 - $100,000 
              
If What is the cost range of the 
procedures/surgeries/operations 
that you perform? (Check all 
appropriate categories, and at 
the same time, rate your 
willingness to substitute an 
equivalent item when ... > 
$100,000 Is Selected 
> $100,000 
              
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Answer If “Q3. If the item in stock is not your preferred brand, are you permitted to order 
whatever you want (your preferred brand)? (Brands are versions of an item and they are used for 
the same purpose, even though they might have different features)” No Is Not Selected 
Q15. What percentage of the items that you utilize in your procedures, fall into the category of 
physician preference items (i.e. you are allowed to indicate your preference)? 
 < %25 
 25% - 50% 
 51% - 75% 
 >75% 
 
Answer If “Q3. If the item in stock is not your preferred brand, are you permitted to order 
whatever you want (your preferred brand)? (Brands are versions of an item and they are used for 
the same purpose, even though they might have different features)” No Is Not Selected 
Q16. How would you characterize the cost of the items for which you are able to specify your 
preference? 
 Low 
 Medium 
 High 
 
Q17. What is your specialization (cardiothoracic, orthopedic … etc.) 
 
Q18. In which state do you work? (Used to determine if there is any difference attributed to 
location) 
 AL AK … … WI WY 
State       
 
 
Q19. What type of healthcare provider is your organization? (Check all that apply) 
 Academic Institution 
 Acute Care Facility 
 Assisted Living Facility 
 Hospital/Medical Center 
 Managed Care Organization 
 Long-Term Care Facility 
 Health System / Network (IDS / IDN) 
 Military/VA/Government affiliated 
 Rehabilitation Center 
 Other ____________________ 
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Q20. What best describe your compensation model? 
 Per wRVU (per work relative value units) 
 Percentage of net collections 
 Percentage of practice "bottom line" 
 percentage of gross charges 
 Per encounter 
 Guaranteed base plus incentive 
 
Q21. Indicate the approximate size of your organization. 
         
Number of 
beds         
Number of 
Employees         
 
 
Q22. How many years have you worked in the healthcare industry? 
 < 2 
 2 - 5 
 6 - 10 
 11 - 20 
 > 20 
 
Q23. What is your gender? 
 Male 
 Female 
 Prefer to not answer 
 
Q24. What is your employment type? 
 Hospital employed 
 Contracted physician group 
 Community physician 
 Other ____________________ 
 
Q25. What is your provider organization's setting? 
 National 
 Rural 
 Suburban 
 Urban 
 Other ____________________ 
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Appendix C.2: Supply Chain Professionals’ Survey 
 
Effect of Physician Preference Items (PPI) on the SKUs Proliferation in Healthcare 
Consent to Participate in a Research Study 
Principal Researcher: Mohammad Shbool 
Faculty Advisor: Dr. Manuel Rossetti 
 
INVITATION TO PARTICIPATE 
You are invited to participate in a research study about Physician Preference Items. You are 
being asked to participate in this study because you either a Physician or a Supply chain 
professional. 
 
WHAT YOU SHOULD KNOW ABOUT THE RESEARCH STUDY 
 
Who is the Principal Researcher? 
Mohammad Shbool, PhD. Candidate, 
(Contact information shown below) 
 
Who is the Faculty Advisor? 
Manuel Rossetti, Ph.D., P.E. 
(Contact information shown below) 
 
What is the purpose of this research study? 
The purpose of this study is to develop a deeper understanding of the role that physician 
preference items play within the healthcare supply chain. 
 
Who will participate in this study? 
We are expecting to have at most 200 physicians participating in this survey, and a 1000 
participants of supply chain professionals who work in the healthcare sector. 
 
What am I being asked to do? 
Your participation will require the following: 
Answering questions in the questionnaire to the best of your knowledge. 
 
What are the possible risks or discomforts? 
There are no anticipated risks to participating. 
 
What are the possible benefits of this study? 
There are no anticipated benefits to the participant. 
 
How long will the study last? 
The survey should take between 10-15 minutes of your time 
 
Will I receive compensation for my time and inconvenience if I choose to participate in this 
study? 
No 
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Will I have to pay for anything? 
No, there will be no cost associated with your participation. 
 
What are the options if I do not want to be in the study? 
If you do not want to be in this study, you may refuse to participate. Also, you may refuse to 
participate at any time during the study. My PhD degree will not be affected in any way if you 
refuse to participate. 
 
How will my confidentiality be protected? 
All information will be kept confidential to the extent allowed by applicable State and Federal 
law.   
All responses by individuals will remain anonymous. Individual participants will only 
be identified in the database with a pin number to eliminate the possibility of 
duplicate entries. Once the survey period is over, the linkages between the pin numbers and 
survey respondents will be eliminated. No questions are presented that will allow for the 
identification of an individual respondent.  Thus, the researchers will not be able to determine the 
identity of any respondents.  The responses will be analyzed and reported for physicians or 
supply chain professionals as a group.  Since individual responses are anonymous, 
individual names and that of their institution will never be associated with any particular 
findings. 
 
Will I know the results of the study? 
At the conclusion of the study you will have the right to request feedback about the results. You 
may contact the faculty advisor, Dr. Manuel Rossetti or Principal Researcher, Mohammad 
Shbool.  
 
What do I do if I have questions about the research study? 
You have the right to contact the Principal Researcher or Faculty Advisor as listed below for any 
concerns that you may have. 
 
Mohammad Shbool, PhD. Candidate, 
University of Arkansas  
Department of Industrial Engineering 
4207 Bell Engineering Center 
Fayetteville, AR 72701 
Phone:  
email:  
WWW:  
 
Manuel Rossetti, Ph.D., P.E. 
Professor and Associate Department Head 
University of Arkansas  
Department of Industrial Engineering 
4207 Bell Engineering Center 
Fayetteville, AR 72701 
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Phone: (479) 575-6756 
Fax: (479) 575-8431 
email: rossetti@uark.edu 
WWW: www.uark.edu/~rossetti 
 
You may also contact the University of Arkansas Research Compliance office listed below if you 
have questions about your rights as a participant, or to discuss any concerns about, or problems 
with the research. 
 
Ro Windwalker, CIP 
Institutional Review Board Coordinator 
Research Compliance 
University of Arkansas 
210 Administration 
Fayetteville, AR  72701-1201 
479-575-2208 
irb@uark.edu 
 
 
I have read the above statement and have been able to ask questions and express concerns, which 
have been satisfactorily responded to by the investigator. I understand the purpose of the study as 
well as the potential benefits and risks that are involved. I understand that participation is 
voluntary. I understand that significant new findings developed during this research will be 
shared with the participant. I understand that my completion of the survey indicates that I agree 
for my responses to be used in this research. I have been presented a copy of the consent form. 
 
_______________________________________________________________________ 
 
Q1. How aware are you of the term “Stock keeping unit (SKU) proliferation?” 
 Not aware 0 
 1 
 2 
 3 
 4 
 5 
 Highly aware 6 
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Q2. What is a possible cause for the SKU proliferation problem? (Please rate following causes 
according to degree of effect). (Definition: SKU proliferation is the increasing of the variety and 
the number of functionally equivalent items that are stocked by inventory management systems 
in response to marketing, acquisitions, sales incentives, and lack of life cycle controls) 
 0 1 2 3 4 5 6 
Physician 
preference 
items 
              
Growing 
size with 
limited 
space 
              
Unpredicted 
schedules 
of needed 
items 
              
Other 
(Please 
specify and 
rate) 
              
 
Q3. How aware are you of the term “Physician preference items?” (Definition of “Physician 
preference items”: costly medical/ surgical items, such as hip and knee implants, cardiac stents, 
mechanical devices…etc., that are selected/preferred by the physician to use for a specific patient 
and procedure.) 
 Not aware 0 
 1  
 2  
 3  
 4  
 5  
 Highly aware 6 
 
Q4. How aware are you of the cost of your ordered items? 
 Not aware 0 
 1  
 2  
 3  
 4  
 5  
 Highly aware 6 
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Q5. Please rate the following factors according to their importance in influencing your 
organization’s decision to stock a specific item. (Two factors can have the same rating if you 
think they are equivalent in importance.) 
 0 1 2 3 4 5 6 
Physician’s 
preference               
Total Cost               
Patient 
outcome               
Manufacturer 
reputation               
Required 
storage space               
Administration 
decision               
Other (Please 
specify and 
rate) 
              
 
Q6. To what extent are the following costs shared with the physicians? 
 0 1 2 3 4 5 6 
Item cost 
(Unit 
purchase 
price) 
              
Total 
supply 
cost 
(Ordering, 
holding, 
and 
handling) 
              
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Q7. To what extent do you think sharing item cost can have a potential impact on managing your 
PPIs? 
 No Impact 0 
 1  
 2  
 3  
 4  
 5  
 High Impact 6 
 
Q8. To what extent do you think sharing total supply cost can have a potential impact on 
managing your PPIs? 
 No Impact0 
 1  
 2  
 3  
 4  
 5  
 High Impact6 
 
Q9. To what extent are you aware of spend analysis practices? (Spend analysis is the process of 
analyzing expenditure data. The purpose of spend analysis is to find ways of reducing 
procurement costs, and monitoring compliance.) 
 Not aware0 
 1  
 2  
 3  
 4  
 5  
 Highly aware6 
 
Q10. To what extent do you perform spend analysis on your PPIs? 
 Not at all0 
 1  
 2  
 3  
 4  
 5  
 Always6 
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Answer If “Q10. To what extent do you perform spend analysis on your PPIs?” (Not at all) Is 
Not Selected 
Q11. How often do you perform spend analysis on your PPIs relative to other items? 
 More 
 The Same 
 Less 
 
Q12. To what extent do you think spend analysis can have a potential impact on managing PPIs? 
 No impact 0 
 1  
 2  
 3  
 4  
 5  
 High potential impact 6 
 
Answer If “Q10. To what extent do you perform spend analysis on your PPIs?” (Not at all) Is 
Not Selected 
Q13. To what extent is spend analysis data shared with physicians? 
 Not at all0 
 1  
 2  
 3  
 4  
 5  
 Always6 
 
Q14. To what extent do you think spend analysis data should be shared with physicians? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q15. To what extent are you aware of capitated pricing practice? (“Capitated pricing is a model 
established that allows healthcare providers to purchase medical products and devices from a 
variety of original equipment manufacturers (OEMs) at set levels based on the level of the 
product. For example there may be 3 levels: Standard, High, and Premium. Each OEM will 
establish their products that fall into each of these categories by a certain set of characteristics 
that make these products “equal” from a clinical effectiveness point of view. Then the healthcare 
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provider will pay each OEM the same amount for any product in each level. For example: $3500 
for all Standards, $5000 for all High, and $7500 for all Premiums. The capitated pricing model 
also allows for OEMs to produce a special or “niche” product that does not fall into these 
categories if they can prove the clinical reasoning” 
http://wiki.answers.com/Q/What_is_capitated_pricing?#slide1) 
 Not aware0 
 1  
 2  
 3  
 4  
 5  
 Highly aware6 
 
Q16. Are you more likely to use capitated pricing on PPI items relative to other items? 
 More 
 The Same 
 Less 
 
Q17. Please rate the potential of utilizing capitated pricing on controlling PPIs in your 
organization. 
 No Impact0 
 1  
 2  
 3  
 4  
 5  
 High potential impact6 
 
Q18. To what extent is the spending of individual physicians monitored and used when making 
decisions regarding PPIs? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always6 
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Q19. To what extent is physician spending compared to budgeted amounts? 
 Not at all0 
 1 
 2 
 3 
 4 
 5 
 Always6 
 
Q20. To what extent are physicians compared to each other on their spending habits? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q21. Please rate your perceived potential impact of utilizing price reduction methods on 
controlling PPIs in your organization 
 No impact 0 
 1 
 2 
 3 
 4 
 5 
 High potential impact 6 
 
Q22. To what extent are you aware of ABC classification practices? (ABC classification is 
categorizing the inventory …. the process of analyzing/categorizing inventory according to 
value, usage amount, revenue generation … etc.) 
 Not aware 0 
 1 
 2 
 3 
 4 
 5 
 Highly aware 6 
 
 
 
161 
 
Q23. How often do you conduct an ABC classification? 
 Never 
 Daily 
 Weekly 
 Monthly 
 Yearly 
If Never Is Selected, Then Skip To “Q28. Please rate your perceived potential impact of utilizing 
ABC classification on controlling PPIs in your organization.” 
 
Q24. Please rate the extent to which you utilize ABC classification on your PPIs based on value. 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q25. Please rate the extent to which you utilize ABC classification on your PPIs based on usage. 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q26. To what extent is ABC classification data shared with physicians? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
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Q27. To what extent do you think ABC classification data should be shared with physicians? 
 Never 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q28. Please rate your perceived potential impact of utilizing ABC classification on controlling 
PPIs in your organization. 
 No impact 0 
 1 
 2 
 3 
 4 
 5 
 High potential impact 6 
 
Q29. To what extent are cross-functional teams utilized in your organization for managing 
supply chain operations involving PPIs. (Cross-functional teams are groups of employees 
involving a range of stakeholders that assist with analyzing and deciding on the approval of new 
item, approving any requested item to be purchased, looking for process improvements in PPI 
management, etc.) 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
If Not at all 0 Is Selected, Then Skip To “Q33. Please rate your perceived potential impact of 
utilizing cross functional team meetings on controlling PPIs in your organization.” 
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Q30. To what extent is the ordering/procurement (supply chain) department represented in cross-
functional team meetings? (Meetings that involve discussion of approving new items, or 
approving requested items to be purchased. This is about items that are not regular, in other 
words PPIs) 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q31. To what extent are physicians represented in cross-functional team meetings? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q32. To what extent do you discuss PPIs in cross-functional team meetings? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q33. Please rate your perceived potential impact of utilizing cross functional team meetings on 
controlling PPIs in your organization. 
 No impact 0 
 1 
 2 
 3 
 4 
 5 
 High potential impact 6 
 
Q34. To what extent are you aware of the value analysis practice/process? (Value analysis (VA) 
is the process of checking an item for its total cost of acquisition, maintenance, and usage over 
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its expected useful life and, if appropriate, to replace it with a more cost effective substitute. At 
the core of the VA process is the task to evaluate features in the item product that don’t add a 
true value to the patient but incur cost to the healthcare provider and patient, and eliminate 
them.) 
 Not aware 0 
 1 
 2 
 3 
 4 
 5 
 Highly aware 6 
 
Q35. To what extent are physicians included in the process of value analysis? 
 Not at all 0 
 1 
 2 
 3 
 4 
 5 
 Always 6 
 
Q36. Please rate your perceived potential impact of utilizing value analysis on controlling PPIs 
in your organization. 
 No impact 0 
 1 
 2 
 3 
 4 
 5 
 High potential impact 6 
 
Q37. Is there any other practice/activity that you think that if adopted might potentially impact 
managing the PPIs? Also fill in any other comments you want to include. 
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Q38. What type of healthcare provider is your organization? (Check all that apply) 
 Academic Institution 
 Acute Care Facility 
 Assisted Living Facility 
 Hospital/Medical Center 
 Managed Care Organization 
 Long-Term Care Facility 
 Health System / Network (IDS / IDN) 
 Military/VA/Government affiliated 
 Rehabilitation Center 
 Other ____________________ 
 
Q39. Indicate the approximate size of your organization. 
  
Number of 
beds  
Revenue  
Approximate 
number of 
employees 
 
Percentage 
of spend on 
PPI items 
 
 
Q40. How many years have you worked in the healthcare supply chain industry? 
  
 2 - 5 
 6 - 10 
 11 - 20 
 >20 
 
Q41. Which of the following best describes your job title? 
 Executive (CEO, CFO, CIO, President) 
 Vice president 
 Director 
 Manager 
 Associate 
 Technician 
 Buyer/Purchasing Agent 
 Other ____________________ 
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Q42. What is your gender? 
 Male 
 Female 
 Prefer to not answer 
 
Q43. What is your department’s annual purchasing budget? 
 >$500K 
 $500K - $1M 
 $1M - $4.9M 
 $5M - $10M 
 $10.1M - $19.9M 
 $20M - $50M 
 >$50M 
 
Q44. What is your organization's setting? 
 National 
 Rural 
 Suburban 
 Urban 
 Other ____________________ 
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Appendix D: Statistical Tests 
Chi-Square χ2 test 
Chi square is the only significance test available for data with both variables measured on the 
nominal scale (basically it was built for nominal data). However, data measured on the 
ordinal and interval scales, organized into categories and presented in a contingency table, 
can also be tested using chi square. 
H0: no difference exists among the categories of the variables (Independent/no association) 
H1: there is a difference (dependent/association between categories of the variables 
 
𝜒2 = � (𝐼0 − 𝐼𝐼)2
𝐼𝐼
, 
where 
f0 = the frequency obtained in each cell 
fe= the frequency expected in each cell under the assumption of no difference.  fe ≥5 
 
There are measures of association (association strength) that can be derived for nominal data 
directly from the calculated chi-square statistic. The most versatile of these measures is 
Cramer’s V, for which the formula is as follows: 
 
𝑉 = � 𝜒2
𝐼(𝑀 − 1), 
where 
n = sample size 
M = Minimum number of rows or columns 
(No association) 0 < V < 1 (Strong association) 
 
Gamma γ: adopted from (Rea and Parker 2005) 
𝛾 =  ∑(𝐼𝑖.∑𝐼𝑠) −∑(𝐼𝑖 .∑𝐼𝐼)
∑(𝐼𝑖.∑𝐼𝑠) + ∑(𝐼𝑖 .∑𝐼𝐼) 
Where 
fi = the frequency of any cell 
fs = the frequency of a cell ordered in the same direction from the subject cell 
(below and right to the fi cell) 
fd = the frequency of a cell ordered in a different (or inverse) direction from the 
subject cell (below and left) 
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→ A positive gamma is read from the upper left corner of the cross-tabulation to the right 
across the top and from the upper left corner down the rows. A negative gamma is read 
again from the upper left and again to the right across the top, but it is read from the 
bottom row to the top row (in contrast to the positive gamma). 
 
→ The chi square serves as the test for the significance of Cramer’s V, phi, and lambda, but 
the presence of ordinal or interval data used in the calculation of gamma permits the use 
of a more direct test of significance for the calculated gamma. 
 
𝑍 =  𝛾 ��∑(𝐼𝑖.∑𝐼𝑠) − ∑(𝐼𝑖.∑𝐼𝐼)
𝐼(1 − 𝛾2) � 
Is the Z score necessary for determining the significance of gamma. 
 
→ Inasmuch as gamma can be either positive or negative, the significance test for gamma’s 
Z score is a two-tail test, with critical Z scores: 
For 95%  𝑍𝛼 = 𝑍0.05 = 1.96    If 𝑍𝛾  > 𝑍𝛼   ∴ significant relationship 
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Appendix E: Surveys’ Extra Results and Analysis 
Appendix E.1: Physicians 
This will include results from both surveys that were not included in the writing body above. 
 
 
 
 
 
 
 
170 
 
 
 
 
 
 
 
 
171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
172 
 
Mann-Whitney U - Awareness of PPI term - Physicians and SC 
Physicians Supply 
chain 
 P Rank SC Rank     
5 7  16.5 57.5  RP 1249 
7 7  57.5 57.5  RSC 2579 
2 7  4 57.5     
7 7  57.5 57.5  NP 41 
5 7  16.5 57.5  NSC 46 
7 7  57.5 57.5     
2 7  4 57.5  UP 1498 
4 7  10.5 57.5  USC 388 
1 7  1.5 57.5     
6 7  24.5 57.5  U 388 
5 6  16.5 24.5     
5 7  16.5 57.5  Z -4.719233063 
3 7  7.5 57.5  P 2.36735E-06 
7 7  57.5 57.5    
5 7  16.5 57.5  Decision Reject 
4 7  10.5 57.5  There is a difference 
7 7  57.5 57.5  
7 7  57.5 57.5  
5 7  16.5 57.5  
6 7  24.5 57.5  
5 7  16.5 57.5  
2 7  4 57.5  
7 7  57.5 57.5  
7 7  57.5 57.5  
5 6  16.5 24.5  
1 7  1.5 57.5  
7 7  57.5 57.5  
7 7  57.5 57.5  
6 7  24.5 57.5  
7 7  57.5 57.5  
5 7  16.5 57.5  
5 7  16.5 57.5  
3 7  7.5 57.5  
7 7  57.5 57.5  
7 7  57.5 57.5  
7 7  57.5 57.5  
6 7  24.5 57.5  
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7 7  57.5 57.5  
7 7  57.5 57.5  
3 7  7.5 57.5  
3 7  7.5 57.5  
 7   57.5  
 7   57.5  
 7   57.5  
 7   57.5  
 7   57.5  
 
 
Kruskal-Wallis Test: Q4 data versus Q4 Categories  
 
Kruskal-Wallis Test on Q4 data 
 
Q4 Categories                             N  Median  Ave Rank      Z 
Knowledge of item cost                   41   5.000      96.6  -0.77 
Previous experience using the item       41   7.000     142.0   4.70 
Relationship with sales representative   41   3.000      39.3  -7.69 
Reputation of this item's manufacturer   41   5.000      86.5  -2.00 
The effectiveness of the item            41   7.000     150.7   5.76 
Overall                                 205             103.0 
 
H = 95.14  DF = 4  P = 0.000 
H = 100.15  DF = 4  P = 0.000  (adjusted for ties) 
 
Kruskal-Wallis Test: Q7 data versus Q7 Text  
 
243 cases were used 
3 cases contained missing values 
 
 
Kruskal-Wallis Test on Q7 data 
 
Q7 Text                    N  Median  Ave Rank      Z 
Administration Decision   40   6.000     129.4   0.73 
Manufacturer Reputation   40   4.000      70.3  -5.09 
Patient Outcome           41   6.000     160.6   3.86 
Physician's preference    41   5.000     120.0  -0.20 
Required storage Space    40   4.000      68.8  -5.23 
Total Cost                41   6.000     180.5   5.84 
Overall                  243             122.0 
 
H = 85.80  DF = 5  P = 0.000 
H = 88.79  DF = 5  P = 0.000  (adjusted for ties) 
 
One-way ANOVA: Q7 data versus Q7 Text  
 
Source    DF      SS     MS      F      P 
Q7 Text    5  217.85  43.57  24.15  0.000 
Error    237  427.62   1.80 
Total    242  645.47 
 
S = 1.343   R-Sq = 33.75%   R-Sq(adj) = 32.35% 
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Level                     N   Mean  StDev 
Administration Decision  40  4.875  1.556 
Manufacturer Reputation  40  3.500  1.340 
Patient Outcome          41  5.512  1.705 
Physician's preference   41  4.732  1.119 
Required storage Space   40  3.475  1.261 
Total Cost               41  6.024  0.935 
 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level                    ---------+---------+---------+---------+ 
Administration Decision                (---*---) 
Manufacturer Reputation  (---*---) 
Patient Outcome                              (---*---) 
Physician's preference               (---*---) 
Required storage Space   (---*---) 
Total Cost                                        (---*---) 
                         ---------+---------+---------+---------+ 
                                4.0       5.0       6.0       7.0 
 
Pooled StDev = 1.343 
 
Kruskal-Wallis Test: Q10 data versus Q10 categories  
 
Kruskal-Wallis Test on Q10 data 
 
Q10 categories                       N  Median  Ave Rank      Z 
Better results                       41   7.000     176.2   5.20 
Cheaper                              41   6.000      98.9  -2.42 
Easier to use                        41   6.000     134.5   1.08 
More features                        41   5.000     103.6  -1.96 
Produced by reputable manufacturer   41   4.000      58.7  -6.39 
Safer for patient                    41   7.000     169.1   4.50 
Overall                             246             123.5 
 
H = 82.45  DF = 5  P = 0.000 
H = 89.08  DF = 5  P = 0.000  (adjusted for ties) 
 
One-way ANOVA: Q10 data versus Q10 text  
 
Source     DF      SS     MS      F      P 
Q10 text    5  182.67  36.53  28.84  0.000 
Error     240  304.00   1.27 
Total     245  486.67 
 
S = 1.125   R-Sq = 37.53%   R-Sq(adj) = 36.23% 
 
 
 
 
Level                      N   Mean  StDev 
Better results            41  6.659  0.530 
Cheaper                   41  5.268  1.323 
Easier to use             41  6.000  0.975 
More features             41  5.366  1.318 
Produced by reputable ma  41  4.146  1.590 
Safer for patient         41  6.561  0.594 
 
                          Individual 95% CIs For Mean Based on 
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                          Pooled StDev 
Level                     --+---------+---------+---------+------- 
Better results                                     (---*--) 
Cheaper                              (---*--) 
Easier to use                                (--*--) 
More features                         (---*--) 
Produced by reputable ma  (--*---) 
Safer for patient                                 (---*--) 
                          --+---------+---------+---------+------- 
                          4.0       5.0       6.0       7.0 
 
Pooled StDev = 1.125 
 
Kruskal-Wallis Test: Q14 Willingness to substitute item vs procedures cost ranges  
 
Kruskal-Wallis Test on Q14 
 
Cost Range        N   Median  Ave Rank      Z 
<$1,000           15   5.000      30.8  -0.61 
$1,000-$5,000     16   5.000      33.0  -0.11 
$5,001-&10,000    15   5.000      35.3   0.41 
$10,001-$20,000   10   5.500      36.0   0.46 
$20,001-$50,000    7   6.000      37.0   0.51 
$50,001-$100,000   3   4.000      23.8  -0.89 
Overall  66              33.5 
 
H = 1.60  DF = 5  P = 0.902 
H = 1.69  DF = 5  P = 0.890  (adjusted for ties) 
 
One-way ANOVA: Q14 Willingness to substitute item vs procedures cost ranges 
 
Source  DF      SS    MS     F      P 
Factor   5    1.99  0.40  0.19  0.966 
Error   60  126.50  2.11 
Total   65  128.48 
 
S = 1.452   R-Sq = 1.55%   R-Sq(adj) = 0.00% 
 
 
                         Individual 95% CIs For Mean Based on Pooled StDev 
Level   N   Mean  StDev    +---------+---------+---------+--------- 
Q14_1  15  4.933  1.534                (------*-------) 
Q14_2  16  5.188  1.328                   (------*------) 
Q14_3  15  5.267  1.534                   (-------*------) 
Q14_4  10  5.300  1.337                  (--------*--------) 
Q14_5   7  5.286  1.604                (----------*----------) 
Q14_6   3  4.667  1.155    (----------------*---------------) 
                           +---------+---------+---------+--------- 
                         3.0       4.0       5.0       6.0 
 
Pooled StDev = 1.452 
 
 
Appendix E.2: Supply Chain Professionals 
 
Kruskal-Wallis Test: Q2 Data versus Q2 Text  
 
Kruskal-Wallis Test on Q2 Data 
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Q2 Text                                     N  Median  Ave Rank      Z 
Growing Size with limited space            46   4.000      41.6  -5.89 
PPI                                        47   6.000     104.5   7.06 
Unpredicted Schedules of needed items      47   5.000      64.7  -1.19 
Overall                                   140              70.5 
 
H = 57.34  DF = 2  P = 0.000 
H = 59.73  DF = 2  P = 0.000  (adjusted for ties) 
 
One-way ANOVA: Q2 Data versus Q2 Text  
 
Source    DF      SS     MS      F      P 
Q2 Text    2  136.68  68.34  45.26  0.000 
Error    137  206.86   1.51 
Total    139  343.54 
 
S = 1.229   R-Sq = 39.79%   R-Sq(adj) = 38.91% 
 
 
 
 
Level                   N   Mean  StDev 
Growing Size           46  3.500  1.472 
PPI                    47  5.915  0.952 
Unpredicted Schedules  47  4.532  1.213 
 
                       Individual 95% CIs For Mean Based on 
                       Pooled StDev 
Level                   -+---------+---------+---------+-------- 
Growing Size            (----*---) 
PPI                                                    (---*---) 
Unpredicted Schedules                (----*---) 
                        -+---------+---------+---------+-------- 
                       3.20      4.00      4.80      5.60 
 
Pooled StDev = 1.229 
 
Kruskal-Wallis Test: Q5 data versus Q5 Text  
 
Kruskal-Wallis Test on Q5 data 
 
Q5 Text                    N  Median  Ave Rank      Z 
Administration Decision   47   3.000      77.4  -5.90 
Manufacturer Reputation   47   4.000      93.0  -4.47 
Patient Outcome           47   6.000     218.5   7.09 
Physician's preference    47   6.000     186.9   4.18 
Required storage Space    47   3.000      94.2  -4.36 
Total Cost                47   6.000     179.0   3.46 
Overall                  282             141.5 
 
H = 127.94  DF = 5  P = 0.000 
H = 131.95  DF = 5  P = 0.000  (adjusted for ties) 
 
 
One-way ANOVA: Q5 data versus Q5 Text  
 
Source    DF      SS     MS      F      P 
Q5 Text    5  392.84  78.57  48.05  0.000 
Error    276  451.32   1.64 
Total    281  844.16 
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S = 1.279   R-Sq = 46.54%   R-Sq(adj) = 45.57% 
 
 
 
 
Level                     N   Mean  StDev 
Administration Decision  47  3.170  1.659 
Manufacturer Reputation  47  3.617  1.407 
Patient Outcome          47  6.213  0.858 
Physician's preference   47  5.617  1.134 
Required storage Space   47  3.638  1.495 
Total Cost               47  5.489  0.906 
 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level                    --+---------+---------+---------+------- 
Administration Decision  (---*--) 
Manufacturer Reputation      (---*---) 
Patient Outcome                                        (---*---) 
Physician's preference                           (---*---) 
Required storage Space        (--*---) 
Total Cost                                      (---*---) 
                         --+---------+---------+---------+------- 
                         3.0       4.0       5.0       6.0 
 
Pooled StDev = 1.279 
 
Kruskal-Wallis Test: Q17 by Q16  
 
Kruskal-Wallis Test on C58 
 
C57        N  Median  Ave Rank      Z 
Less       4   4.000       9.5  -2.18 
More      32   6.000      27.3   2.91 
The same  10   4.500      16.9  -1.76 
Overall   46              23.5 
 
H = 9.35  DF = 2  P = 0.009 
H = 9.91  DF = 2  P = 0.007  (adjusted for ties) 
 
* NOTE * One or more small samples 
 
  
One-way ANOVA: Q17 by Q16  
 
Source  DF     SS    MS     F      P 
C57      2  19.33  9.67  5.83  0.006 
Error   43  71.27  1.66 
Total   45  90.61 
 
S = 1.287   R-Sq = 21.34%   R-Sq(adj) = 17.68% 
 
 
                            Individual 95% CIs For Mean Based on 
                            Pooled StDev 
Level      N   Mean  StDev  --------+---------+---------+---------+- 
Less       4  3.500  1.732  (------------*------------) 
More      32  5.563  1.268                               (----*---) 
The same  10  4.600  1.174                  (-------*-------) 
                            --------+---------+---------+---------+- 
                                  3.0       4.0       5.0       6.0 
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Pooled StDev = 1.287 
 
 
Appendix F: Chapter’s 3 Material 
Appendix F.1: Value Analysis Example 
Value Analysis Decision-Making Criteria Matrix for New Requests 
Product:       VAT Member: ______________ 
Please place “X” for each category.  Blanks will be considered 0 points. 
Category Negative  Neutral  Positive  
Financial:  
Compared with the cost of the current 
product, process, project or the cost of 
not implementing a change. Cost 
includes decreased product cost, 
inventory and/or increased 
reimbursement. 
Increased cost 
 
 
 
1           2         3         4 
Cost neutral 
 
 
 
5                   6                 7 
 
Decreased cost 
 
 
 
    8             9          10 
Quality:  
Relates to the quality of a proposed 
product compared with the current 
Lower quality 
 
1           2          3         4  
Same quality 
 
5                   6                 7 
  
Higher quality 
 
     8             9          10  
Impact:  
Relates to the impact the product has on 
clinical indicators such as length of stay, 
patient or employee safety, and mortality 
Worse impact 
 
 
2           4          6         8 
Same impact 
 
 
10               12               14 
  
Better impact 
 
 
    16            18          20 
Clinical evidence: 
Support of the product, process, or 
project 
Inadequate evidence or 
lack of evidence 
 
 
1           2          3         4   
Evidence that supports and 
opposes, is limited, or is 
tentative in assumptions 
 
5                   6                 7 
 
Evidence and studies that 
are well constructed and 
supportive 
 
      8              9        10 
  
 
 
Recommendations 
Not Recommended 
at this Time 
( < 25 points) 
*Recommended Only if 
Funds Available 
(26-39 points) 
Highly Recommended 
(40-50 points) 
 Indicates technology might not do one or 
more of the following:  replace more costly 
existing technology, generate new “net” 
revenue, reduce clinical costs, generate 
new referrals, or improve quality of patient 
care 
Indicates technology is likely to do one or 
more of the following: replace more costly 
existing technology, generate new “net” 
revenue, reduce clinical costs, generate new 
referrals, or improve quality of patient care. 
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• Allocations for VAT requests that score in the “Recommend only if funds are available” 
category will occur bi-annually (December and June). 
  
 
 
Comments: 
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
________________________________________________ 
 
Appendix F.2: Stakeholders and Objectives Definitions 
Stakeholders 
Identifying the stakeholders is an initial step in the value hierarchy tree structuring. This 
facilitates the definition of stakeholder objectives and the mapping of the objectives to measures, 
which defines the list of criteria.  Fundamental objectives are objectives that we inherently care 
about and are included in the process. Means objectives indicate how fundamental are obtained. 
In the medical items/devices selection process, stakeholders interested either directly or 
indirectly in the decision are: physicians, nurses, patients, hospital financial administrators, 
supply chain professionals, and vendors. Stakeholders will be involved from an inside point of 
view, i.e. of what is important for the healthcare organization when selecting the item. Decision 
makers are those who make the decision, while stakeholders are those who are interested in the 
decision or its results. In the following, objectives with their definitions are presented for each 
stakeholder, and measures for each objective as well in both list and hierarchy format. 
 
1. Physicians desire to maximize treatment effectiveness by: 
1.1. Selecting items that have the best efficacy 
1.2. Selecting items that have the best effectiveness 
1.3. Selecting items that shorten required time for performing the treatment 
1.4. Selecting items that have the best safety/risk/side-effects record 
1.5. Selecting items that have distinguishing features that make it better than other items for 
the proposed usage 
1.6. Selecting items that they are good using due to skills they developed in practice 
(experience) 
 
2. Physicians desire to maximize patient’s outcome when using an item by: 
2.1. Selecting items that shorten patient’s length of stay in the hospital 
2.2. Selecting items that maximize quality-adjusted life years 
2.3. Selecting items that have the best safety/risk/side-effects record 
2.4. Selecting items that have the lowest rates of infection 
2.5. Selecting items that have the best disposition 
 
3. Physicians desire to maximize patient safety by: 
3.1. Selecting items that have the best reliability 
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3.2. Selecting items that have the best durability 
3.3. Selecting items that have the best safety/risk/side-effects record 
3.4. Selecting items that have the least amount of issues or problems during use 
 
4. Physicians desire to maximize their satisfaction when using an item by: 
4.1. Selecting items that are supported by staff with high ability to solve problems 
4.2. Selecting items that are available for testing or trials by physicians for as long as 
possible 
4.3. Selecting items that are supported with updates from vendors concerning safety, issues, 
or best practices on regular basis 
4.4. Selecting items that have easy instructions for preparation and use 
4.5. Selecting items that are the easiest to use 
4.6. Selecting items that require the least amount time for additional training 
4.7. Selecting items that are expected to be available as long as possible 
 
 
5. Patients desire to have their health problems cured to the best outcome possible by: 
5.1. Selecting items that maximize treatment effectiveness 
5.2. Selecting items that shorten required time for performing the treatment 
5.3. Selecting items that shorten patient’s length of stay in the hospital 
5.4. Selecting items that maximize quality-adjusted life years 
5.5. Selecting items that have the best safety/risk/side-effects record 
5.6. Selecting items that have the lowest rates of infection 
5.7. Selecting items that have the best disposition 
5.8. Selecting items that have the longest expected working life 
5.9. Selecting items that satisfy their preferences 
 
6. Nurses desire to reduce time spent on item management by: 
6.1. Selecting items that need less time and effort to prepare for treatments 
6.2. Selecting items that are easy to handle and manage in storage unit 
7. Nurses desire to maximize patient safety by: 
7.1. Selecting items that have the least amount of issues or problems during use 
 
 
8. Hospital administrators desire to maximize patients’ satisfaction by: 
8.1. Selecting items that result in shortest possible length of stay 
8.2. Selecting items that satisfy patients preferences 
 
9. Hospital administrators desire to maximize physicians’ satisfaction by: 
9.1. Selecting items that are the easiest to use 
9.2. Selecting items that require the least amount time for additional training 
9.3. Selecting items that require the least amount time for performing the treatment 
9.4. Selecting items that are expected to be available as long as possible 
9.5. Selecting items that are available for testing or trials by physicians for as long as 
possible 
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10. Hospital administrators desire to minimize the liability associated with medical practice by: 
10.1. Selecting items that make the treatment safer 
10.2. Selecting items that have the least amount of associated medical lawsuits/claims 
 
11. Hospital administrators desire to maximize market share by: 
11.1. Selecting items that increase patient acquisition 
11.2. Selecting items that increase reimbursement rates 
11.3. Selecting items that result in lower patient readmission rates 
11.4. Selecting items that increase patient retention 
11.5. Selecting items that ensure that profitable physicians want to practice at the hospital 
11.6. Selecting items that require the least amount time for performing the treatment 
11.7. Selecting items that have the longest expected working life 
 
12. Hospital administrators desire to maximize nurses’ satisfaction by 
12.1. Selecting items that require the least amount of time for additional training 
 
13. Healthcare supply chain professionals desire to maximize SC performance by: 
13.1. Selecting items that have easy instructions for handling, need least amount of time for 
managing (loading, unloading, moving) and not easy to break 
13.2. Selecting items that have longest expected expiry possible 
13.3. Selecting items that are eligible for urgent delivery or from a vendor who offers urgent 
delivery 
13.4. Selecting items that can be provided with the lowest possible minimum order quantity 
13.5. Selecting items from vendors who provide most flexible payments’ terms possible 
13.6. Selecting items that improve traceability 
13.7. Selecting items from vendors with reliable track records 
13.8. Selecting items that increase lead-time reliability 
13.9. Selecting items that are easiest to handle and manage by nurses in storage unit 
 
 
Definitions 
Purpose: the overall purpose or fundamental objective of the decision analysis process. In this 
research, the objective is to improve the control and effective use of PPI items within the 
healthcare supply chain. 
 
Objectives: fundamental goals of related stakeholders 
 
Criteria/value measures: the standards which determine degree of achieving the objectives of 
stakeholders. In other words, it is numerical representation of each objective; it measures 
the attainment of the objective. 
 
Weights: relative importance of each criterion to the overall objective, sum of weights should be 
1, also known as swing weights.  
 
Value hierarchy tree: a pictorial structure presenting the value hierarchy. 
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Tree Levels 
→Purpose: the overall goal/objective of the decision analysis process. In this research, the 
objective is to improve the control and effective use of PPI items within the healthcare 
supply chain. 
 
→Objectives: fundamental goals of related stakeholders 
 
→Criteria/metrics: the standards which determine degree of achieving the 
objectives of stakeholders. In other words, it is numerical representation of 
each objective; it measures the attainment of the objective. 
 
Following are the objectives as main headings (Bold) followed by related criteria. 
 
Treatment effectiveness: is how well the treatment attained its intended result 
Item efficacy: The extent to which an item/drug/medical device has the ability to produce its 
intended beneficial effect (or therapeutic effect) in expert hands and under ideal 
circumstances (clinical trials or laboratory studies) see (Marley 2000) and (Efficacy 
2015). This is a measure of the effectiveness but during trials, when the item is still 
tested. We prefer items with higher efficacy 
Item effectiveness: The extent to which an item/drug/medical device achieves its intended 
effect in practice of medicine (during actual use in real life). In other words, the item 
can be evaluated when history of data becomes available through observational studies 
of real practice (Marley 2000). We prefer to choose an item that is more effective. 
Side effects/Risks: the possibility that an item/medical device could cause an unwanted or 
unexpected negative effect ranging from minor (e.g. dry mouth) to serious (e.g. 
bleeding or heart attack). Observed problems in clinical trials are called “adverse 
events”, they might or might not be related to the item/medical device under study. 
Once that relationship is discovered, the problem is called “adverse effect” or as 
commonly known “side effects” (Medicine Safety and You 2011). When item has been 
used before, it is the total percentage of injury or death-related events over all events 
for this item. This measure could be accompanied with an exponential value function 
where a high score (life threatening) will hugely inflate the effect on the score, and a 
low score (non-life threatening) will have less effect. Risk may be measured using 
historical data of cases. We prefer to choose the item with lowest side effects possible. 
Item distinguishing features: the extent to which an item/device has extra special useful 
features that make this item different than others for the proposed usage. For example, 
an item could be lighter, coated …etc. we prefer an item with unique features. 
Physician’s experience using the item: physician’s practical opinion of the item after using 
and observing the item in practice/events (experience aspects included are: how long 
the physician has been using this item, how professional/good/skilled he is in using this 
specific item). An item that the physician is more experienced in using is preferred. 
Item’s Safety: the extent to which the item is considered safe. Probability that the 
item/medical device perform its intended function safely under specified conditions 
throughout a specified time (expected life). Another definition by (Bajaria 2000) is “the 
measure of unanticipated interruptions during customer use.” This includes issues and 
problems during use, which can be defined as: occurrences of issues/problems faced 
 
 
183 
 
when used the item from physician’s experience standpoint. This is different than the 
ease of application since it could be easy to apply an item, yet a physician could have 
faced problems with the item like fracture, fatigue … etc. It is also different than the 
risk/side-effects of using the item, since risk is about consequences and complications 
of a problem. We prefer a safer item; one that is more reliable and give less issues 
during use. 
 
Patient’s Outcome: highly satisfied patients are those who had their health problems cured to 
the best outcome possible. The goal is to improve long term patient outcome, and 
consequently satisfaction. Mainly, patient outcome can be measured by: 
 
Length of stay: is total number of days the patient needed from admission until discharging. It 
is a measure of patient’s outcome. 
Quality-adjusted life year: is a measure of patient’s outcome which represents an assessment 
of both quality and quantity of life lived. A value measure for this criterion can be 
defined as the arithmetic product of life expectancy and a measure of the quality of the 
remaining life-years. It assumes that a year of life lived in perfect health is worth 1 
QALY (1 Year of Life × 1 Utility value = 1 QALY) and that a year of life lived in a 
state of less than this perfect health is worth less than 1. See (Phillips and Thompson 
2009) 
Infection rates: percentage of infection of patients after procedures due to using specific item. 
When having more items, probability of infection will be higher. 
 
Item’s expected working life: the expected period of time the item/device will work 
effectively on the patient. It can be indicated as durability, which is: probability 
(ability) that an item will have a long continuous useful life relative to other similar 
items. A measure of durability is represented by the duration of item ownership. We 
prefer to choose an item that is expected to last longer 
 
 
Clinicians’ Satisfaction: the degree to which physicians and nurses are satisfied with items’ 
choices. 
Product support ability: existence of a trained team from the manufacturer/supplier  and their 
ability to provide support and regular updates related to the item to the medical staff 
when using the item 
Product trials: the extent to which the manufacturer/supplier allows healthcare organization 
to test the item before using it for as long as possible (using it for a grace period). 
Easy of instructions for preparation: how easy and straightforward the instructions are for 
item’s preparation and usage. 
Ease of actual use of the item: Physician’s opinion about the item’s ease of application 
(actual use) from his experience standpoint. 
Additional training time: extra training needed to learn about the new item. Basically the 
item is either an update to an existing one (for which the physician has previous 
training) , or similar to one that the physician has been already trained on. 
Required time to do the treatment: if time required is less than that when using other similar 
items. This is specifically important for three main reasons: first is to avoid fatigue of 
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physicians who are doing the procedure, second is to avoid fatigue of the patient, and 
third is to lower infection rates by exposing the patient’s internal tissues to the outside. 
 
Organizational benefits:  
 
Patient acquisition rate: rate of acquiring patients for healthcare services and treatments 
Reimbursement rates: Expected reimbursement rates associated with procedures due to using 
this item 
Patient readmission rate: is readmission of the patient after discharge due to follow-up 
needed, complications …etc. 
Patient retention: measures the return rate for patients for new services 
Profitable physicians: are physicians whom existence in the healthcare organization means 
more profit generation due to their good reputation (patients will come for them) and 
they are highly skilled in doing treatments and working with items such that they waste 
less, give better outcome, less time ... etc. 
Medical Lawsuits/claims: lawsuits cases and claims raised by patients due to health problems 
consequences/death caused by malfunction in device/item or unexpected unwanted 
results. 
 
Supply chain performance: effect of PPI selection on SC performance 
 
Ease of handling and managing: effort and time needed to handle and manage the item in 
storage within the organization’s supply chain. 
Flexibility of minimum order quantity: ability of manufacturer/supplier to provide flexible 
order quantities (minimum possible unit of measure). 
Ability of urgent delivery: the extent to which the manufacturer/supplier is willing/able of 
providing urgent delivery for this specific PPI 
Lead-time reliability: minimum delivery lead-time, minimum lead-time variability, and 
minimum uncertainty in these measures. It is measured by the coefficient variation of 
the lead-time, (ratio of the standard deviation to the mean). 
 
 
1. Physicians 
a. To maximize treatment effectiveness 
i. Maximize item’s efficacy 
ii. Maximize item’s effectiveness 
iii. Minimize required time for performing the treatment 
iv. Minimize side effects/risk (maximize safety) 
v. Maximize physician’s experience using the item 
vi. Maximize item’s performance due to the distinguishing features that 
the item has 
b. To maximize patient’s outcome 
i. Minimize patient’s length of stay 
ii. Maximize quality-adjusted life years 
iii. Minimize side effects/risk (maximize safety) 
iv. Minimize infection rates 
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v. Maximize disposition state 
c. To maximize treatment safety 
i. Maximize reliability 
ii. Maximize durability 
iii. Minimize side effects/risk (maximize safety) 
iv. Minimize issues and problems during use 
d. To maximize their satisfaction 
i. Maximize gaining of product support and problems’ solving 
ii. Maximize testability of the item 
iii. Maximize availability of regular updates from vendor 
iv. Maximize ease of instructions for preparation and use 
v. Maximize ease of use 
vi. Minimize time needed for additional training 
vii. Maximize item’s long term availability in market 
 
2. Patients 
a. To maximize patient’s outcome 
i. Minimize required length of stay 
ii. Minimize required time for performing the treatment 
iii. Maximize quality-adjusted life years 
iv. Minimize side effects/risk (maximize safety) 
v. Minimize infection rates 
vi. Maximize disposition state 
vii. Maximize expected item’s working life 
viii. Maximize preference 
 
3. Nurses 
a. To minimize time spent on items’ management  
i. Minimize the time required in preparing items/tools for use in 
treatments 
ii. Maximize ease of handling and management in storage unit 
iii. Minimize time needed for additional training 
b. To maximize treatment safety 
i. Minimize issues and problems during use 
 
4. Hospital administration 
a. To maximize patients’ satisfaction 
i. Maximize patient’s outcome 
ii. Minimize required length of stay 
iii. Maximize patients’ preference satisfaction 
b. To maximize physicians’ satisfaction 
i. Maximize ease of use 
ii. Minimize time needed for additional training 
iii. Minimize required time for performing the treatment 
iv. Maximize item’s long term availability in market 
v. Maximize testability of the item 
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c. To minimize the liability associated with the use of items on procedures 
i. Minimize side effects/risk (maximize safety) 
ii. Minimize amount of associated medical lawsuits/claims 
 
d. To Maximize expected market share 
i. Maximize patients acquisition 
ii. Maximize the reimbursement rates associated with procedures 
iii. Minimize readmission rates 
iv. Maximize patient retention 
v. Maximize attractiveness for profitable physicians 
vi. Minimize required time for performing the treatment 
 
e. To maximize nurses’ satisfaction 
i. Minimize the time required in preparing items/tools for use in 
treatments 
ii. Maximize ease of handling and management in storage unit 
iii. Minimize time needed for additional training  
 
5. Supply chain professionals 
a. To maximize SC performance 
i. Maximize the ease of handling and managing 
ii. Maximize expiry 
iii. Maximize ability of urgent delivery 
iv. Maximize flexibility of minimum order quantity 
v. Maximize ability to have flexible payments’ terms 
vi. Increase the traceability of the use of the item: does vendor provide 
ways to track the item? 
vii. Maximize vendor’s good reputation 
viii. Maximize lead-time reliability: this includes delivery lead-time (time 
from placing the order until receiving shipment in SC), lead-time 
variability, on-time delivery (history on-time shipments). 
ix. Maximize ease of handling and management in storage unit 
 
Appendix F.3: Objectives and Value Measures Review 
PPI Objectives Hierarchy Input 
The purpose of this feedback form is to capture your opinion regarding the definitions of the 
objectives and their sub-objectives, as well as the value measure's scale for each sub-objective. 
This is meant to be done after the presentation about the car example. Following  to this page, 
you will be presented with the objectives hierarchy to visualize it (you will also be sent a copy 
via email). The complete list of definitions will also be sent to you in a separate document. We 
will need your input on 2 main things: definitions and the value measure scale. The first level of 
the tree includes the 5 objectives which we think are overall objectives. They also help 
organizing the lower level objectives (sub-objectives) into more meaningful groups which makes 
it easy to read the tree. For the first level, it is just about definition, do you agree or not. For all 
 
 
187 
 
sub-objectives, you will be asked few questions like, on a scale from 1 (I don't agree) to 5 (I 
extremely agree), please rate to what extent you agree to the definition. By agreement, we mean 
how much you think the definition captures the term. The more you feel the definition represents 
the objective, the higher you would rate it. If you have no idea about a particular objective, 
please leave that rating box blank. Next question is if you agree to the value measure (VM) Scale 
or not, on a scale from 1 (don't agree) to 5 (extremely agree), please rate to what extent you agree 
to the defined scale of the value measure. In case you need any clarification, please call 
Mohammad Shbool on 479-409-9957 or email: mshbool@uark.edu 
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Q1 Does the first level of objectives in the hierarchy make sense to you? (1- No it does not make 
sense, 5-Yes it is good) 
 1 2 3 4 5 
Treatment effectiveness           
Patient outcome           
Clinician satisfaction           
Organizational benefits           
Internal supply chain performance           
 
Answer If Each sub-objective is accompanied with a value measure (metric), which defines how 
this objective's attainment will be measured. The definition is simply a rubric or scale that 
defines lowest, high...  - 1 Is Selected Or Each sub-objective is accompanied with a value 
measure (metric), which defines how this objective's attainment will be measured. The definition 
is simply a rubric or scale that defines lowest, high...  - 2 Is Selected 
 
Q4 In the previous question, you scored less than 3 for some objectives, please explain why. 
(List the objective and any changes to the definition or just define it as you think it should be) 
 
Q5 For the first objective (Treatment effectiveness), please rate to what extent you agree on the 
definition for each of its sub-objectives.  (1- No it does not make sense, 5-Yes it is good). 
 1 2 3 4 5 
Item efficacy           
Item effectiveness           
Side effects/Risks           
Physician's experience using the item           
Item distinguishing features           
Item safety (Reliability)           
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Q6 Each sub-objective is accompanied with a value measure (VM), which defines how this 
objective's attainment will be measured. The VM scale is simply a rubric that defines lowest, 
highest and some intermediate points of the possible score levels of the specific objective. (Note: 
the lowers level objectives "sub-objectives" are accompanied with value measures, while the first 
level is not). Referring to the "Treatment Effectiveness" group of sub-objectives, please rate to 
what extent you agree on the VMs scales provided in the document we sent to you. 
 1 2 3 4 5 
Item efficacy           
Item effectiveness           
Side effects/Risks           
Physician's experience using the item           
Item distinguishing features           
Item safety (Reliability)           
 
 
Answer If For the first objective (Treatment effectiveness), please rate to what extent you agree 
on the definition for each of its sub-objectives.&nbsp; (1- No it does not make sense, 5-Yes it is 
good).  - 1 Is Selected Or For the first objective (Treatment effectiveness), please rate to what 
extent you agree on the definition for each of its sub-objectives.&nbsp; (1- No it does not make 
sense, 5-Yes it is good).  - 2 Is Selected Or Each sub-objective is accompanied with a value 
measure (VM), which defines how this objective's attainment will be measured. The VM scale is 
simply a rubric that defines lowest, highest and some in...  - 1 Is Selected Or Each sub-objective 
is accompanied with a value measure (VM), which defines how this objective's attainment will 
be measured. The VM scale is simply a rubric that defines lowest, highest and some in...  - 2 Is 
Selected 
Q7 In the previous questions, you scored less than 3 for some objectives, please explain why. 
(List the objective and any changes to the definition or the VM scale) 
 
Q8 For the second objective (Patient Outcome), please rate to what extent you agree on the 
definition for each of its sub-objectives.   (1- No it does not make sense, 5-Yes it is good). 
 1 2 3 4 5 
Patient length of stay           
Quality-adjusted life years           
Infection rates           
Disposition state           
Item's expected working life           
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Q9 Referring to the "Patient Outcome" group of sub-objectives, please rate to what extent you 
agree on the VMs scales provided in the document we sent to you. 
 1 2 3 4 5 
Patient length of stay           
Quality-adjusted life years           
Infection rates           
Disposition state           
Item's expected working life           
 
 
Answer If For the second objective (Patient Outcome), please rate to what extent you agree on 
the definition for each of its sub-objectives.&nbsp;  (1- No it does not make sense, 5-Yes it is 
good).  - 1 Is Selected Or For the second objective (Patient Outcome), please rate to what extent 
you agree on the definition for each of its sub-objectives.&nbsp;  (1- No it does not make sense, 
5-Yes it is good).  - 2 Is Selected Or We are still talking about the second group of sub-
objectives, please rate to what extent you agree on the VMs scales provided in the document we 
sent to you.  - 1 Is Selected Or We are still talking about the second group of sub-objectives, 
please rate to what extent you agree on the VMs scales provided in the document we sent to you.  
- 2 Is Selected 
Q10 In the previous questions, you scored less than 3 for some objectives, please explain why. 
(List the objective and any changes to the definition or the VM scale) 
 
Q11 For the third objective (Clinician Satisfaction), please rate to what extent you agree on the 
definition for each of its sub-objectives.   (1- No it does not make sense, 5-Yes it is good). 
 1 2 3 4 5 
Ability of provider's staff to solve Problems           
Testability of the item           
Availability of regular updates           
Ease of instructions for preparation and use           
Ease of use of the item           
Time needed for additional training           
Item's long term availability           
Time needed for performing the treatment           
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Q12 Referring to the "Clinician Satisfaction" group of sub-objectives, please rate to what extent 
you agree on the VMs scales provided in the document we sent to you. 
 1 2 3 4 5 
Ability of provider's staff to solve Problems           
Testability of the item           
Availability of regular updates           
Ease of instructions for preparation and use           
Ease of use of the item           
Time needed for additional training           
Item's long term availability           
Time needed for performing the treatment           
 
 
Answer If For the third objective (Clinician Satisfaction), please rate to what extent you agree on 
the definition for each of its sub-objectives.&nbsp;  (1- No it does not make sense, 5-Yes it is 
good).  - 1 Is Selected Or For the third objective (Clinician Satisfaction), please rate to what 
extent you agree on the definition for each of its sub-objectives.&nbsp;  (1- No it does not make 
sense, 5-Yes it is good).  - 2 Is Selected Or We are still talking  about the third group of sub-
objectives, please rate to what extent you  agree on the VMs scales provided in the document we 
sent to you.  - 1 Is Selected Or We are still talking  about the third group of sub-objectives, 
please rate to what extent you  agree on the VMs scales provided in the document we sent to you.  
- 2 Is Selected 
Q13 In the previous questions, you scored less than 3 for some objectives, please explain why. 
(List the objective and any changes to the definition or the VM scale) 
 
Q14 For the fourth objective (Organizational Benefits), please rate to what extent you agree on 
the definition for each of its sub-objectives. (1- No it does not make sense, 5-Yes it is good). 
 1 2 3 4 5 
Patient acquisition           
Reimbursement associated with procedures           
Readmission           
Patient retention           
Attractiveness of profitable physicians           
Amount of associated medical lawsuits/claims           
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Q15 Referring to the "Organizational Benefits" group of sub-objectives, please rate to what 
extent you agree on the VMs scales provided in the document we sent to you. 
 1 2 3 4 5 
Patient acquisition           
Reimbursement associated with procedures           
Readmission           
Patient retention           
Attractiveness of profitable physicians           
Amount of associated medical lawsuits/claims           
 
 
Answer If For the fourth objective (Organizational Benefits), please rate to what extent you 
agree on the definition for each of its sub-objectives. (1- No it does not make sense, 5-Yes it is 
good).  - 1 Is Selected Or For the fourth objective (Organizational Benefits), please rate to what 
extent you agree on the definition for each of its sub-objectives. (1- No it does not make sense, 5-
Yes it is good).  - 2 Is Selected Or We are still talking  about the fourth group of sub-objectives, 
please rate to what extent you  agree on the VMs scales provided in the document we sent to you.  
- 1 Is Selected Or We are still talking  about the fourth group of sub-objectives, please rate to 
what extent you  agree on the VMs scales provided in the document we sent to you.  - 2 Is 
Selected 
Q16 In the previous questions, you scored less than 3 for some objectives, please explain why. 
(List the objective and any changes to the definition or the VM scale) 
 
 
Q17 For the fifth objective (Internal Supply Chain), please rate to what extent you agree on the 
definition for each of its sub-objectives. (1- No it does not make sense, 5-Yes it is good). 
 1 2 3 4 5 
Required preparation time of item by nurses           
Ease of handling and management by nurses           
 
 
Q18 Referring to the "Internal Supply Chain" group of sub-objectives, please rate to what extent 
you agree on the VMs scales provided in the document we sent to you. 
 1 2 3 4 5 
Required preparation time of item by nurses           
Ease of handling and management by nurses           
 
 
Answer if For the fifth objective (Internal Supply Chain), please rate to what extent you agree on 
the definition for each of its sub-objectives. (1- No it does not make sense, 5-Yes it is good).  - 1 
is selected Or For the fifth objective (Internal Supply Chain), please rate to what extent you 
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agree on the definition for each of its sub-objectives. (1- No it does not make sense, 5-Yes it is 
good).  - 2 Is Selected Or We are still talking  about the fifth group of sub-objectives, please rate 
to what extent you  agree on the VMs scales provided in the document we sent to you.  - 1 Is 
Selected Or We are still talking  about the fifth group of sub-objectives, please rate to what 
extent you  agree on the VMs scales provided in the document we sent to you.  - 2 Is Selected 
Q19 In the previous questions, you scored less than 3 for some objectives, please explain why. 
(List the objective and any changes to the definition or the VM scale) 
 
 
Q20 Anything else you would like to say? 
 
 
Appendix F.4: Value Measures Scales 
The 10 Natural Value Measures Score Levels (Scale) 
Proportion of treatments that achieved the intended effect during ideal trials % from 20 to 100 
Proportion of treatments that achieved the intended effect during actual use % from 20 to 100 
Reliability % from 0.6 to 1.0 
Total # of days stayed # of days from 0 to 5 
Expected years*Quality of living (QALY) QALY from 0.1 to 1.0 
Infection percentage % from 0 to 100 
Acquired patients rate % from 10 to 100 
Reimbursement rate % from 40 to 100 
Readmission rate % from 0 to 100 
Retention rate % from 10 to 100 
 
Side effects/risks constructed scale (7-points scale) 
Scor
e Definition 
Valu
e 
0 No side effects 100 
1 Minor side effects (Dry mouth, itching …) 95 
2 Major injuries nonlife threatening 80 
3 
Serious life threatening (heart attack, internal bleeding…), % of death related events less 
than 20% 40 
4 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
>20% & <40% 15 
5 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
>40% & < 60% 5 
6 
Serious life threatening (heart attack, internal bleeding…), % of death related events 
>60% 0 
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Physician's experience using the item Multidimensional constructed scale 
Score Definition Value 
1 Highly skilled physician using the item/device, and experience >10 years 100 
2 Highly skilled physician using the item/device, and experience >5 & <10 years 90 
2 Medium skilled physician using the item/device, and experience >10 years 90 
3 Highly skilled physician using the item/device, and experience <5 years 70 
3 Medium skilled physician using the item/device, and experience >5 & <10 years 70 
4 Low skilled physician using the item/device, and experience >10 years 60 
5 Medium skilled physician using the item/device, and experience <5 years 40 
6 Low skilled physician using the item/device, and experience >5 & <10 years 20 
7 Low skilled physician using the item/device, and experience <5 years 0 
 
Prefer items that have more distinguishing/unique features 
Score Definition Value 
0 No distinguishing features 0 
1 Few extra features 50 
2 Noticeable distinguishing features 100 
 
Expected Working life years (categories scale) 
Score Definition Value 
1 <= 1 year 0 
2 1-3 years 25 
3 >3 & <6 years 50 
4 6-10 years 75 
5 >10 years 100 
 
Maximize supplier ability to provide product support 
Score Definition Value 
1 Not able at all 0 
2 Able to solve description problems (like: missing information,  25 
3 Ability to solve minor technical problems 50 
4 Ability to solve major technical problems with a delay 75 
5 Ability to solve major technical problems on the spot 100 
 
Maximize supplier ability to support product trials 
Score Definition Value 
1 Not testable 0 
2 Limited time testability 50 
3 Long time testability 90 
4 Unlimited time testability 100 
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Prefer items that have easier instructions for preparation and use 
Score Definition Value 
1 No instructions 0 
2 Complicated instructions 25 
3 Moderately easy instruction 55 
4 Very easy instructions 100 
 
Maximize the actual Ease of Use of the item 
Score Definition Value 
1 Very difficult 0 
2 Moderately difficult 50 
3 Very easy 100 
 
Minimize time needed for additional training 
Score Definition Value 
1 No time needed 100 
2 small amount of time relative to similar items 90 
3 Moderate amount of time needed 50 
4 Very long time needed 0 
 
Minimize time needed for performing treatment 
Score Definition Value 
1 Short time 100 
2 Moderate time 50 
3 Longer than other items 0 
 
Maximize attractiveness of profitable physicians 
Score Definition Value 
1 
Low likely physicians in general will be attracted (i.e. the item is less preferred by 
physicians than other similar items, or the likelihood of physicians to come just 
because the healthcare provide is using this item, is low) 
0 
2 
Moderately likely physicians in general will be attracted (i.e. the item is preferred 
by physicians as similar as similar items, or the likelihood of physicians to come just 
because the healthcare provide is using this item, is medium) 
50 
3 
Highly likely physicians in general will be attracted (i.e. the item is more preferred 
by physicians than other similar items, or the likelihood of physicians to come just 
because the healthcare provide is using this item, is high) 
100 
 
Minimize amount of associated medical lawsuits/claims 
Score Definition Value 
1 Low amount of lawsuits cases and claims 100 
2 Medium amount of lawsuits cases and claims 50 
3 High amount of lawsuits cases and claims 0 
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Prefer items that are easier to handle and manage 
Score Definition Value 
1 Very difficult 0 
2 Moderately difficult 50 
3 Very easy 100 
 
Maximize flexibility of minimum order quantity 
Score Definition Value 
1 Not flexible, should order big quantity relative to the item type 0 
2 flexible with minimum order quantity, but still there are limits 50 
3 Very flexible, can order any quantity 100 
 
Maximize suppliers' ability of urgent delivery 
Score Definition Value 
1 Not at all 0 
2 Sometimes able 25 
3 Able with a considerable amount of time 50 
4 Able to deliver whenever needed 100 
 
Maximize lead-time reliability 
Score Definition Value 
1 Not reliable, the lead-time is highly variable, the CV is big 0 
2 Somewhat reliable, the lead-time is Intermediate variable 25 
3 Good reliability, low lead-time variability 60 
4 Highly reliable, lead-time reliability is almost 0 100 
 
 
 
 
Appendix F.5: Excel Macros 
Function ValuePL(x, Xi, Vi) 
  i = 2 
  Do While x > Xi(i) 
    i = i + 1 
  Loop 
  ValuePL = Vi(i - 1) _ 
    + (Vi(i) - Vi(i - 1)) * (x - Xi(i - 1)) / (Xi(i) - Xi(i - 1)) 
End Function 
 
Function ValueE(x, Low, High, Monotonicity, Rho) 
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    Select Case UCase(Monotonicity) 
        Case "INCREASING" 
            Difference = x - Low 
        Case "DECREASING" 
            Difference = High - x 
    End Select 
    If UCase(Rho) = "INFINITY" Then 
        ValueE = Difference / (High - Low) 
    Else 
        ValueE = (1 - Exp(-Difference / Rho)) / (1 - Exp(-(High - Low) / Rho)) 
    End If 
End Function 
 
Notes: 
• given an array of X values, Xi, and corresponding value array (Vi), ValuePL returns 
interpolated value 
• Xi array must be monotonically increasing as i increases 
• Given x, low and high scores of the value measure, and monotonicity (Increasing or 
Decreasing), ValueE returns normalized exponentially interpolated value 
• Rho is the exponential constant. If Rho = infinity, the value curve becomes a straight-line 
• This Excel macro is adopted from (C. W. Kirkwood 1997). 
 
Appendix F.6: Evaluation Feedback Questions 
Q1.  The whole framework captures the PPI problem. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q2.  The objectives and sub-objectives represent critical components in this decision area? 
1 I don’t agree        2        3        4        5  I strongly agree 
Q3.  This framework would improve the value analysis process. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q4.  This framework would be easy to implement. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q5.  The time needed to make a decision would be decreased/ improved. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q6.  This framework would be implementable in my company. 
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1 I don’t agree        2        3        4        5  I strongly agree 
Q7.  The quality of the decision should be improved. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q8.  All aspects of the different stakeholders have been incorporated. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q9.  The framework satisfactorily represents the multiple competing criteria within a PPI 
problem related to all stakeholders. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q10.  It captures the importance of the objectives. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q11.  Breaking the analysis out in the way would be beneficial. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q12.  Understanding the sensitivity of swing weights would be important. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q13.  This framework adds more visibility of the decision value and consequences 
1 I don’t agree        2        3        4        5  I strongly agree 
Q14.  This process (framework) educated me and made me think with more objectivity 
about the problem. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q15.  Please, rate your perceived potential impact of implementing this decision framework 
on the PPI selection process. 
1 I don’t agree        2        3        4        5  I strongly agree 
Q16.  Anything else you would to say? 
